










The handle http://hdl.handle.net/1887/36504 holds various files of this Leiden University 
dissertation 
 
Author: Esch, Edith van 
Title: Clinical implications of immune cell infiltration in vulvar intraepithelial  neoplasia 



































 esch Edith van Esch
VULVAR INTRAEPITHELIAL 
NEOPLASIA
clinical implications of immune cell infiltration in 
Clinical implications of 
immune cell infiltration 
in vulvar intraepithelial 
neoplasia 
UITNODIGING
Voor het bijwonen van de openbare 





Peggy de Vos van Steenwijk
p.j.de_vos_van_steenwijk@lumc.nl
0641240628
op dinsdag 1 december 2015 om 15.00u in 
het Academiegebouw 
Rapenburg 73 te Leiden 
U bent van harte uitgenodigd voor de 
receptie ter plaatse na afloop van de 
promotie.
Edith van Esch 
door 
Edith van Esch 
Van Swietenstraat 138




Clinical implications of immune cell infiltration in 
vulvar intraepithelial neoplasia
Edith van Esch
Clinical implications of immune cell infiltration in vulvar intraepithelial neoplasia
Edith van Esch 
The research presented in this thesis was performed at the Departments of Gynaecology, 
Clinical Oncology and Pathology of the Leiden University Medical Center, the Netherlands. 
Cover: Liselot Roben
Layout and printing: Gildeprint – Enschede
ISBN: 978-94-6233-118-1
All rights reserved. No parts of this thesis may be reproduced, stored or transmitted in any 
form or by any means without permission of the copyright owner. 
© 2015 E.M.G. van Esch 
Publication of this thesis was financially supported by: BMA B.V. (Mosos), ChipSoft B.V., ISA 
Pharmaceuticals, de Nederlandse Vereniging voor Vulvapathologie (NVvVP) the department 
of Clinical Oncology LUMC and the department of Pathology LUMC.




de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 1 december 2015
klokke 15.00 uur
door
Edith Margarethe Gertrude van Esch
geboren te Tilburg in 1984
Promotiecommissie
Promotores:  Prof. dr. S.H. van der Burg
 Prof. dr. J.B.M.Z. Trimbos
Co-promotores:  Mw. dr. M.I.E. van Poelgeest 
Overige leden:  Prof. dr. H.W. Nijman - Universitair Medisch Centrum Groningen  
 Prof. dr. T.H.B.M. Smit




Chapter 1 General introduction 9
Chapter 2 Treatment failure in patients with HPV 16-induced vulvar  35
 intraepithelial neoplasia: understanding different clinical responses 
 to immunotherapy 
 Expert Rev. Vaccines 2012 Jul;11(7):821-40
Chapter 3  Clinical characteristics associated with development of recurrence  71
 and progression in usual-type vulvar intraepithelial neoplasia. 
 Int J Gynecol Cancer 2013 Oct;23(8):1476-83
Chapter 4 Alterations in classical and nonclassical HLA expression in recurrent  87
 and progressive HPV-induced usual vulvar intraepithelial neoplasia 
 and implications for immunotherapy.
 Int J Cancer 2014 Aug 15;135(4):830-42
Chapter 5  Expression of coinhibitory receptors on T cells in the  109
 microenvironment of usual vulvar intraepithelial neoplasia is 
 related to proinflammatory effector T cells and an increased 
 recurrence-free survival. 
 Int J Cancer 2015 Feb; 136:95-106
Chapter 6 Intraepithelial macrophage infiltration is related to a high number  131
 of regulatory T cells and promotes a progressive course of HPV-induced 
 vulvar neoplasia. 
 Int J Cancer 2015 Feb; 136: 85-94
Chapter 7  Analysis of myeloid cells and lymphocytes by expression of  151
 co-inhibitory molecules and phosphorylation of signal transduction 
 activators of transcription (STAT) after stimulation in peripheral 
 blood of patients with high grade usual vulvar intraepithelial neoplasia 
 Manuscript in preparation 
Chapter 8  Summary and General discussion  197
Chapter 9 Nederlandse samenvatting 215
Addendum List of abbreviations 225
 Dankwoord  231
 Curriculum Vitae  237




















































































General Introduction  |  11
In the last two decades a clear role of the immune system in tumor biology has been 
established for a wide variety of tumors. All types of immune cells can infiltrate both 
the tumor stroma and epithelium and often it is the balance between these cells that is 
associated with disease outcome1. The importance of the immune system in both rejecting 
and promoting tumors is stressed by the fact that the updated hallmarks of cancer, as defined 
by Hanahan and Weinberg in 20112, now also comprise avoidance of immune destruction 
and tumor promoting inflammation. Furthermore, the exploitation of tumor immunity to 
treat tumors, also named ‘immunotherapy’ was appointed as the breakthrough of the year 
in 20133. Currently, many different immunotherapeutic approaches are being developed or 
combined as new treatments for cancer. 
This thesis is dedicated to studies on the role of the immune system in the development of 
human papilloma virus (HPV) induced (pre-)malignancies of the vulva. It has been widely 
established that the immune system has an important role in protection against HPV and 
that it fails to protect a percentage of patients against the development of HPV-induced 
neoplasia. Immunotherapeutic approaches to treat this disease are being tested, but 
are successful in only a certain percentage of patients. Following an introduction on the 
immune system, a summary on the interaction between the immune system and HPV is 
given. In addition, the development and treatment of vulvar intraepithelial neoplasia (VIN) 
is discussed. Despite previous studies, our current knowledge on the immune response in 
VIN lesions is deemed insufficient to understand why patients respond or fail to respond 
to immune based therapies. The aim of this thesis was to increase this knowledge by the 
studies that are outlined at the end of this chapter. 
1.1. Immune system 
The immune system protects us from potential dangerous environmental factors as invasion 
of viruses, bacteria, fungi or parasites but also from the development of cancers. Different 
types of immune cells originate from the bone marrow where pluripotent stem cells divide 
and differentiate into progenitor cells that form the lymphoid, myeloid and erythrocyte/
megakaryocyte lineages respectively4. The lymphoid lineage develops into B-cells, T cells 
and natural killer (NK) cells. The myeloid lineage develops into granulocytes (neutrophils, 
eosinophils and basophils), mast cells and monocytes which differentiate into dendritic cells 
and macrophages in tissues. The erythrocyte/megakaryocyte lineage forms erythrocytes 
and platelets4. The immune system is divided into two types of immune responses to 
pathogens; the non-specific innate immune response and the antigen-specific adaptive 








































12  |  Chapter 1
is required for an optimal response to threats and is mediated by a complex interaction of 
different cell types, cytokines and chemokines. 
1.1.1. The innate immune response 
The innate immune system is the inherited first line defence against a pathogen that 
responds immediately upon encounter. The innate immune system activates adaptive 
immune responses, regulates inflammation, mediates in immune homeostasis, is non-
specific as it has no antigen specificity and does not produce an immunological memory to 
threats4,5. The main components are the physical epithelial barriers formed by the skin and 
mucosal surfaces, phagocytic neutrophils, monocytes and macrophages, dendritic cells, NK 
cells and the complement system4. 
The innate immune system recognizes pathogens through Pathogen Recognition Receptors 
(PRRs) present on and in different cells of the innate immune system and epithelial cells. 
The PRR recognize the molecular components of pathogens called pathogen-associated 
molecular patterns (PAMPs)6. PRRs are divided into two groups; the secreted and circulating 
PRRs and the transmembrane and intracellular signal transducing receptors. The first 
group includes antimicrobial peptides, collectins, lectins and pentraxins and these PRRs 
induce direct lysis of the pathogen, enhance phagocytosis and support the transmembrane 
PRRs5. The latter group of transmembrane and intracellular-transducing PRRs are plasma 
membrane bound and intracellular Toll-like receptors (TLRs), C-type lectin receptors, 
Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and RIG-1 like 
receptors (RLRs)5. Membrane bound PPRs are expressed by a variety of innate immune cells 
and on antigen presenting cells (APCs). In antiviral responses TLRs are essential (TLR 3, 4, 
7, 8 and 9) since they trigger a pro-inflammatory response after activation of the NF-kB 
pathway5 and TLR-agonists (e.g. TLR-4) can be used to restore immunogenicity in tumors 
lacking the TLR ligand7,8. 
In response to local factors, CD14+ myeloid cells can differentiate into APCs9. APCs process 
the antigens and present components on the cell surface to activate T cells in the lymph 
nodes. Three different professional APCs are known; macrophages, dendritic cells (DCs or 
Langerhans cells (LCs) as they are called when residing in the epidermis) and B lymphocytes5. 
Monocytes are the systemic circulating precursors of macrophages. Macrophages are 
present in infected tissues and are the first line defence of the innate immune system to 
eliminate extracellular pathogens by release of cytokines, chemokines and inflammatory 
mediators that activate other immune cells, create a state of local inflammation and recruit 
neutrophils and monocytes to the site of infection4. Macrophages are also attracted to 
developing cancers where they can be roughly categorized into tumor suppressive type 1 









































General Introduction  |  13
DCs ingest, process and present antigens which are subsequently shown to T cells in order to 
activate adaptive immunity or in case of self-antigens to maintain tolerance5. The outcome 
of such an interaction depends on the maturation status of DCs as well as their functional 
phenotype. In order to combat viruses and cancers, DCs need to mature and produce IL-
12. Maturation of DCs is reflected by the production of pro-inflammatory cytokines, the 
increased expression of MHC-class I and II, as well as the co-stimulatory molecules (e.g. 
CD80 and CD86). DCs are considered to be the most potent cells to activate the adaptive 
immune system5 (Fig. 1). 
Figure 1 The innate and adaptive immuneresponse and T cell differentiation








































14  |  Chapter 1
NK cells are activated by cytokines and inflammatory mediators produced by macrophages 
and neutrophils and recognize and lyse virus infected or tumor cells. NK cells recognize 
healthy host cells from pathogens through killer immunoglobulin-like receptors (KIRs), 
which recognize major-histocompatibility (MHC) class I molecules expressed on healthy 
cells5. Activated NKs induce apoptosis and secrete cytokines to promote innate immunity 
and contribute to adaptive immune responses. 
1.1.2. The adaptive immune response
The adaptive immune response is a highly specific immune response mediated by T cells 
and B cells, which is slow in onset but acquires a memory function and is essential in 
control of pathogens and transformed cells10. B cells produce antibodies (Ig) to neutralize 
pathogens and prevent an infection. Depending on the different environmental factors in 
the microenvironment, APCs will become activated, differentiate and migrate to the local 
lymphoid tissues to present antigens to naïve T cells after which effector and memory 
T-cell phenotypes develop. Naïve T cells circulate in the blood and lymph nodes. T cells can 
recognizes small fragments (peptides) of antigens presented in the context of MHC class 
I or MCH class II molecules via their T-cell receptor (TCR). MHC class I is expressed on the 
majority of somatic cells and presents peptides of intra-cellular antigens to CD8+ cytotoxic T 
cells (CTL). CTLs are pivotal to control and kill infected cells or induce tumor cell lysis via their 
production of IFNγ, TNFα and granzymes. MHC class II molecules are expressed by immune 
cells, in particular APCs, but also by epithelial cells in inflamed tissue. MHC class II presents 
processed extracellular antigens to CD4+ T cells. CD4+ T cells are essential in regulating the 
immune response and are categorized upon their function and profile of secreted cytokines. 
Type 1 Th (Th1) helper cells are characterized by their production of the pro-inflammatory 
cytokines IFNγ, TNFα and IL-2 and the expression of the transcription factor Tbet. Th1 
responses aid the induction, maintenance and effector function of CD8+ CTL, as well as 
support the polarisation and activation of M1 macrophages. Type 2 Th (Th2) helper cells 
can secrete the type 2 cytokines IL-4, IL-5, IL-10 and by Gata3 expression. They are on the 
other hand known for their immune inhibitory T-cell responses by Tregs (Th3) and TGF-β. 
Moreover they are well known to induce humoral immune responses, the activation of B 
cells and thereby the formation of Ig antibodies. More recently Th17 subset of CD4+ T cells 
were added to the phenotypes characterised by IL-17 production however their role as pro-
inflammatory or anti-inflammatory T cells is still under debate as they have been isolated 
in several autoimmune diseases and have been isolated in different human cancers11. The 
final subtype of CD4+ T cells are regulatory T cells known for they key role in maintenance 
of peripheral tolerance to tumors by secretion of suppressive cytokines as IL-10 and TGF-β 
and a number of mechanisms to suppress other T cells or APC. Tregs express high CD25 and 
transcription factor FoxP3. The differentiation of T cells is influenced by different cytokine 









































General Introduction  |  15
1.2. HPV and immunity 
HPV in the etiology of cervical cancer was first proposed by Harold zur Hausen in the 1970s12-
14. In 1982, HPV-DNA was detected in VIN for the first time12,15. HPV is the most common 
sexually transmitted pathogen worldwide and is a DNA virus that infects the basal cells of 
squamous epithelium when the epithelial surface is disrupted through minor damage of the 
genital mucosa allowing access of the virus to the basal cells of the epithelium16-18. Over 100 
types of HPV are identified which are subdivided into low risk (non-oncogenic; e.g. lr-HPV 
6 and 11) and high risk (hr)HPV (oncogenic; e.g. hr-HPV 16 and 18)19. The life time risk of 
acquiring an HPV infection is estimated at 80%, 40% of female adolescents become infected 
at least once with a hrHPV and in the majority of cases the infection is asymptomatic and 
is cleared within two years17,20-22. Persistent infections develop only in less than 10% of the 
infected women and are causally related to the development of intraepithelial neoplasia of 
the cervix (cervical intraepithelial neoplasia (CIN)), vagina (vaginal intraepithelial neoplasia 
(VAIN)), anus (anal intraepithelial neoplasia (AIN)) and/or vulva (VIN) and their subsequent 
progression to invasive squamous carcinoma 17,20,21,23,24. The risk factors associated with HPV-
induced disease are the life time number of sexual partners, smoking and the use of oral 
contraceptives25,26. 
The early viral oncoproteins of HPV (E1, E2, E4-E7) are the key factors in progression of HPV-
induced disease and have different and synergistic functions in the maintenance, replication 
and progression of a potential HPV associated lesion16,18,19,27. E6 and E7 are the pivotal players 
and are consistently expressed in the basal layers of the epithelium in malignant tissue 
resulting in enhanced cell proliferation and subsequent viral genome replication16. In the 
suprabasal layers viral replication takes place and E1, E2 and E5 are expressed while in the 
most superficial layers, the late structural proteins L1 and L2 encapsulate newly made viral 
particles which are released to the epithelial surface16. Since there is no cytopathic phase or 
systemic viraemia in a HPV infection, the potential exposure of HPV to the immune system 
is reduced and causes delay in the activation of the immune system. The high incidence of 
persistent HPV infections and subsequent HPV-related malignancies in immunosuppressed 
individuals indicate towards the key role of the adaptive cellular immune system in 
protection against HPV-induced lesions28,29. In addition, only a small fraction of infected non-
immunosuppressed subjects develop progressing epithelial lesions or cancer17,18,20. Both the 
innate and the adaptive immune system play an essential role in the protection against HPV. 
1.2.1. Innate immunity to HPV
Keratinocytes form the first line of defence against HPV and express PRRs (TLR9 in 
differentiated keratinocytes and TLRs 1-3, TLR 5, TLR6, TLR10, RIG-1, protein kinase R and 








































16  |  Chapter 1
of viral components to the all sorts of PRRs during early stages of viral infection leads to 
direct NF-kB activation which results in the upregulation of pro-inflammatory cytokines but 
only activation by RLRs and some TLRs results in activation of interferon regulatory factors 
and the production of antiviral type I interferons30-37. 
These pro-inflammatory cytokines and chemokines subsequently influence the migration 
and function of APCs, with Langerhans cells and dermal DCs as main representatives 
in the skin as well as migration of T cells38,39. The wide variety of PRRs present in human 
keratinocytes reflects their ability to respond to different classes of pathogens and 
HPV infected keratinocytes should be able to sense the presence of HPV31,33,40. However 
persistent HPV infections reflect a failure of the immune system to control the infection and 
several immune escape mechanisms of HPV are present27. Although several mechanisms 
how HPV evades the innate immune system have been described, the exact role of HPV is 
undetermined and many details still remain unknown.
The relatively long time to induce spontaneous clearance of HPV in 12-18 months reflects 
the ability of HPV to efficiently evade the immune system20. To start as a result of intracellular 
shedding of HPV in the basal cells of the epithelia, HPV is able to reduce the exposure to 
the immune system in absence of a systemic viraemia revealing a delayed activation of the 
immune system. Moreover HPV infected keratinocytes display suppressed signalling to NF-
kB downstream of the PRR, IFNγ and TNFR pathways 31,41-44. This results in a lower production 
of antivirals such as type I IFNs, pro-inflammatory and chemotactic cytokines which will lead 
to a decreased attraction and activation of APC and T cells. The up regulation of UCHL-1 
is an example of how hrHPV interferes with the signalling of PPRs and hampers cytokine 
production and activation of the immune system37. 
Furthermore HPV is able to reduce the antigen-presentation to T cells as the L2 protein 
suppresses functional and phenotypic maturation of LCs44,45 and in HPV infected epithelia a 
lower number of LCs is described46,47. This latter is probably due to diminished chemokine 
production and lack of cell migration and it has been shown that HPV affects the CD40 
signalling resulting in less chemo attractants and failure to enhance immune cell migration48. 
One can conclude that HPV hampers the activation of the adaptive immune system by 
interference with function and migration of APCs present in the epithelial and is able to 
induce T-cell tolerance by non-properly activated APCs in the absence of pro-inflammatory 
signals42. 
1.2.2. Humoral immunity to HPV 
The majority of HPV infected patients fail to induce immunoglobulin-G (IgG) antibodies 
to the HPV viral capsids L1 and L2 considering the large proportion of 30-50% of patients 
who never seroconvert 49,50. During an HPV infection these IgG levels are low and these IgG 
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The presence of these IgG L1 and L2 antibodies do not protect against a re-infection and 
they neither clear HPV-induced lesions51-55. In patients HPV-induced cancer IgG antibodies 
reactive to E6 and E7 are induced with seroconversion in 20% of FIGO stage I patients to 
more than 50% in FIGO stage III56,57. In early stage disease IgG E6 more frequently where IgG 
E7 is observed in patients after viral clearance although IgG E6 and E7 levels have no effect 
on prognosis at the stage of cancer56-58. 
1.2.3. Cellular immunity to HPV 
Adaptive HPV specific CD4+ and CD8+ type 1 T-cell responses to the early oncoproteins are 
essential components of the immune response in the protection against the development 
and progression of HPV induced disease54,59-61. In a group of healthy subjects approximately 
60% of cases display a strong Th1 T-cell reactivity against the early oncoproteins E2, E6 and 
E760,62. The presence of both lesion infiltration and circulating HPV-specific CD4+ and CD8+ T 
cells is related to spontaneous regression and clearance of HPV-induced lesions whereas this 
type of immunity is weak or lacking in patients with progressive HPV-induced diseases53,63-69. 
In one third of patients with CIN or cervical cancer HPV-specific immunity to E6 and E7 is 
detected however these T cells are generally not able to produce IFNγ and consist of either 
Th2, non-polarised T cells or Tregs53,69-71. 
The importance of the Th1 HPV-specific immune response to the early HPV oncoproteins is 
supported by the data from clinical trials where regression of HPV 16-induced uVIN lesions 
is related to a strong and broad CD4+ Th1 HPV specific T-cell response54,72-76. At the time 
of spontaneous regression of HPV-infected genital warts, the lesions are infiltrated with 
CD8+ cytotoxic T-cells, CD4+ T-cells and macrophages77. The HPV specific T-cell responses 
to L1 on the other hand have no clinical significance as they are found the majority of both 
healthy controls and patients and these responses induced by preventive vaccination with 
L1 particles are not able to clear established infections54,78. 
The mechanisms underlying a failure to properly activate HPV-specific T cells or the 
tolerization of an already induced effector response are gradually unravelled. In high grade 
lesions or tumors HPV-specific effector cells may be suppressed by regulatory T cells (Tregs) 
as they are strongly associated with the prognosis of HPV induced disease and are known 
to actively inhibit the proliferation and cytokine production of activated CD4+, Th1 and 
CD8+ T cells79,80. Moreover, T-cell function can be influenced by the expression of inhibitory 
molecules, including CTLA-4, PD1, NKG2a and TIM3 by activated T cells which after cognate 
with their ligands, e.g. PD-L1 and Galactin-9 may result in suppression of their effector 
function, including the migration of T cells to the lesions81-85. Furthermore, transformed cells 
may resist an immune attack by CD8+ cytotoxic HPV specific T cell via the down regulation 
of HLA class I molecules which is frequently observed in HPV induced neoplasia 80,86,87. 








































18  |  Chapter 1
neoplasia may play a role in inhibition of the host immune response by induction of Th2 
cytokines and hampering of CD8+ T-cell activity as well41. 
1.3. Vulvar Intraepithelial Neoplasia 
VIN is a chronic premalignant skin disorder of the vulva associated with high recurrence 
rates after standard treatment12. Since 2004 VIN lesions are classified into usual type VIN 
(uVIN), historically called VIN 2 and 3, and differentiated type VIN (dVIN) according to 
the International Society for the Study of Vulvovaginal Disease (ISSVD)12,88. Condylomata 
acuminata (in old nomenclature VIN 1 lesions) are in general exophytic benign tumors 
mainly induced by low risk HPV infections HPV 6 and 1189. uVIN and dVIN differ completely 
from each other with respect to etiology, malignant potential and treatment and should 
therefore be distinguished as different entities of vulvar disease12,90. 
1.3.1 Differentiated VIN
dVIN is associated with chronic dystrophies of the vulva like lichen sclerosus and lichen 
planus. It occurs mainly in older women and its incidence accounts for <2- 5% of all VIN 
lesions12,88,91. dVIN is associated with invasive vulvar squamous cell carcinoma and its 
malignant potential is estimated 5.6 fold higher than uVIN12,91,92. dVIN has a high degree 
of cellular differentiation and the absence of widespread architectural disarray, no nuclear 
pleomorphism and no diffuse nuclear atypia12,92,93.The histopathological features of dVIN are 
much more subtle compared to uVIN and its therefore frequently confused with a benign 
dermatosis or epithelial hyperplasia and there is a high interobserver variability12,92,93. 
The incidence of dVIN was shown to increase nine fold over the last decades from 0.013 
to 0.121:100.000 women. Moreover, 32.8% of women previously diagnosed with dVIN 
developed a vulvar squamous cell carcinoma in a median time of 22.8 months91.
1.3.2. Usual VIN 
uVIN is caused by a persistent HPV infection. In the majority of the cases (90%), high risk type 
HPV16 is detected12,94-98. In old nomenclature uVIN is also referred to as Bowen’s disease, 
classic VIN, undifferentiated VIN, erythroplasia of Queyret and squamous cell hyperplasia 
with atypia89,99. Worldwide uVIN, established at 2:100.000 women, is increasing in incidence 
reflecting the increase in HPV infections in young women 35-40 years of age17,20,91,100,101. The 
incidence is higher in Caucasian women than among black, Asian or Hispanic women and 
the highest peak of reported uVIN cases is between 40-49 years of age which reveals an 
age-adjusted incidence of 5:100.000 women12,102-104. The diagnosis of uVIN is related to the 
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immunocompromised patients by either HIV infection or transplantation patients12,105. 
uVIN often causes severe and long-lasting complaints of pruritus, pain and sexual dysfunction 
in the majority of the patients12,88. The clinical features of uVIN are highly variable; lesions 
are uni- or multifocal and can differ in size, number, color and shape12,102. The surrounding 
skin or mucosa is often unaffected and the location of uVIN is often around the introitus and 
involving the labia minora although the whole vulvar and (peri)anal skin can be affected12,102. 
Importantly uVIN is associated with multicentric disease affecting cervix, vagina and/
or anus in 22-71% of uVIN patients highlighting the importance of regular gynaecological 
examination and performing cervical cytology102,106,107. 
The malignant potential of uVIN is estimated at 3-4% after treatment and 9% without 
treatment within 1 to 8 years12,108. In relation to the age of diagnosis, the malignant potential 
is established to 2.7% for women younger than 29 years in a median time of 50 months and 
of 8.5% for women older than 75 years in a median time of 25 months91,102. Because of its 
low spontaneous regression rate of estimated 1.5% and often severe symptoms, treatment 
of uVIN is often warranted12,108-110. 
1.3.2.1. Histopathological features of uVIN
uVIN histologically resembles CIN and other HPV-associated intraepithelial neoplasias and 
is diagnosed and characterised by proliferation of atypical basal cells93. The characteristic 
appearance of uVIN is recognizable already at low magnification due to obvious cytological 
and architectural abnormalities99. The epithelium is characterised by epithelial thickening 
and surface hyperkeratosis and/or parakeratosis and is composed of a closely packed 
population of undifferentiated cells with enlarged hyperchromatic nuclei with mitotic and 
apoptic activity and loss of cell maturation89,93,99,102. Moreover below the basal membrane 
lymphocyte infiltrate characterises the dermis89,93,99,102. Due to the enlarged nuclei of atypical 
cells the histologic feature of uVIN presents as crowded cells with large dark nuclei and a 
small amount of eosinophilic cytoplasm89,102 (Fig. 2a). Depending on the level of the atypical 
proliferating cells respectively above the lower two-thirds of the epithelium the uVIN lesion 
is classified as either VIN 2 or VIN 3, nowadays high grade uVIN lesions89. uVIN is divided into 
warty and basaloid types based on the architecture and appearance of the intraepithelial 
lesions but these subtypes are only part of a spectrum of uVIN with overlapping morphology 
and there is little need in dividing into these subtypes89,99. In case of cell invasion through the 
basal membrane into the dermis either a microinvasive (<1mm) or macroinvasive (>1mm) 
squamous cell carcinoma is diagnosed. The differentiation, however, especially between 
uVIN and early microinvasive carcinoma may be difficult. Invasion is suggested by the 
following features: irregularity in the size and shape of nests, cytoplasmic eosinophilia of 
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Additional immunohistochemistry by p16, Ki67 (Fig. 2b+2c) or p53 may be of help in 
the determination of a high grade uVIN lesion. p16 is a surrogate marker for HPV which 
nuclei and cytoplasmic staining correlated with a high-risk HPV infection because the early 
oncoprotein E7 inactivates the retinoblastoma protein (pRb) resulting in overexpression 
of p16 in HPV infected epithelia18,89,93,99,111. p16 is a tumor suppressor protein that inhibits 
the cyclin-dependent kinases which phosphorylate the pRb, responsible for maintenance 
of the cell cycle and apoptosis18. Differentiated VIN is usually p16 negative99. Furthermore 
staining for Ki67 a proliferation marker was shown to be well correlated with the presence 
of HPV DNA and can help in the distinction of the level and type of VIN lesions with positive 
staining throughout the epithelial thickness in case of high grade uVIN89,99. Staining for the 
overexpression of mutated p53 aids the detection of dVIN as 90% of the dVIN cases express 
mutated p53, whereas this is generally absent in uVIN cases due to the expression of the 
oncoprotein E689,93,99. 
1.3.2.2. Therapies in uVIN
Treatments for uVIN are aimed at both relief of symptoms and prevention of progression 
into (micro-) invasive lesions. Expectative management by close follow up of the uVIN lesions 
is advocated in case of no complaints and no suspicion of malignant disease112. Nowadays 
conventional surgical treatments as surgery or laser ablation are increasingly replaced by 
immunotherapy as imiquimod (Aldara®), both in standardised and experimental settings, 
with promising clinical responses however in a notable number of patients these therapies 
fail to induce clinical responses72,74,113-115. 
1.3.2.2.1. Surgical treatment of uVIN 
Surgical treatment options are: cold knife surgery, laser CO2 therapy or loop electrosurgical 
procedure (LEEP)116. Local excision by cold knife surgery aims to remove all visible lesions 
and is still performed as the therapy of choice. If positive excision borders predict the 
development of recurrent disease is still under debate although they do not predict 
development of invasive disease and extensive surgeries do therefore not guarantee a 
cure and should be avoided12,102,108-110,117-119. A 5 mm peripheral margin is generally accepted 
for the management of local resection of uVIN and a resection up to 4 mm in depth is 
recommended however in mucosal areas the resection depth does not need to exceed 1 
mm since there are no sebaceous glands in this epithelial area102,120. Recurrence rates range 
from 20-40% and recurrences are associated with multifocal disease and smoking102,118,119,121. 































































































































































































22  |  Chapter 1
Laser therapy is a destructive technique that preserves normal vulvar anatomy and function 
resulting in good cosmetic and functional results. The response rate and prevention of 
development of invasive vulvar cancer are warranted by this therapy even in wide multifocal 
lesions12,102,122. The disadvantage of this method is that due to the tissue destruction no 
tissue for histological examination is available. Therefore, prior to surgery several biopsies 
should be performed in order to exclude (micro) invasion of the uVIN lesion as much as 
possible12,102. In the thickest part of the lesion the (micro) invasion is most likely and biopsies 
should be concentrated here102. The complete response rate of laser surgery is 75% and 
recurrence rates are comparable to excision. The reported shorter recurrence-free survival 
after laser therapy is probably a reflection of a higher proportion of multifocal lesions 
treated with laser vaporisation rather than a reflection of therapy failure102,116,119,121,123.
By LEEP a wide local excision of the uVIN lesion can be performed with the advantage that 
the resected tissue is available for histologic examination102. The recurrence rate of LEEP is 
estimated at 20% at 48 months follow up124. 
1.3.2.2.2. Immunotherapies in treatment of uVIN
Regarding the potential disfiguring interventions of conventional therapies related to 
psychosexual problems, several medical and immunotherapies are nowadays replacing 
conventional therapies in both standardised (imiquimod) and experimental settings12,108,121,125. 
However to date none of these therapies are approved for VIN treatment by the FDA (Food 
and Drug Adminstration)102. Immunotherapy is promising, however, some patients are 
refractory to therapy72,74,113-115.
Imiquimod 
Imiquimod is an immune modifier and induces T-cell activation by activation of macrophages 
and pro-inflammatory cytokine release and has antiviral and antitumor activity12,126,127. 
Topical application of imiquimod crème preserves the anatomy and function of the vulva 
and by inhibition of viral replication, the causative agent HPV is targeted12. Imiquimod 
induces viral clearance, normalisation of immune cell infiltrate and a high number of clinical 
responses ranging from complete responses of 35-81% and partial responses in 10-46% 
of uVIN lesions with low recurrence rates in long term follow up113,128,129. The side effects 
as local inflammatory reaction, itching, burning and flu-like symptoms are common and 
can be treated with NSAIDs without interference with imiquimod therapy130. Responses to 
imiquimod are associated with pre-existing HPV-specific T-cell responses whereas imiquimod 
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Photodynamic Therapy (PDT) 
Photodynamic therapy induces oxygen-induced cell death by use of a tumor-localizing 
photosensitizer, 5-aminolevulinic acid (ALA), in combination with non-thermal light102,131. 
PDT results in direct tumor destruction and reduces destruction of normal surrounding tissue 
and activates the local immune system by activation of APCs, recruitment of effector cells 
and activation of tumor specific immunity132,133. Responses range from 40-60% and similar 
efficacy and recurrences were found in PDT compared to laser and local excision121,134-136. 
Advantages of PDT are minimal tissue destruction, preservation of normal anatomy and 
short healing time121. 
Therapeutic vaccination 
Preventive HPV vaccines are aimed at the induction of Ig antibodies and prevent HPV 
infection and subsequent lower genital tract neoplasia137. In contrast, therapeutic vaccines 
aim to induce or reinforce HPV specific CD4+ and CD8+ T-cell responses and destroy HPV-
infected cells138. Several types of therapeutic HPV vaccines have been developed showing 
different rates of immunogenicity and clinical success138,139. 
Two recombinant vaccines; TA-HPV encoding HPV 16 and 18 E6 and E7 and TA-CIN consisting 
of HPV 16 L2E6E7 fusion proteins were used either single doses or booster vaccinations in 
VIN patients. Despite clinical responses there was no obvious correlation with the vaccine 
induced immune response neither after a three booster regimen with TA-CIN140-142. After 
vaccination the antibody and T-cell responses to L1 were stimulated although they were 
not sufficient to clear the lesions and clinical responses were low143. Reinforcement of HPV 
specific T-cell response by therapeutic vaccination has shown promising clinical responses, 
especially when combined with imiquimod72,74,114. After 8 weeks of topical imiquimod 
application followed by three doses of TA-CIN in a 4 week interval, complete regression 
percentage was seen in 68%74. Importantly, an increased CD4+ and CD8+ T cell infiltration in 
the lesions was associated with a favourable clinical outcome74.
A synthetic long peptide (SLP) vaccine composed of HPV16 E6 and E7 peptides induced strong 
HPV-specific immune responses associated with clinical responses in high grade VIN patients. 
In patients with larger lesions, the HPV-specific immune response was lower compared to 
the small lesions and there were more vaccine induced Tregs in these patients72,144. The 
correlation between clinical effectiveness and immune responses is confirmed in a second 
vaccination trial where the HPV-16 SLP vaccine for HPV 16 positive uVIN was combined with 
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1.3.2.2.3. Antiviral therapies
Cidofovir has antiviral activity and may induce apoptosis of the HPV infected cells102. In a 
small cohort 25% of patients showed a complete response after therapy with 1% cidofovir146. 
Reported side effects are ulceration at application site and pilous areas were refractory to 
therapy146. 
In HIV positive patients topical cidofovir 1% was efficient in short term treatment with 15% 
complete responses, 26% partial responses and 21% stable disease of high grade peri-anal 
intraepithelial neoplasia (PAIN) and VIN147. Moreover side effects of pain, burning, irritation 
and ulceration of skin were acceptable147. In a recent randomised controlled trial cidofovir 
1% was compared to imiquimod 5% revealing comparable results of approximately 45% 
complete responses, 87% treatment adherence and 40% of adverse events. Thus in addition 
to imiquimod, cidofovir also forms an active, safe and feasible alternative to surgery in 
treatment of uVIN148. 
Topical IFNα has been used in uVIN with a clinical response of 67% although the local side 
effects and high costs ensured that this therapy was no longer used for uVIN therapy149. A 
different form of IFNα, pegylated-IFNα, is now available with different pharmacokinetic and 
chemical properties as well as less side effects. Pegylated-IFNα potentially is of interest to 
treat uVIN since IFNα is known to play an important role in activation of durable anti tumor 
responses because IFNα drives the generation of IFNγ producing CD4+ and CD8+ T cells and 
promotes the proliferation and survival of T cells150-152. 
1.4. Immune responses in uVIN 
Where cellular immune responses against HPV protect against the development and 
progression of HPV-induced disease, these responses are either weak or absent in most 
patients with uVIN54,59-61. A lack of proper chemokine signal for DCs to migrate towards the 
lymph node and present HPV to naïve T cells is an explanation for the lack or insufficient HPV-
specific immune response153. Systemic HPV-16 specific Th1 T-cell responses are detected in up 
to 50% of patients with HPV 16 induced high grade VIN. These responses are not associated 
with spontaneous regression of the uVIN lesions, however, these pre-existing responses 
are suggested to positively correlate with clinical efficacy of immunotherapy54,61,74,115,140. 
Treatment failure on the other hand, is related to absence of HPV specific immunity and the 
high number of recurrences in uVIN after conventional treatment may as well be related to 
absent or weak HPV specific immune responses72,74,115. 
The local immune response in the microenvironment of uVIN is characterised by an 
immune active dermis and immunosuppressive epidermis since the epidermis of uVIN is 
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LCs while the dermis displays an influx of mature DCs, NK cells and both CD4+ and CD8+ T 
cells154,155. Moreover, some uVIN lesions are infiltrated by high numbers of Tregs74,113,115,154,156. 
Clinical response to immunotherapy in uVIN is associated with normalisation of immune 
cell counts and an increase in intralesional CD8+ T cells as well to low numbers of Tregs and 
lower numbers of macrophages74,115,156,157. In addition, HLA class I expression was present 
in clinical responders to PDT and there was an increase in infiltrating CD8+ T cells after 
therapy in these lesions157. Failure to respond to immunotherapy may be related to a local 
immunosuppressive microenvironment since clinical responders were highly infiltrated with 
DC/LCs, CD4+ and CD8+ T cells before vaccination 74,113-115,154,156. Despite these suggestions 
however knowledge on the uVIN microenvironment is limited. 
1.5. Outline thesis
With the studies presented in this thesis we aimed to gain more basic knowledge about 
the pivotal role of both the local and systemic immune responses in uVIN as a prelude 
to understand non-responsiveness to immunotherapy and to optimize the use of 
immunotherapeutic approaches for HPV-associated anogenital disease. Therefore we 
studied the local and systemic immune responses in uVIN patients extensively. In Chapter 2 
a detailed review of the literature on innate and adaptive immune responses and potential 
causes for failure of immunotherapy in uVIN patients is given. In Chapter 3 we studied the 
potential clinical prognostic factors of recurrence and progression in uVIN as this allows 
us better to estimate the impact of the immunological responses observed in this patient 
group. 
The role of T cells in the protection and regression of uVIN lesions indicate the importance 
of the infiltration in HPV-infected/transformed cells. HLA downregulation might allow 
premalignant lesions as uVIN to escape immune surveillance and to progress into invasive 
cancer. In Chapter 4 the alterations of both classical and non-classical HLA molecules in uVIN 
patients were studied. We show that (partial) loss of HLA is not hard-wired (e.g. genetically 
caused) but soft-wired as it can be restored for instance by exposure to IFNγ. 
In Chapter 5 we focus on the expression of a number of known immune inhibitory molecules 
which may interfere with the function of lesion-infiltrating immune cells. We analysed the 
expression of IDO (Indoleamine 2,3-dioxygenase) and Galectins 1, -3 and -9 within the 
tumor microenvironment and the expression of inhibitory molecules PD1, TIM3 and NKG2a 
on T cells in relation to immune infiltration and clinical outcome. 
Subsequently in Chapter 6 we describe the infiltration of uVIN by different types of myeloid 
cells as determined by the expression of CD14+, CD33+ and CD163+ and their association 
with clinical outcome of uVIN lesions, which is subsequently followed by integrated analysis 
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Finally, the data of our first vaccination trial in patients with uVIN suggested that there 
might be a difference in the patient’s capacity to respond to the first vaccination144. A 
strong response to the first vaccine dose is associated with complete clinical success. We 
hypothesized that there may be differences in the immune status of the treated patients 
which can explain their reactivity to vaccination. In Chapter 7 we analysed the expression 
of inhibitor receptors on T-cells (TIM3, PD1, NKG2a, CD94 and CTLA4) and macrophages in 
blood of clinical responders and non-responders to estimate potential biomarkers involved 
in recurrence or progression of uVIN lesions. Furthermore in Chapter 7 we focus on signal 
transduction activators of transcription (STAT) phosphorylation in different immune cells 
after stimulation with cytokines and immunomodulatory agents as IFNα and GM-CSF. 
The general discussion Chapter 8 gives an overview of the findings presented in this thesis 
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Abstract 
A failure of the immune system to launch a strong and effective immune response to high 
risk HPV is related to viral persistence and the development of anogenital (pre)malignant 
lesions such as vulvar intraepithelial neoplasia (VIN). Different forms of immunotherapy, 
aimed at overcoming the inertia of the immune system, have been developed and met 
with clinical success. Unfortunately these, in principal, successful therapeutic approaches 
also fail to induce clinical responses in a substantial number of cases. In this review we 
summarize the traits of the immune response to HPV in healthy individuals and in patients 
with HPV induced neoplasia. We discuss the potential mechanisms involved in the escape of 
HPV-induced lesions from the immune system and indicate gaps in our knowledge. Finally, 
the interaction between the immune system and VIN is discussed with a special focus on the 
different forms of immunotherapy applied to treat VIN and the potential causes of therapy 
failure. We conclude that there are a number of pre-existing conditions that determine the 
patient’s responsiveness to immunotherapy and that an immunotherapeutic strategy in 
which different aspects of immune failure are attacked by complementary approaches will 
improve the clinical response rate. 
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Introduction 
Vulvar intraepithelial neoplasia (VIN) is a chronic vulvar skin disease with malignant 
potential that often causes severe and long-lasting complaints of pruritis, pain and sexual 
dysfunction.[1] In 2004, VIN lesions were classified according to the International Society for 
the Study of Vulvovaginal Disease into; usual type VIN (uVIN), historically called VIN 2 and 
3, and differentiated type VIN (dVIN).[1,2] The incidence of dVIN accounts for less than 5% 
of all VIN lesions, occurs in older women, and is associated with chronic dystrophies of the 
vulva such as lichen sclerosus and lichen planus.[1-3] dVIN has a high malignant potential 
(5.6 fold compared to uVIN).[1,3] UVIN is caused by a persistent human papilloma virus 
(HPV) infection, in particular HPV type 16, which is present in over 90% of cases.[1,4,5] The 
incidence of uVIN, approximately two per 100,000 women, is increasing worldwide and is 
related to the increase of HPV infections in young women.[3,6-9] UVIN occurs predominantly 
in younger women (peak incidence 40 years), tends to be multifocal in 60% of patients and is 
correlated with smoking.[1,2] Progression rates to malignancy of uVIN are estimated at 3-4% 
after treatment and 9% without treatment in 1–8 years, whereas spontaneous regression 
of VIN occurs in less than 1.5%.[10,11] Treatments are therefore aimed at both relief of 
symptoms and prevention of progression into (micro-)invasive lesions. Conventional surgical 
treatment is often disfiguring, mutilating and suboptimal, as reflected by the high recurrence 
rates of 20-40% and physical and psychological morbidities.[10,12-14] 
HPV is a DNA virus that infects the basal cells of the genital epithelia, in particular the 
squamous epithelium, and is the most common sexually transmitted pathogen worldwide.
[9,15] Over 100 types of HPV are identified, which are subdivided into low risk (non-
oncogenic; e.g. lr-HPV 6 and 11) and high risk HPV (oncogenic; e.g. hr-HPV 16 and 18)[16] 
Approximately 60% of young women are infected with either an hr-HPV (40%) or lr-HPV 
(20%) within the5-year period after they become sexually active, while the lifetime risk 
of acquiring an HPV infection is estimated at 80%.[8,9,17,18] In most cases the infection 
is asymptomatic and is cleared within 1 year.[8,17] Persistent infections only develop 
in less than 10% of the infected women and are causally related to the development of 
intraepithelial neoplasia of the cervix (CIN), vagina (VAIN), anus (AIN) and/or vulva (VIN) 
and their subsequent progression to invasive squamous- or adeno-carcinoma.[8,9,17,19,20] 
Multicentric disease affecting the cervix, vagina and/or anus have been described in 22–
71% of VIN patients.[21,22] The risk factors associated with HPV-induced disease are the 
lifetime number of sexual partners, smoking (as it results in a decreased local immune 
response), and the use of oral contraceptives (of which the estrogens may increase cellular 
proliferation via an effect on the early oncoproteins of HPV).[23,24] 
The early viral oncoproteins of HPV (E1, E2 and E4–E7) are the key factors in progression 
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maintenance, replication and progression of a potential HPV associated lesion.[15,16,25,26] 
These early oncoproteins influence several signal transduction pathways such as the cell 
proliferation pathway due to inactivation of cell cycle arrest protein p16INK4A, the TNF-α and 
IFN pathways.[26] The pivotal players E6 and E7 are constitutively expressed in malignant 
tissue and their expression results in enhanced cell proliferation and subsequent viral 
genome replication.[15] E6 downregulates p53 and expression of the proapoptotic protein 
BAK, leading to resistance to apoptosis and increased chromosomal instability.[25] E7 binds 
to and degrades the retinoblastoma susceptibility protein (pRB), which leads to apoptosis. 
By transcriptional activation of the cyclin A and cyclin E genes, E7 regulates cell proliferation 
and downregulates p16INK4A, which can counteract the function of E6.[25] The E1 protein is 
essential in HPV replication where the E2 protein acts both as a replication and transcription 
activator.[16] E2 represses the viral promoter of E6 and E7 during early stages of infection.
[27] Carcinogenic progression is accompanied by integration of the viral genome into the 
host cell DNA which disrupts E1 and E2 function and enables upregulation of E6 and E7 
expression.[27] E5 appears to be important in the early course of infection by stimulating 
cell growth and preventing apoptosis following DNA damage.[25] 
The high prevalence of hr-HPV infection in uVIN has lead to the suggestion that therapy 
should aim for the immunological eradication of virus-infected cells. Different types of 
local and systemic forms of immunotherapy have already been described with encouraging 
clinical results; in a number of trials almost half of the treated patients had durable complete 
lesion regression.[28-33] Notwithstanding these successes, these therapeutic approaches 
also fail to induce clinical responses in a substantial number of cases. The aim of this review 
is to provide insight into the nature of HPV-induced disease, to indicate the gaps in our 
knowledge of the interaction between uVIN and the immune system and to identify the 
possible causes of immunotherapy failure as a guide to optimize the immunotherapy of 
uVIN.
 
Immunity to HPV infection 
Infection with HPV occurs when the epithelial surface is disrupted through minor damage of 
the genital mucosa, thereby allowing access to the basal cells of the epithelium.[25] Here, 
the early proteins E6 and E7 are expressed.[15] In the suprabasal layers, E1, E2 and E5 are 
expressed and viral replication takes place.[15] In the most superficial layers, newly made 
viral DNA is encapsulated by the late structural proteins L1 and L2 and the new virions are 
released by wear and tear of the epithelial surface.[15] The absence of a cytopathic phase 
or systemic viraemia reduces the potential exposure of HPV to the immune system and 
causes delay in the activation of the immune system. This is not absolute as over 80% of 
the HPV infections are controlled within 2 years after infection.[8,17,34] There is strong 
evidence that both the innate and the adaptive arms of the immune system play a role in 
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Innate immunity
The innate immune system acts as the first line of defense against invading viruses. 
Keratinocytes express pathogen recognition receptors (PRRs), including the membrane 
bound toll-like receptors (TLR), the cytoplasmic NOD-like receptors (NLR) and RNA helicase 
retinoic-acid-inducible gene I (RIG-1) and melanoma differentiation-associated gene 5 
(MDA5).[35-39] The latter two recognize double-stranded viral RNA in the cytoplasm and 
are constitutively expressed in human keratinocytes.[36-38] The TLR family (TLR 1-10) 
recognizes different molecular patterns; TLR3 recognizes double-stranded RNA, TLR7 
and TLR8 recognize single-stranded RNA found during viral replication, whereas TLR9 
recognizes unmethylated CpG motifs common in viral DNA.[35,36,40] TLR3 is expressed in 
undifferentiated keratinocytes while the expression of TLR9 in undifferentiated keratinocytes 
is debated or present at very low levels.[38-40] Both TLR3 and TLR9 are capable of regulating 
proinflammatory responses, whereas TLR7 and TLR8 were not functionally expressed in 
undifferentiated keratinocytes.[38-40] However, human keratinocytes are able to upregulate 
TLR7 in response to stimulation with poly I:C, which is a strong agonist for TLR3, RIG-I and 
MDA5, suggesting that under inflammatory conditions the keratinocytes may become 
responsive to immune-modifying TLR7 agonists.[37] Binding of viral components to these 
receptors during early stages of viral infection leads to direct NF-kappa-B activation, which 
results in upregulation of pro-inflammatory cytokines, and/or activation of type I interferon 
(IFN) response genes, including transcription factors IRF3 and IRF7 regulating the production 
of antiviral and pro-inflammatory cytokines (e.g. GM-CSF, IL-1β, TNF-α, IL-10, IL-12, MIP3α).
[35-40] Proliferative cytokines and chemokines influence the migration and function of 
antigen presenting cells (APCs), with Langerhans cells (LCs) and dermal dendritic cells (DCs) 
being their main representatives in the skin.[41,42] This wide variety of PRRs present in 
human keratinocytes reflects their ability to respond to different classes of pathogens and 
HPV infected keratinocytes should be able to detect the presence of HPV genomic DNA 
directly via TLR9 or indirectly via RIG-I.[36,38] 
Cellular immunity 
The important role of the immune system in protection against HPV-induced lesions is 
demonstrated by the high incidence of persistent HPV infections and subsequent HPV-
related malignancies in immunosuppressed individuals.[43,44] On the other hand, only a 
minority of infected non-immunosuppressed subjects develop progressing epithelial lesions 
or cancer.[8,9,17-20,45] Composite data indicate the importance of CD4+ T-cells in the 
control of HPV-induced disease as more severe lesions are observed in HIV+ patients with low 
numbers of circulating CD4+ T-cells.[45,46] In addition, the increase in CD4 cell count after 
anti-retroviral treatment correlates with the regression of HPV-induced CIN lesions in HIV+ 
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viral antigens by activated LCs and DCs. Depending on the different environmental cues in 
the microenvironment; the APC will adopt a certain state of differentiation and migrate to 
the local lymphoid tissues to present antigens to naïve T-cells. Depending on the status of 
the APC, as reflected by the levels of co-stimulatory or inhibitory molecules and its cytokine 
production (e.g. IL-12 or IL-10), a T-cell response will be induced that can consist of different 
types of CD8+ T-cells, CD4+ helper T-cells (Th-cells) and regulatory T-cells (Tregs).[47,48] At 
the time of spontaneous regression of HPV-infected genital warts, the lesions are infiltrated 
with CD8+ cytotoxic T-cells (CTL), CD4+ T-cells and macrophages.[49] Approximately 60% of 
the healthy subjects display a directly ex-vivo detectable type 1 (i.e. IFNγ associated) T-cell 
reactivity against the early oncoproteins E2, E6 and E7.[50,51] Spontaneous regression and 
clearance of HPV-induced lesions is associated with the presence of both lesion infiltration 
and circulating CD4+ and CD8+ T-cells directed against the early oncoproteins whereas this 
type of immunity is weak or lacking in patients with progressive HPV-induced diseases.
[45,52-58] These data indicate that type 1 T-cell responses to the HPV 16 early proteins play 
an important role in the protection against persistent HPV infection.This notion is sustained 
by the data obtained from clinical trials in which the full regression of HPV 16-induced high-
grade vulvar lesions is strongly associated with the presence of a proliferative or type 1 HPV-
specific T-cell response prior to the treatment.[30,59] Moreover, clinical regression after 
immunotherapy by vaccination is associated with the strength (i.e. breadth and magnitude) 
of the vaccine-induced proliferative and/or IFNγ-associated HPV-specific T-cell response.
[29,31,60,61] Notably, a directly ex-vivo detectable type 1 T-cell reactivity against the late 
structural antigen L1 is not only found in healthy subjects but also in the majority of patients 
with HPV-induced disease.[55] Furthermore, strong type 1 L1-specific T-cell responses are 
induced by vaccination with L1 virus like particles (VLPs), yet these vaccinations are not able 
to induce clearance of established infections.[55,62] Together these observations indicate 
that the response against L1 is not essential for T-cell mediated protection once a person is 
infected by hr-HPV.
Humoral immunity
Antibodies to the HPV viral capsids L1 and L2 can be detected from approximately 6 months 
post infection although 30-50% of patients with persistent infections never seroconvert.
[63,64] Immunoglobulin-G (IgG) seroconversion rates appear to be higher among women 
with persistent infection over a long period of time.[65] In general, IgG antibody responses 
to HPV L1 and L2 are weak during infection (i.e. at low levels) and do not protect against 
re-infection with the same HPV type or clear HPV-induced lesions as discussed above.[66-
68] However, the induction of high levels of antibodies to the virus capsid protein – via 
prophylactic vaccination with VLPs – prevents viral infection very efficiently and has led 
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prophylactic vaccine protection times depend on follow-up in the clinical trials and range 
from 4 to 9 years.[69-71] However, no accelerated clearance of existing viral infections has 
been observed despite these high antibody levels.[62] Antibodies reactive to E6 and E7 are 
also frequently found in patients with HPV-induced cancer and their induction appears to 
be dependent on the clinical stage of disease, with approximately 20% of seroconverters at 
FIGO stage I up to more than 50% in stage III.[72,73] Particularly in early stage disease, the 
antibody response to HPV 16 E6 is more frequently found compared to E7.[72,73] While 
it does not appear to affect prognosis at the stage of cancer, positive humoral reactivity 
to E7 was observed in patients who had cleared the viral infection rather than patients 
with persistent infection.[74] Although these antibodies are not expected to exert any 
direct effect on infected or transformed cells, their presence indicates active priming of 
an underlying T-cell response. Notably, HPV-specific T-cell responses are also found more 
frequently in cervical cancer patients with more advanced stages of disease.[75]
Immunogenetics 
Besides environmental and lifestyle factors, host genetic factors are likely to play a role in 
persistence and appearance of HPV-induced neoplasia. The antigen processing machinery 
(APM) and human leukocyte antigen (HLA) class I molecules are key in the presentation 
of antigenic peptides to CD8+ T cells and, therefore, are important in the destruction of 
virally infected or transformed cells.[76,77] Defects in the APM and HLA molecules thus may 
contribute to viral escape, persistence and ultimately induce malignancies. From an array 
of 13 non-synonymous coding single nucleotide polymorphisms (SNPs) in the LMP2, LMP7, 
TAP1, TAP2, and ERAP1 genes, the allele distributions at the LMP7-145, TAP2-651, ERAP1-
12, and ERAP1-730 loci differed significantly between cases and controls with the major 
allele at the LMP7 and TAP2 loci and the minor allele at both ERAP1 loci associated with 
increased risk for cervical carcinoma.[76,77]
Over 800 different HLA class I and class II alleles have been defined and it is possible that 
some HLA molecules may be more or less suitable to present HPV-derived peptides and as 
such influence the ability to clear an HPV infection or HPV-induced neoplasia.[78] Indeed, the 
susceptibility or resistance to HPV infection and HPV-induced lesions has been associated to 
particular HLA alleles, albeit that many of these findings were not consistent across different 
populations.[79] A protective effect of HLA class II DRB1*13/DBQ1*0603 alleles is the most 
consistently found association, although the effect was only significant in 47% of studies.
[79] HLA-DRB1*07 and DRB1*15/DQB1*0602 have been associated with an increased risk 
of HPV-induced cervical neoplasia in The Netherlands and we confirmed that HLA-DRB1*07 
was overrepresented in Dutch patients with HPV 16-positive cervical cancer whereas HLA-
DRB1*13 was underexpressed in patients with cervical cancer compared to controls.[75,80] 
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allele combinations present in >5% of women with squamous cell carcinoma of the cervix, 30 
were significantly associated with an increased risk, with all but one including DQB1*0301.
[81] Among the six co-expressed alleles that were associated with a decreased risk, four 
comprised DQB1*02.[81] The particular associations between disease and HLA class II 
alleles but not HLA class I alleles gain extra weight through the detection of predominant 
HLA class II –restricted CD4+ T-cell responses over HLA class I-restricted CD8 T-cell responses 
in healthy individuals and patients.[61,82,83] Furthermore a study of 49 candidate immune 
response and DNA repair genes revealed that a SNP in the innate immune gene IRF3 was 
associated with increased HPV persistence.[84] Reports on the influence of particular 
SNPs in the IL-10 gene are debated and those described to influence the production of the 
immunosuppressive cytokine TGFβ did not differ between cases and controls.[85-87] A SNP 
in the chemokine receptor 2 – which binds the macrophage recruiting chemokine MCP-1 – 
was associated with a decreased risk for cervical cancer.[86] SNPs in the promoter region of 
TNFγ or the receptor of IL-4 were associated with increased risk for cervical cancer.[86,88]
Other potential genetic factors involved in the progression of HPV-induced neoplasia 
may comprise genetic differences in the genes of the innate immune response (e.g. PRR 
pathways, activation of transcription factors), genes of the antigen presenting pathway, 
genes involved in APC activation and migration, or genes involved in T-cell migration and/
or differentiation and in chemo- or cytokine production. For example, WHIM (Warts, 
Hypogammaglobulinemia, Infections, and Myelocathexis) syndrome is a rare congenital 
immunodeficiency disorder characterized by high susceptibility to HPV infection and is 
associated with autosomal dominant heterozygous mutations in the gene for the CXCR4 
chemokine receptor.[89] WHIM is characterized by the marked reduction of circulating 
naïve T cells. T cells bearing this mutated chemokine receptor display an increased migratory 
response to CXCL12. It has been suggested that the increased migratory response results in 
the capture of these cells in the bone marrow [89], removing them from the periphery and 
as such potentially precluding their response to HPV.
Immune escape in HPV-induced disease - lessons from cervical neoplasias
Persistent viral infections reflect a failure of the host’s immune system to control infection 
where several immune escape mechanisms of HPV are present [Box 1] (reviewed in [26,90]). 
While viral clearance or regression is associated with the presence of circulating CD4+ and 
CD8+ T-cells, viral persistence corresponds with a weak or absent early antigen specific T-cell 
response.[45,53,55,58,75] The systemic HPV-specific immunity to E6 and E7 is detected in 
approximately one third of patients with CIN or cervical cancer. The T-cell responses detected 
are generally not associated with the capacity to produce IFNy and can consist of Th2 cells, 
non-polarized T-cells, or even regulatory T-cells.[45,56,58,59,75,82,91,92] Remarkably, 
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are broad and aimed at both E6 and E7. When stimulated ex-vivo, they produce only low 
amounts of IFNy, but in the presence of APC-stimulating compounds cytokine production 
increases.[82,83] Interestingly, in cervical cancer patients, deep infiltration of the tumor 
within the normal tissue correlates with the presence of circulating HPV-specific T-cells and 
a better survival of patients.[75] Cumulatively, these studies suggest that the T-cells are 
locally not sufficiently stimulated and may even be suppressed.
Impaired antigen presentation and activation of innate immunity
Initial infection by HPV causes a cascade of viral gene expression, replication of the viral 
genome and enhanced cell proliferation.[26] One of the major sensors of DNA viruses 
is TLR9. Expression of TLR9 is either lacking or at very low levels in the undifferentiated 
basal cell layer of the squamous epithelia.[38] Furthermore, infection of keratinocytes 
with recombinant retroviruses expressing the HPV 16 E6 and E7 oncoproteins inhibits TLR9 
transcription and facilitates functional loss of TLR9-regulated pathways.[93] This indicates 
that infected keratinocytes are not able to signal via TLR9, however, other viral PRRs might be 
employed.[38] Despite the presence of these other intracellular PRRs which allow infected 
cells to attract the immune system, the mean clearance time of HPV is 12-18 months, 
indicating that HPV still manages to delay or escape recognition and immune activation.
[8,17] HPV does not affect the expression of different virus-sensing PRR, but genome wide 
expression profiling studies have demonstrated that the presence of HPV was associated 
with downregulation of components of the antigen presenting pathway, the inflammasome, 
the production of antivirals such as type I interferons, pro-inflammatory and chemotactic 
cytokines and activated pathogen receptors. Notably, many of the downregulated genes are 
found in a network that is strongly interconnected by IL-1β, a crucial cytokine to activate 
adaptive immunity.[38] HPV+ keratinocytes were also shown to respond less well to 
interferon stimulation.[94,95] This concurs with the observation that interferon-inducible 
genes are downregulated via inhibition of the JAK-STAT activation response pathway and 
downregulation of the active STAT 1 (i.e. phosphorylated or pSTAT-1), which is the primary 
regulator of the interferon response.[38,96] 
In addition, HPV might also hamper activation of the adaptive immune system by regulating 
the function and migration of antigen presenting cells present in the epithelia. When viral 
particles are taken up by LC this does not necessarily result in an antiviral response. The 
structural L2 protein of HPV is able to suppress phenotypic and functional maturation of 
LCs and therefore can limit adequate antigen presentation to T-cells.[97,98] Furthermore, 
the number of LCs is reduced in HPV infected lesions compared to normal tissue.[99-101] In 
one of our studies the number of LCs varied extensively in cervical cancer and was related 
to increased migration under the influence of TNF-α.[41] The lower number of LCs is thus 
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precursor cells to replenish LC migrated out of the tissue.[42] Last but not least, the absence 
of pro-inflammatory signals in HPV-infected epithelia can result in inappropriately activated 
APCs and upon cognate interaction with T-cells they will induce T-cell tolerance.(reviewed 
in [102]) 
Alterations in Human Leukocyte Antigen (HLA) expression 
Cervical cancer patients in whom circulating HPV-specific T-cells are detected display a 
longer survival after chemoradiotherapy than patients without a detectable T-cell response.
[75] These T-cells may contribute to the antitumor response or reflect an ongoing CD8+ 
T-cell sustained tumor-specific immune response as they are only found in patients with HLA 
class I positive tumors.[103] Downregulation of HLA class I (HLA- A, -B and -C) is frequently 
observed in cervical neoplasia and may result in an escape of the tumor cells from cytotoxic 
T-cell attack.[80,104] Defects in HLA class I expression are caused by a variety of mechanisms, 
including loss of heterozygosity at chromosome 6p, β2-m or HLA class I mutations, defective 
expression and function of components of the antigen processing machinery (APM) and/or 
due to lack of IFNy expression.(reviewed in [105])[80,104,106] The HPV-encoded E5 and E7 
proteins have also been implicated in downregulation of HLA class I.[26] Downregulation 
of HLA-A is associated with worse survival of patients with cancer.[107] Induction of HLA 
class II molecules is observed in the majority of cancers and can be mediated by cytokines 
such as IFNy.[108] HLA-II expression (HLA-DR, -DQ and -DP) was observed in 67% of CIN 
I, 58% of CIN II, 93% of CIN III and in 75% of cervical cancers.[108] In each histological 
category HLA-DR was most commonly expressed and HLA-DQ least commonly expressed.
[108] Interestingly, analysis of CD4+ HPV 16- and 18- specific tumor infiltrating T-cells (TILs) 
revealed that the vast majority (>80%) of CD4+ T-cells were restricted to HLA-DQ or –DP and 
not to HLA-DR, suggesting that immune escape at the HLA-DQ-restricted CD4+ T-cell level 
may have occurred.[82] This would also agree with the protective effect of some HLA-DR/
DQ combinations found to be associated with protection against HPV-induced cancer.[79] 
The expression of HLA-class II molecules might contribute to a successful response since 
activated CD4+ Th1 cells in the tumor environment enhance the recruitment, proliferation 
and effector function of CD8+ T-cells.[109] However, it is still unclear if the expression of 
HLA class II by tumor cells can also hamper the immune response and may favor tumor 
outgrowth as HLA class II may also induce tumor promoting signaling by rendering the CD4+ 
T-cells anergic after cognate interactions in the presence of immunoinhibitory cytokines and 
lack of co-stimulatory molecules as CD40 or by activating/inducing Tregs.[110] 
Next to the classical HLA class I and II molecules, cervical tumor cells have been reported 
to express HLA-G. (Figure 1)[111-113] This non-classical HLA type plays an important 
role in tumor-driven immune escape as it inhibits the function of natural killer (NK) cells, 
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transcripts ILT-2 and ILT-4 and the killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4).
[111] The expression of HLA-G in cervical lesions is associated with progression from pre-
malignant to malignant lesions and may play a role in inhibiting effective host immune 
responses by inducing Th2 cytokines.[111,112] 
Another non-classical HLA type is HLA-E, which by engagement of the inhibitory CD94/
NKG2A receptor expressed by NK and CTLs hampers the activity of these cells in the tumor. 
(Figure 1)[114] While NK-cells are not frequently observed, CTLs are detected in the tumors 
of many patients.[107,115] Notably, up to 50% of the CD8+ TILs expressed the inhibiting 
CD94/NKG2A receptor, whereas CD4+ TILs hardly expressed this receptor.[114] HLA-E is 
overexpressed in more than 80% of cervical tumors.[114] 
A third non-classical HLA molecule is the MHC class I chain-related molecule A (MICA), 
which is expressed on normal epithelium but is weak or absent in ~60% of cervical cancer 
cases.(Figure 1)[107] MICA interacts with the stimulating NKG2D receptor on both CD8+ 
T-cells and NK-cells and enhances the effector function of these cell types.[107,116] A 
low expression or absence of MICA was shown to be associated with worse survival when 
analyzed in the context of the ratio between CD8+ T-cells and Tregs and the expression of 
HLA-A.[107] Downregulated expression of MICA, in addition to weak expression of HLA-A, 
may surpass the threshold for the infiltrating CD8+ T-cells to exert their tumoricidal function.
Induction of regulatory T-cells 
There is a strong correlation between the ratios of CD4+, CD8+ and tumor-infiltrating Tregs 
and the prognosis of HPV-induced disease.[75,107,117,118] CD4+ Tregs are shown to 
inhibit the proliferation and cytokine production of activated naïve CD4+ T-cells and Th1 
cells and are also able to prevent the activation of CTLs by preventing the expression of 
the IL-2 receptor alpha (CD25) and inhibiting IL-2 production.[117] Tregs influence several 
other pathways to suppress the anti-tumor response, including induction of suppressive 
macrophages, upregulation of IL-10, induction of indoleamine 2,3-dioxygenase (IDO)-
positive APCs and TGFβ production.(reviewed in [117]) In cervical dysplasia, Tregs appear 
to be attracted by CXCL12, a ligand of CXCR4.[119] Importantly, part of the regulatory T cell 
repertoire comprises HPV-specific Tregs that recognize the same antigens as HPV-specific 
effector cells.[117] Upon cognate interaction with the HLA class II-positive tumor cells these 
CD4+ Tregs become activated and can suppress other immune cells within the lesions and 
tumors.[58,91] Furthermore, as these antigens are also used for therapeutic vaccination 
strategies, vaccination may result in the expansion of HPV-specific Tregs and subsequently 
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Inhibition of T-cell function or infiltration
Exhaustion of CD4+ and CD8+ T-cells during viral infection or malignancies has been 
associated with expression of the co-inhibitory molecules cytotoxic T-lymphocyte antigen-4 
(CTLA-4), program death-1 (PD-1), T-cell immunoglobin mucin-3 (TIM-3) and B- and T- 
lymphocyte attenuator (BTLA).(Figure1)[120-123] The interaction between PD-1 receptor 
expressed by effector or Tregs, and program death ligand 1 (PD-L1(B7-H1)) and/or PD-L2 
(B7-DC) results in the induction of apoptosis, anergy or exhaustion of effector T-cells.[124-
126] Approximately half of the tumor-infiltrating T-cells in cervical cancer are PD-1 positive. 
PD-L1, however, is only occasionally expressed by cervical cancer cells. Interestingly, patients 
with PD-L1 positive tumors, infiltrated with relatively high numbers of CD4+FoxP3+ Tregs, 
show a better survival than patients with relatively high numbers of infiltrating Tregs, but 
negative for PD-L1.The impairment of the PD-1 positive Tregs by the PD-L1 expressing tumor 
cells may potentially result in a survival benefit.[126] 
The ligand for TIM-3 is Galectin 9 (Gal-9). Their interaction results in a decreased Th1 and 
CTL immunity by inducing apoptosis of Th1 cells as well as by inhibiting the function of 
CTLs and Th1 cells.[120,122,127] A decreased Gal-9 expression is inversely associated with 
malignant potential or differentiation of cervical cancer.[128] Gal-1 and Gal-3, however, 
have also been implied in the inhibition of T-cell responses and their expression is increased 
during the progression of HPV-induced neoplasia.[129,130] 
Another molecule that may hamper the immune response is the cell surface glycoprotein 
CD200 (OX-2). This protein can be expressed by many types of human cancers.[131-134] 
Co-cultures of CD200-expressing, but not CD200-negative, tumor cells suppressed the 
production of Th1 cytokine by T-cells, the cytolytic activity of CTL and the IFNγ response of 
NK-cells.[131,132] In the transplantable EMT6 mouse breast cancer model, the neutralization 
of CD200 led to a decreased tumor growth and an increased number of cytotoxic anti-tumor 
immune cells in the tumor draining lymph node.[133] Tumor-cell expressed CD200 also 
hampers the function of tumor-associated APCs.[134,135]
Finally, T-cells can also be physically hampered to infiltrate the lesions. We found that a high 
expression of versican – one of the extracellular matrix components produced by stromal 
cells - in the stroma was associated with a low number of tumor-infiltrating T-cells and in 
particular a low number of CD8-positive T-cells.[136] In addition, a study of the expression 
of the mucosal homing receptor, α(4)β(7) surface integrin, on T-cells and its ligand mucosal 
addressin cell adhesion molecule-1 (Madcam-1) on vascular endothelial cells in cervical 
tissue revealed that the ability of α(4)β(7)(+) CD8(+) T-cells to gain access to cervical 
epithelium strongly depended on the expression of Madcam-1, which was absent in lesions 
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Microenvironment 
The local microenvironment may also play a role in HPV-induced lesions. The expression of 
cytokines such as IL-10 and TGF-β, the increase in tumor-associated macrophages, Tregs 
and IDO-expressing APCs can all help to suppress local immunity. (Figure 1)[138-142] TGF-β 
is overexpressed in CIN and cervical cancer.[143,144] It prevents T-cell infiltration into 
tumors, inhibits T-cell activation and mediates Treg-induced immunosuppression.[145] The 
immunoregulatory enzyme IDO was found to be expressed in high grade CIN and cervical 
cancer, and is particularly expressed by IL-10-producing stromal myeloid cells. Diffuse 
expression in cervical cancer was correlated with an unfavorable outcome.[140,146,147] 
Macrophages exist in many flavors ranging from a tumor-rejecting phenotype (M1 type) 
to the well known tumor promoting macrophages (M2 type). Monocytes recruited to 
lesions or tumors can differentiate towards M1 or M2 types depending on the local 
milieu. The M2 macrophages mediate direct effects on tumor growth, vascularisation 
and local immunosuppression.(reviewed in [148]) Furthermore, they produce cytokines 
and chemokines resulting in alteration of the phenotype and function of local DCs and 
the modulation of T-cell responses. The differentiation towards M2 macrophages can be 
the direct result of tumor cells producing prostaglandin E2 (PGE2) and IL-6. Blocking the 
tumor-expressed cyclooxygenase-2 (COX-2), and thereby the production of PGE2, as well 
as IL-6 restores the normal differentiation of monocytes to DCs.[149] Expression of COX-
2 is upregulated following overexpression of E5 in cervical carcinoma cell lines.[90] The 
expression of COX-2 by cervical tumors is associated with a poor response to chemotherapy.
[150] 
Interestingly, macrophages display plasticity in their differentiation, allowing them to switch 
from one type to another type depending on the local milieu. Tumor infiltrated Th1 cells can 
stimulate a tumor rejecting environment by switching M2 tumor promoting macrophages 
into activated M1 tumor-rejecting macrophages via CD40–CD40 ligand interactions and the 
production of IFNy.[149] Another cell type reported to play a role in the suppression of 
immune responses are myeloid-derived suppressor cells (MDSCs). These cells are able to 
directly inhibit T-cell responses and promote tumor progression.[151] However, the role 
of both tumor associated macrophages and MDSCs in the clinical outcome of HPV-induced 
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Figure 1 Immune escapes mechanisms and possible solutions 
depicts all potentially involved co-inhibitory receptors, ligands and HLA expression and their role in the suppression 
of the immune system; TIM-3 and Galectin 9 (induction of apoptosis Th1 cells and inhibition of CTL and Th1 
function), CD200R and CD200 (suppress function of Th1, CTL and NK-cells), PD-1 and B7-H1 (PD-L1) (induction 
of apoptosis, anergy or exhaustion of effector T-cells), CTLA-4 and B7-H1/H2 (inhibition of T-cell function), BTLA 
and B7-H4 (inhibition of T-cell proliferation, cytokine production, CTL function and memory cell generation), 
Galectin 1 and TCR, CD45, CD43, CD7, pre-BCR (induction of T-cell apoptosis, inhibition of T-cell function, Treg-
mediated immune suppression and inhibition of B-cell signaling and activation), Galectin 3 and TCR, CD45, CD43, 
CD7 (induction of T-cell apoptosis and inhibition of T-cell function, alternative activation of macrophages), HLA-G 
and ILT2, ILT4 and KIR2DL4 (inhibition of T-cell function, CTL lysis, induction of tolerant APC), HLA-E and NKG2A/
CD94 (inhibition of tumor cell lysis by NK-cells and CTLs), MICA and NKG2D (enhances the function of NK and CTLs). 
Moreover potential immunostimulating (green) and inhibition or blocking of inhibitory factors (red) to 
overcome some immune escape mechanisms are depicted which are of potential benefit and might improve the 
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Immunity to HPV in vulvar intraepithelial neoplasia 
VIN lesions are histologically characterized by an increased infiltration with CD4+ T-cells, 
macrophages but not LCs or CD8+ T-cells when compared to normal vulvar tissue.[152-155] 
Low-grade VIN has relatively higher numbers of CD8+ T-cells than CD4+ T-cells.[153,155] A 
recent study on a large series of patients and controls confirm these results with respect 
to the infiltration of the dermis, but also suggests that there is an increase in mature DC 
and plasmacytoid DC in the dermis.[152] In the epidermis, however, the number of LCs, 
immature DC, plasmacytoid DC and CD8+ T-cells seems to be slightly reduced.[152] The 
gene signature of VIN generally reflected an ongoing immune response and revealed 
a strong downregulation of the transcription factor peroxisome proliferator-activated 
receptor gamma (PPARγ), which is a negative regulator of DC maturation and function.
[156] The slightly reduced number of LCs in high grade VIN can be the result of enhanced 
emigration via downregulation of E-cadherin and LC activation by TNF-α and IL-1β, but it 
may also reflect a decreased immigration of precursors due to a lower MIP-3α production by 
keratinocytes.[100,157] Interestingly in non-HPV-related dVIN, a number of LCs were found, 
suggesting that HPV induces LC activation and migration.[158] The increase of mature 
DCs in the dermis of VIN appears to indicate that persistent HPV infection does lead to 
maturation of DCs, making it most likely that disturbed immigration is the culprit in the 
inaccurate initiation of a strong adaptive immune response, leaving only a weak dermal 
influx with CD4+, CD8+ and Tregs.[152,153,156,159] Depending on the study, up to half of 
patients with a HPV 16-induced high grade VIN lesion display a directly detectable ex vivo 
HPV 16-specific IFNy-associated type 1 T-cell response against E2, E6 and/or E7.[59,160,161] 
The presence of such HPV 16-specific Th1 responses is generally not associated with 
regression of VIN, although the clinical efficacy of treatment with imiquimod cream or 
electrocoagulation of the lesion is associated with the presence of such a pre-existing HPV 
16-specific IFNy-associated T-cell response.[30,31,54,59] The absence of HPV 16-specific 
immunity is associated with treatment failure and may contribute to the high number of 
recurrences after treatment.[29-31,162] The critical role of a strong and broad systemic and 
local CD4+ and CD8+ HPV 16-specific proinflammatory T-cell response in order to clear usual 
VIN is demonstrated by therapeutic vaccination studies.[29,31,60,161,163-166] HPV 16 L1-
specific serological responses are detected in the great majority of VIN patients but are not 
related to clinical outcome and is associated with a risk of developing VIN.[59,162,167] NK 
cells are sporadically found in the epidermis but were found to be more than doubled in 
numbers in the dermis of VIN lesions compared with healthy women[152] and may reflect 
co-infiltration with dermal effector T cells and Tregs. Furthermore, in VIN, the intensity of 
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Similar to the other HPV-induced anogenital diseases, people carrying the HLA-DRB1*13 
and -DQB1*05 alleles are associated with a decreased risk of HPV 16-induced high grade VIN 
or vulvar cancer, whereas HLA-DQB1*03 is strongly associated with an increased risk.[169] 
Downregulation of HLA class I was found in nine out of 11 vulvar carcinomas (82% total 
loss), irrespective if they were HPV-induced or not.[155] In these 11 carcinomas HLA-class 
II expression was not upregulated.[155] In VIN, 19% total loss of HLA-class I was observed 
both in dVIN and uVIN. In addition, in 21% of usual VIN biopsies HLA-class I was found 
to be downregulated.[155] Whilst there are many mechanisms leading to changes in HLA 
expression[105], which part is still reversible via IFNγ remains to be established, particularly 
since the presence of an HPV-specific IFNγ-associated T-cell response is correlated with 
regression of lesions. 
In vulvar neoplasia both Gal-1 and Gal-3 were shown to be upregulated from normal 
vulvar tissue to high grade VIN and vulvar carcinoma.[170] The expression of Gal-1 on 
macrophages adjacent to the neoplastic cells became stronger with the increase in disease 
severity, whereas the neoplastic cells stained negative or weak for Gal-1.[129,170] Gal-
3 staining was observed mostly in the epithelial cells but was also found in endothelial 
cells and macrophages. The vast majority of VIN cases did not express Gal-3. However, 
in approximately 60% of the vulvar carcinomas, Gal-3 expression by the cancer cells was 
moderate or strong.[171] The potential role of these and the other co-inhibitory factors 
discussed above in the T-cell response to HPV-induced VIN need to be determined. 
Immunotherapy and potential causes of failure in VIN 
A successful immunotherapeutic approach probably requires resetting many parameters in 
the immune response to HPV. Therefore, immunotherapy for VIN must be aimed at adequate 
priming of T-cells, altering the balance between effectors and Tregs, increasing the homing 
of T-cells to the lesion, preventing exhaustion of the immune response, and overcoming 
inhibition by creating an immune stimulatory environment that allows the immune system 
to work.[172] At present, a number of immunotherapeutic approaches have been tested 
with varying degrees of clinical success. Although some of these approaches showed some 
clinical efficacy in patients with VIN, a substantial number of cases failed to display a clinical 
response to immunotherapy. The potential causes of which will be discussed below.
Topical immunotherapy
In the early 1990s, 21 patients were treated with topical IFNγ with or without nonoxynol-9. 
Nine patients displayed a complete response for at least 1 year and overall 67% of the patients 
showed an objective clinical response. However, due to serious local side effects and high 
costs this therapy is no longer pursued.[173,174] More recent data showed that IFNα plays 
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the generation of IFNγ-producing Th-cells and CTL as well as promoting the proliferation and 
survival of T-cells.[176] The use of pegylated IFNα may overcome the side effects previously 
observed in IFNα therapy of VIN patients because it differs in pharmacokinetic and chemical 
properties and is associated with fewer side effects compared to the topically used one.
[177]
Imiquimod (Aldara®) is a topically applied immune response modifier that acts by binding 
to TLR7 resulting in activation of NF-kB, which is followed by secretion of multiple pro-
inflammatory cytokines such as TNF-α, type 1 IFNs, IL-12 and activation of DCs.[178,179] 
Topical imiquimod has been used to treat HPV-induced high grade VIN lesions and resulted 
in viral clearance, normalization of immune cell infiltrate and clinical responses even in long-
term follow up.[28,32,33,180] Complete regressions were observed in 26–100% of patients 
whereas 0–60% displayed partial regression and 0–37% experienced recurrence.[180] In two 
randomized controlled trials with imiquimod as treatment of high grade VIN, the first trial 
demonstrated complete regression in 81% of the 21 patients and partial regression in 10%, 
whereas the other trial reported a complete regression in 35% and partial response in 46% 
of the 26 patients.[28,32] Treatment in general is well tolerated, however local side effects 
of inflammation and burning are common, but can safely and successfully be treated with 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).[28,32,181] Regression of the lesions in 
the last study was associated with a pre-existing IFNy-associated HPV 16-specific CD4+ T cell 
response and afterwards with normalization of the lesional immune cell infiltrate.[59,159] 
Imiquimod did not induce or enhance the HPV 16-specific CD4+ T-cell response.[59] Non-
responsiveness corresponded to the local attraction of macrophages and the presence of 
Tregs.[31,159] Notably, HPV 16-specific Tregs comprise both FoxP3+ and FoxP3- suppressor 
cells and are characterized by the production of both IFNγ and IL-10.[91] It can be envisaged 
that they also play a role in VIN lesions as they are found in high grade premalignant lesions 
of the cervix.[58] 
Photodynamic therapy (PDT) in combination with topically applied 5-aminolevulinic acid 
(ALA) is a relatively new treatment regimen for VIN that exploits the interaction between a 
tumor-localizing photosensitizer and non-thermal light to induce oxidation reactions, which 
lead to tissue necrosis.[182] ALA-based PDT is particularly attractive as this drug is activated 
in rapidly growing cells, thereby reducing damage to the normal surrounding tissue.[182] 
PDT results in direct tumor destruction as well as induction of local inflammation resulting 
in the activation of APCs, recruitment of effector cells and subsequently the activation of 
tumor-specific immunity and development of immune memory.[183,184] PDT can also have 
an immunosuppressive effect, but this is prevented by reducing the rate of light delivery.
[185] Clinical responses of VIN to PDT vary widely ranging from 20 to 60% of complete 
histological responses and in 52–89% of the patients it resulted in symptom relief.(reviewed 
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non HPV-associated VIN as well as in pigmented and hyperkeratinic VIN lesions.[155,187] 
Moreover, clinical responders retained the expression of HLA-class I and displayed a 
treatment-associated increase in the numbers of infiltrating CD8+ lymphocytes. In contrast, 
non-responders showed loss of HLA-class I and low numbers of infiltrated immune cells.
[155,187] 
Advantages of PDT are a short healing time, minimal tissue destruction and preservation 
of the normal anatomy of the vulva. However, recurrence rates are high (48.7%) and do 
not differ significantly from conservative treatments with CO2 laser and surgical excision.
[12] In an attempt to increase the immune infiltration and response to PDT of HPV-induced 
VIN, a combination therapy of imiquimod and subsequent photodynamic therapy was 
given. The overall response rate was 65%, with 20% complete responders and 40% partial 
responders after 1 year.[30] Indeed, imiquimod treatment resulted in an increased CD8+ 
T-cell infiltration in the group of treated patients, but no differences were found between 
non-responders and responders within this treated group. Non-responders demonstrated 
relatively stronger infiltration with FoxP3+ T-cells after imiquimod. Clinical responders 
displayed a stronger HPV-specific proliferative T-cell response.[30] Together, these studies 
indicate that topical immunotherapy, particularly imiquimod, changes the microenvironment 
to allow more immune cells to infiltrate into the lesions. When these T-cells display the 
correct phenotype, as potentially found in patients with circulating HPV-specific T-cells, this 
infiltration may result in clinical responses. By contrast, when the immune cells display an 
immune suppressive phenotype (Tregs, M2 macrophages) the patients will not successfully 
react to the therapy. 
Systemic immunotherapy by vaccination
Therapeutic vaccines aim to reinforce the HPV-specific IFNγ-associated CD4+ and CD8+ 
T-cell responses. As previously reviewed, different types of therapeutic vaccines have been 
developed and tested in Phase I/II clinical trials in an attempt to eliminate HPV 16-associated 
disease. The types of vaccines comprise recombinant viral vectors, peptides, fusion proteins, 
DNA, antigen-pulsed DCs and virus-like particles.(reviewed in [188]) Although some vaccines 
showed high immunogenicity, vaccination has led to limited clinical successes in HPV induced 
diseases. Part of it can be explained through the failure of some vaccines to induce a strong 
and broad HPV 16-specific CD4+ and CD8+ T-cell response.(reviewed in [188]) 
Different vaccine formulations have been tested in patients with HPV-induced VIN. In general, 
these vaccines were shown to be safe and immunogenic in most cases. A live recombinant 
HPV vaccine expressing the HPV 16 and HPV 18 E6 and E7 genes (TA-HPV) was tested in 12 
women with high grade VIN or VAIN of up to 15-years duration in a single dose injection.
[161] A total of 42% of the patients showed at least a 50% reduction in total lesion size and 
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an increased IFNy-associated HPV-specific T-cell response in six patients, who showed 
a concomitant clinical response.[161] However, in four women no vaccine-induced T-cell 
response was observed while two of them showed a >50% reduction in lesions size.[161] This 
vaccine was also tested in 18 women diagnosed with VIN that had persisted for 6-months to 
17-years. Eight patients showed an increase in the HPV E7-specific IFNy response, of which 
four displayed a weak response. One patient showed a complete clinical response and 
seven others a partial response. There was no obvious correlation with the vaccine-induced 
response, probably because only the response to two well defined HLA-A*0201 restricted 
CTL epitopes was measured. E6/E7-specific proliferative responses were measured in 50% 
of the patients.[164] Interestingly, a comparison of the local immune infiltrate revealed that 
the lesions of the group of clinical responders were, on average, highly infiltrated with DC/
LCs, CD4+ and CD8+ T-cells before vaccination. There was no difference in the number of 
CD68+ macrophages between the two groups. Notably, the numbers of VIN-infiltrating CD4+ 
and CD8+ T-cells did increase in the group of non-responders after vaccination, albeit not to 
the level of the clinical responders.[164] This indicates that the capacity of the immune cells 
to infiltrate the lesion represents another hurdle to be overcome. 
Another vaccine formulation consisting of HPV 16 L2E6E7 fusion protein (TA-CIN), which was 
given to ten women diagnosed with high grade VIN as three booster vaccinations after they 
were primed with TA-HPV 7–15 months earlier.[165] All patients displayed a proliferative 
response to the L2E6E7 fusion protein, but it is not clear how often this response was 
made against the L2 component. IFNγ-associated CD8+ T-cell responses to two of the 
HLA-*0201 restricted E7 epitopes were detected in three patients. One patient showed a 
complete response and one a partial response (>50% reduction in lesion size). There was 
no correlation found between the outcome of the immune assays and clinical reactivity.
[165,166] Preclinical studies on heterologous prime-boost immunizations with TA-CIN and 
TA-HPV showed that the best vaccination protocol would consist of priming with TA-CIN to 
focus the immune response toward the oncoproteins, and boosting with TA-HPV to increase 
the magnitude of the E6/E7-specific response. Therefore, a group of 27 patients with HPV 
16+ VIN 3 and two patients with VAIN 3 was vaccinated with three doses of TA-CIN at four 
week intervals followed by a single boost of TA-HPV. This resulted in one complete response 
and five partial responses.[166,189] Analysis of the HPV 16 E6/E7-specific IFNγ-associated 
T-cell response using pools of overlapping peptides of E6 and E7 was performed in 25 
patients, three of which showed a pre-existing response to E6. In nine patients, the vaccine-
induced IFNγ-associated T-cell response was detected after vaccination, including two of 
the patients with a pre-existing immune response. The responses were mainly focused at 
the E6 protein and not at E7. Two patients showed a strong IFNγ-associated T-cell response. 
Of the six clinical responders, five patients showed an E6-specific IFNγ response, including 
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a strong combination in mouse models - resulted in no advantage over a single TA-HPV 
vaccination in patients with VIN.[166,189]
Peptide vaccines are attractive because they are well tolerated in humans, relatively 
inexpensive to produce and easy to design. A vaccine consisting of synthetic long peptides 
(SLP), spanning the complete amino acid sequence of the two oncogenic proteins E6 and 
E7 of HPV 16, was safe and highly immunogenic in patients with cervical cancer as reflected 
by the strong IFNγ-associated HPV 16-specific CD4+ and CD8+ T-cell responses detected.
[190,191] In a Phase II trial, 20 patients with high grade HPV 16+ VIN were vaccinated three 
to four times at 3 week intervals.[29] After 12 months follow-up, a clinical response rate 
of 79% and a complete and durable regression of the lesion in 47% of the patients was 
reported. Patients with a good clinical response displayed significantly smaller lesions at 
study entry than those who did not.[29] Characteristically, patients with a smaller VIN3 
lesion displayed a strong and broad IFNγ-associated HPV-specific CD4+ T-cell response to 
HPV 16 E6 and E7. There was no difference between patients with small or larger lesions 
in the immune response to recall antigens. The patients with a smaller lesion displayed 
a distinct peak in the amount of cytokines produced by peripheral blood mononuclear 
cell (PBMCs) isolated after the first vaccination, suggesting that HPV 16-specific immune 
responsiveness is already predetermined. By contrast, in patients with larger lesions, higher 
frequencies of vaccine-enhanced HPV 16-specific Tregs were observed.[29,60] At present in 
our institute, a Phase II randomized trial in patients with HPV 16 positive high grade VIN is 
almost completed in which imiquimod is applied to site where the HPV 16 E6/E7-SLP vaccine 
is injected in an attempt to improve the Th1 polarization of the responding T-cells and as 
such clinical responses. In a peptide-based vaccine in patients with melanoma, imiquimod 
appeared to enhance the immunological response to the vaccine.[192] As a response to the 
observation that non-responders to PDT exhibited a loss of HLA-class I, a pilot study was 
performed on the available pretreatment biopsies of the HPV 16-SLP vaccinated patients. 
This revealed that (partial) loss of HLA-class I in the VIN lesions could be observed before 
vaccination across non and clinical responders, indicating that (partial) loss of HLA does not 
always prevent successful outcome of vaccination.[unpublished results] The expression of 
HLA class I may potentially be restored by the presence of IFNγ produced by HPV-specific 
CD4+ T-cells that recognize their epitope in HLA-class II, with as a result that the recruited 
CTL once again can exert their cytotoxic function.[109] Alternatively, CD4+ T-cells have a 
direct antiproliferative effect on HLA class II positive cells of the lesion. 
Combined local and systemic immunotherapy
Clearly, there are a number of immunotherapeutic strategies that are promising for the 
treatment of VIN, but are not able to induce complete regressions of the lesions in every 
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with the extent of the pre-treatment immune infiltrate in high grade VIN[164] and that 
this infiltrate can be enhanced by the use of imiquimod[30], a vaccine trial was designed in 
which imiquimod treatment for 8 weeks was followed by three intramuscular doses of TA-
CIN at 4-week intervals.[31] A total of 19 women with (1–20 years of) high grade VIN were 
treated. After treatment with imiquimod, six patients showed a complete regression and 
this increased to 11 women after vaccination with TA-CIN. After one year of follow-up, 12 of 
the 19 treated women displayed a complete regression.[31] The group of clinical responders 
showed a stronger E6- and E7-specific proliferative response than non-responders. 
Imiquimod treatment was expected to raise the numbers of lesion infiltrating immune cells. 
Indeed a small but significant increase in the numbers of CD8+ T-cells was detected. After 
vaccination, the group of responders showed an increased CD4+ and CD8+ T-cell infiltration. 
By contrast, the group of non-responders showed an increase in the number of lesion-
infiltrated Tregs.[31] In comparison to their previous study where imiquimod was followed 
by PDT, not only the number clinical responders was much higher, but also the numbers of 
infiltrating CD4+ and CD8+ T-cells in the lesions did not return to pre-imiquimod levels as 
was seen with PDT[30], suggesting that the vaccine-induced HPV 16-specific T-cell response 
mediated this effect. However, similarly to what was observed after HPV 16-SLP vaccination, 
TA-CIN vaccination resulted in the undesirable side effect of enhanced the number of Tregs 
in the group of non-responders.[31,60]
Conclusion and Future 
Overall, one can conclude that clinical complete regression of HPV-induced disease can be 
obtained if the numbers of HPV-specific CD4+ and CD8+ T-cells are strongly enhanced and 
the lesions are (preconditioned to) allow immune cell infiltration. Clearly, a number of pre-
existing conditions (e.g. lesion size, presence of Tregs, lack of immune infiltration, lack of 
HPV-specific IFNγ-producing T-cells, number of infiltrated macrophages, lack of HLA class I 
expression) may determine the patient’s responsiveness to immunotherapy. Other factors 
that may influence responsiveness to therapy, such as the type of infiltrating macrophages 
(M1 or M2), the presence of MDSCs, the expression of Madcam or the expression of inhibitory 
molecules, which are all known to influence the immune response in other HPV-induced 
or chronic viral diseases, still need to be addressed. The consistent observation that non-
responders display enhanced numbers of Tregs after therapy suggests that new modalities 
should be sought that alter the balance between Tregs and IFNγ-producing effectors in favor 
of the latter. Tregs are known to suppress the induction of the IFNγ-producing Th1 cells that 
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Expert commentary 
VIN is the first HPV-induced disease in which real immunotherapeutic clinical successes have 
been achieved. In comparison to CIN and cervical cancer, VIN is, however, less well studied 
with respect to its interaction with the immune system. Most studies on the immune 
response to HPV in uVIN have been performed in clinical trials. On the one hand, this allows 
immune parameters to be studied in the context of therapy-induced outcome and as such 
may reveal parameters associated with success or failure. On the other hand, such studies 
are generally focused on the mechanism of action of the therapy and therefore do not 
consider other immune factors. Furthermore, most studies are performed in small cohorts 
of patients which limits the value of findings or significantly obscures potentially important 
findings. Although it is acceptable to translate findings from other HPV-induced diseases 
to the study of VIN, they do need to be confirmed preferably in larger cohorts with known 
clinical follow-up. Gaps in the knowledge of the interaction of HPV and the immune system 
in VIN include the absence or limited studies on (non-classical) HLA expression, the presence 
of co-inhibitory molecules or the presence of local inhibitory microenvironmental factors as 
macrophages and cytokines. Considering that VIN does respond to immunotherapy, in-depth 
studies should be performed to fully understand why it works, as well as to understand what 
we need to circumvent in patients who would otherwise not respond for immunotherapy of 
HPV-induced tumors to be successful. Based on what is already known, we think that HPV-
induced VIN is an immunologically active disease as reflected by marked infiltration with 
T-cells and the presence of IFNγ-associated T-cell responses, when compared, for instance, 
to HPV-induced CIN. Importantly, while evidence accumulates that HPV-specific T-cells play 
a role in all HPV-induced diseases, the results of the vaccine trials definitely show that HPV-
specific T-cells play a role in the control and regression of VIN. Moreover, these trials show 
that even high grade HPV-induced lesions can undergo immune-driven regression. However, 
when HLA expression is lost, infiltration with Tregs and macrophages, or the per individual 
differences in immune infiltration is considered, VIN is similar to the other HPV-induced 
high grade lesions or cancers. It is therefore likely that the development of new treatment 
options of this premalignant lesion will follow the same route as that for cancer. Here, one 
must consider applying immunotherapeutic vaccines in the adjuvant setting but may also 
include the use of low dose chemotherapy to obtain certain immunological effects such as 
Treg depletion. For instance, a single dose of cyclophosphamide improved IFNγ-associated 
T-cell responsiveness to vaccination in ovarian cancer.[195] In view of what has been found 
already, it is highly likely that a combination of immunotherapeutic strategies is required to 
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Five-year view 
At present the successes of different (combined) immunotherapies in the treatment of VIN 
are encouraging and unprecedented. However, non- or partial treatment responders are 
also being reported and this will spark studies that focus on unraveling the mechanisms 
underlying the differences in clinical responsiveness. Interestingly, there are several roads 
that lead to clinical success. These – in our opinion – complementary immune strategies all 
target different aspects of immune failure. We expect that combinations of these strategies 
will be tested. To the end, this will lead to either patient selection in cases where there is 
no strategy to overcome an immunological problem or to a number of combinations of 
immunotherapeutic strategies that together may solve the problems. One may consider, 
for instance, blocking the co-inhibitory molecules by antibodies, depletion of Tregs before 
therapy, depletion or re-differentiation of macrophages, increasing T-cell homing by 
the induction of local inflammation and the use of IFNα to polarize Th1/CTL responses. 
Combination of imiquimod, vaccines and IFNα are the most likely to be tested within the 
near future. 
Key-issues 
•	 Usual type VIN is a chronic premalignant disease caused by a persistent oncogenic 
HPV 16 infection in 90% of cases. 
•	 Successful treatment of HPV-induced VIN is associated with an enhanced and broad 
HPV 16-specific CD4+ and CD8+ T-cell response against the oncoproteins E6 and E7.
•	 Several types of immunotherapeutic approaches have met clinical success in 
high grade VIN although a notable number of patients fail to respond to these 
immunotherapeutic strategies.
•	 Knowledge of the interaction between VIN and the immune system is limited. 
•	 Immune escape mechanisms that play a role in VIN are loss of HLA, immune 
infiltration with Tregs and macrophages, or the lack of infiltrating CTLs. 
•	 Studies on the role of inhibitory molecules on T-cell function and the reversibility of 
HLA loss in VIN are needed. 
•	 Combinations of immunotherapies targeting different aspects of the failing immune 
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Box 1 Potential causes of immunotherapy failure and how to correct this (Figure 1)
Lack of a robust CD4+ and CD8+ HPV-specific T cell response. 
The accumulated data show that a strong and broad IFNγ-associated HPV-specific T-cell response 
is required for complete regression of the VIN lesion. Although some patients spontaneously 
develop a respectable HPV-specific immune response, many do not. Immunotherapeutic 
strategies that do not comprise vaccination may fail in patients either by lacking HPV-specific 
immunity or by developing a dominant Th2 response.
•	 Lack of HPV-specific immunity: The immune system should come into contact with 
sufficient amounts of antigen for sustained periods to become activated. The first choice 
would be to vaccinate patients with a highly immunogenic vaccine that induces both CD4+ 
and CD8+ T-cell responses. Alternatively, one could use lesion destructive therapies that 
are known to result in the activation of T-cells such as PDT or cryoablation. 
•	 Wrong polarization of HPV-specific immunity: Stimulation of the immune system with E6 
and E7 antigens (delivered to the APC via natural mechanisms, vaccines or destructive 
therapies) to induce a strong Th1/CTL polarization requires optimal activation of APC. TLR 
3 and 9 agonists are known to appropriately stimulate human APC and could be injected 
either locally or at the site of vaccination. Alternatively, one could use pegylated IFNγ as 
this is known to prevent Th2 responses and to drive Th1/CTL responses. 
Inhibition of T-cell function and infiltration.
As a group, VIN lesions are well infiltrated with CD4+ and CD8+ T-cells, however, this varies a great 
deal between individuals. Despite strong infiltration with T-cells, they are incapable of inducing 
the spontaneous regression of VIN lesions. Immunotherapeutic strategies aiming to induce 
HPV-specific immunity have a better response rate in patients displaying considerable immune 
infiltration before treatment, except when there are high numbers of regulatory T-cells present. 
•	 Regulatory T-cells: Non responsiveness to therapy is associated with the presence as well 
as enhancement of regulatory T cell numbers. Part of the regulatory T-cell population 
is HPV-specific. In the immunotherapeutic strategies that aim to induce HPV-specific 
immunity, an increase in circulating and local regulatory T-cells is observed in clinically 
non-responding patients. Preferably, modalities to deplete or disarm regulatory T-cells 
should be included in the immunotherapeutic strategy. A number of different methods 
have been tried without much success. So far, low dose cyclophosphamide treatment 
has produced consistent results, suggesting that low dose chemotherapy should be 
considered as a treatment option. Since it is not the number of regulatory T-cells per se 
but the balance between regulatory T-cells and effectors that is important one could try 
to use adjuvants that alter the balance between these two populations in favor of the 
effector cells. 
•	 Expression of co-inhibitory molecules: Overall there is little data on the expression of co-
inhibitory molecules by T-cells, immune cells in the microenvironment or the epithelial 
cells in patients with VIN. Clearly, the increase in severity of VIN lesions is associated with 
an increased expression of galectin-1 and galectin-3 in VIN. These galectins are known 
to disrupt T-cell function and to induce apoptosis in melanoma. Similarly, the interaction 
between T-cell-expressed TIM3 and galectin-9 disrupts T-cell function. The use of galectin 
inhibitors or antibodies to TIM-3 may alleviate inhibition. The role of other inhibitory 
molecules has not been studied in VIN but extrapolation of what is known from other 
HPV-induced diseases and other types of cancers, suggest that PD1 and CTLA-4 may play 
a role. For the latter molecule a clinically effective blocking antibody has been approved 
for melanoma, whereas for PD-1, several clinical grade antibodies are being developed. 
These might be added to the immunotherapeutic strategy. Potentially, CD200/CD200R 
interaction may also play a role. An antibody to CD200 has been tested in the treatment 
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•	 Inhibition T-cell infiltration: A lack of Madcam-1 expression on the vasculature of CIN 
lesions was associated with a failure of T-cells to infiltrate the lesions and this may also 
explain why in a number of patients VIN lesions are not infiltrated by T-cells or not reactive 
to therapy. Madcam-1 is upregulated by TNFα, which may explain why the use of topical 
imiquimod can enhance immune infiltration of VIN lesions. 
Microenvironmental factors.
•	 Lesion associated macrophages: VIN lesions display an increased infiltration with 
macrophages and non-responsiveness to imiquimod treatment corresponded with a local 
attraction of higher numbers of macrophages, suggesting that the macrophages detected 
display a tumor-promoting M2 profile and not the tumor-rejecting M1 profile, but this is 
yet to be confirmed. In HPV-induced cervical cancer, IL-10 producing M2 macrophages can 
be induced by tumor produced PGE2 and IL-6. COX-2 is variably expressed in VIN[168], 
but the expression of IL-6 is unknown. If M2 macrophages are involved, treatment could 
consist of IL-6R blocking antibodies (e.g. Tocilizumab) as used in rheumatoid arthritis and 
COX inhibitors. Alternatively, it has been shown that the interaction between Th1 cells 
and M2 macrophages switch the latter to activated IL-12 producing M1 macrophages. 
This suggests that if an immunotherapeutic approach results in enough lesion infiltrating 
Th1 cells, there might even be a benefit from the macrophages as they help to change the 
microenvironment to become more favorable. 
•	 IDO: The expression of IDO is found in high-grade CIN and cervical cancer, where it is 
associated with clinical outcome. The IDO inhibitor 1-methyltrypthophan may be utilized 
if IDO plays a role in VIN. 
•	 MDSC: myeloid-derived suppressor cells in many cancers can suppress the infiltrated 
effector T- cells by various mechanisms, although their exact role remains to be 
determined. 
The expression of classical and non-classical HLA molecules.
•	 Loss of HLA-class I (-A,-B,-C): Downregulation of HLA-class I molecules may hamper the 
efficacy of HPV 16-specific CD8+ T-cells to exert their function. If this downregulation is 
irreversible meaning that there are genetic alterations which cannot be restored one may 
deselect such patients for immunotherapy. If the downregulation is reversible, meaning 
that it can be restored by IFN, then an increased infiltration of the lesion with Th1 cells 
should suffice to restore HLA expression. Alternatively, a local injection with pegylated 
IFNα or IFNγ during the treatment may help to promote HLA expression. 
•	 HLA-G: In CIN lesions the expression of this molecule is associated with progression and 
the induction of Th2 responses. No intervention options are yet available.
•	 HLA-E: This molecule is expressed by the majority of cervical cancer where it can bind 
to the inhibiting CD94/NKG2A receptor expressed by up to 50% of the tumor-infiltrating 
CD8+ T-cells. No blocking antibodies have been developed to prevent this interaction to 
occur. 
•	 MICA: This molecule binds to the co-stimulatory molecule NKG2D expressed by CD8+ 
T-cells. Downregulation of this molecule by cervical cancer cells is associated with lower 
patient survival. MICA is known to be upregulated by TNFα, suggesting that a local pro-
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Abstract 
Objective
To identify clinical characteristics associated with recurrence and progression in patients 
with uVIN which may function as prognostic factors and aid the treatment of patients with 
HPV-related disease of the genital tract.
Methods
A retrospective chart review was performed in 73 patients with uVIN treated in the LUMC 
between 1990 and 2012. All medical records were reviewed for demographics, treatment 
type, pathology reports and recurrence and progression rates. 
Results 
Mean age of diagnosis was 43 years and uVIN was symptomatic in 60.1% of patients. Median 
follow up time was 49 months. High risk HPV was found in 86.3% of patients. Smoking was 
reported in 76.8% of patients. 11 of 73 patients were immune compromised. Multicentric 
HPV-related disease of the cervix or vagina was reported in 75.3% of patients. Recurrences 
were diagnosed in 50.7% of patients after first treatment type that consisted of excision 
(45.2%), laser (34.2%), imiquimod (8.2%) and combination of excision and laser (12.3%). 
Higher recurrence rates were only correlated with multifocality of uVIN lesions. Excision, 
imiquimod therapy, and unifocal lesions showed an increased recurrence free survival. HPV 
type, smoking, multicentric disease, use of topical steroids and positive surgical borders 
were not related to a shorter recurrence free survival. Progression into vulvar carcinoma 
occurred in 11 (15.1%) of patients, 4 of whom were immune compromised. These patients 
showed a shorter progression free survival of 54 months vs. 71.5 months.
Conclusion
There are no clinical characteristics that form prognostic factors in uVIN, except for 
multifocality of lesions, that is correlated with a higher recurrence rate. Furthermore, 
progression of uVIN to carcinoma was accelerated and increased in immune compromised 
patients, suggesting that studies of local immunity in uVIN may reveal potential prognostic 
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Introduction 
Vulvar intraepithelial neoplasia (VIN) is a chronic premalignant skin disease that can be 
classified into usual type VIN (uVIN), (old nomenclature VIN 2 /3), and differentiated type 
VIN (dVIN)1. dVIN occurs in postmenopausal women and is associated with lichen sclerosus 
whereas uVIN, accounting for 90% of VIN cases, is caused by a persistent human papilloma 
virus (HPV) infection, mainly high risk HPV type 162,3. uVIN has an increasing incidence 
worldwide in young women possibly due to the increase of HPV infections4,5. HPV is among 
the most common sexually transmitted diseases, with a lifetime risk of infection of 80%5. 
HPV-induced disease of the lower genital tract and its outcome are influenced by the host 
immune response, smoking, and immunosuppression6-8. It has been known for long that 
cellular immune responses against HPV protect against the development and progression of 
HPV-induced disease9,10. In the majority of uVIN patients HPV specific responses are either 
weak or absent11,12. Spontaneous regression is low and estimated at 1.5% of cases2,13,14. 
uVIN has a malignant potential in 3% of treated and 9% of untreated patients in 1-8 years 
2,13,15. The malignant potential of uVIN in immune compromised patients is 50-fold higher in 
comparison to the general population16. 
Patients with uVIN often suffer from severe and often long-lasting complaints of pruritis, 
pain and sexual dysfunction. Standard treatment for uVIN has been for a long time 
surgical (local excision and laser treatment). The aim of treatment is relief of symptoms, 
exclusion and reduction of the risk on invasive disease, and restoration of normal anatomy. 
If symptoms lack, expectative management of uVIN by close follow up visits can be 
advocated17. Conventional treatments are well known to be complicated by high recurrence 
rates, disfigurement of vulvar anatomy and impact on psychosexual function18,19. At present, 
a shift from conventional surgical therapies towards (experimental) immunotherapies such 
as the topical agent imiquimod (Aldara®, 3M Pharmaceuticals, St Paul,MN), photodynamic 
therapy, and therapeutic vaccination is visible with the aim to induce clearance of HPV, 
preserve vulvar anatomy and reduce psychosexual morbity2. Responsiveness to imiquimod 
treatment is associated with pre-existing HPV specific T-cell responses11,20,21. Reinforcement 
of the HPV-specific T-cell response by therapeutic vaccination has shown promising clinical 
responses of established HPV induced anogenital neoplasia, especially when vaccination was 
combined with imiquimod20,22,23. Despite these promising clinical results a notable number of 
patients are not able to respond to these immunotherapies20,22,24. There is a need to identify 
factors associated with patients who are at risk of non-responsiveness to (immuno)therapy, 
developing recurrences and progression into vulvar carcinoma. These predictors may assist 
in choice of therapy alternative to the complexity and limited possibilities of surgery25. We 
therefore performed a retrospective study in a single centre cohort to determine possible 
risk factors associated with the development of recurrences and progression into invasive 
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Materials and Methods 
A retrospective chart review was performed of 136 patients with uVIN who were treated in 
our institution between 1990 and July 2012. This study was approved by the medical ethic 
committee of the Leiden University Medical Center. Patients participating in our vaccination 
trials were excluded from this study22. Patients with micro- (n=9) or macroinvasive vulvar 
carcinoma (n=16) at first diagnosis and missing demographic baseline information (n=38) 
were also excluded from analysis which revealed a group of 73 patients with uVIN. 
Demographic information, treatment type, pathology reports and clinical outcomes were 
reported. Recurrent disease was defined as diagnosis of uVIN after successful treatment 
without residual disease. Residual disease was defined as the presence of visible lesions 
immediately after therapy. Histological examination of margins of excision specimens were 
analyzed by an experienced pathologist. History of concomitant disease defined as abnormal 
cervical cytology, CIN, VAIN or cervical cancer was documented. Progressive disease was 
defined as the development of a (micro-) invasive carcinoma and consists of both occult 
carcinomas in a persistent lesion as well as development of a carcinoma in the follow up 
after therapy. 
All uVIN samples included in this study were typed for HPV on the first lesion of uVIN by 
HPV16 PCR with a HPV16 specific primer set followed by HPV genotyping using the INNO-
LiPA HPV genotypine Extra line probe assay (Innogenetics, Ghent, Belgium) in case of HPV16 
negativity26,27.
In data analysis the statistical software package SPSS 20.0 (SPSS Inc., Chicago, IL) was used. 
Group comparisons of demographic characteristics were performed by Pearson’s Chi-square 
test or Mann-Whitney test. Univariate analysis by Cox-regression was used for comparison 
of recurrence-free survival analysis (RFS) and progression free survival (PFS). RFS thereafter 
was analyzed by Cox proportional hazards regression in respect of smoking status, lesion 
type, age, treatment modality and concomitant disease. RFS was measured from date of 
first treatment until the date of recurrence or last follow up whereas PFS was measured 
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Results 
The mean age at diagnosis of uVIN was 43 years (range 19-84 years) with a median FU time 
of 49 months. All patient characteristics are shown in (table 1). The majority of patients 
(60.3%) presented with complaints of pruritis, pain or discomfort at time of diagnosis. 
Lesions were multifocal in 43.8% and unifocal in 52.1% of the patients. Of the included 
patients, 65.8% were current smokers at diagnosis of uVIN, 11% former smokers, 13.7% 
non-smokers and from 4.1% patients smoking state was unknown. Eleven patients used 
immunosuppressive medication; 4 with autoimmune disease (Crohn’s disease, rheumatic 
arthritis and systemic lupus erythematosus), 6 allograft recipients and 1 HIV positive patient. 
Topical corticosteroids were used by 40.9% of patients during one or more periods in the 
follow up. Multicentric disease, determined by cytological or histological diagnosed cervical 
or vaginal dysplasia (CIN and/or VAIN), was present in 75.3% of patients during follow up 
and most patients (83.6%) developed uVIN after diagnosis of cervical dysplasia in a median 
time of 65 months (range -51 to 335 months) whereas only a small number of patients 
developed CIN after uVIN (table 1). 
First therapy in the treatment of uVIN (table 2) was surgical excision in 33 patients (45.2%), 
laser therapy in 25 patients (34.2%), laser and excision in 9 (12.3%) and imiquimod in 6 (8.2%) 
of patients after a median time of 2 months after diagnosis in a range of 0-158 months. More 
unifocal lesions were treated with excision (21 vs. 10, ns) whereas patients treated with 
combination of laser and excision often had multifocal lesions (2 vs. 6, ns) (table 2). A total of 
70 excisions were performed in 50 patients of which 71.4% had histological positive margins. 
Similarly, in 61.5% of the combined laser and excision therapies (n=13) the excisions borders 
were considered positive for uVIN. Residual disease was found in 34 patients (46.6%) which 
resulted in the use of adjuvant therapy in 30 patients. Residual lesions occurred in 15.7% 
after excision, in 22.9% after laser therapies, in 57.1% after imiquimod treatment, and in 








































76  |  Chapter 3





























































































































Clinical prognostic factors in usual VIN  |  77
Concomitant disease
None



















Table 2: Primary treatment and lesion type (N=) 
Excision Laser Aldara Laser and Excision Chi2
Unifocal 21 (67.7%) 13 (52%) 2 (33.3%) 2 (25%)
Multifocal 10 (32.2%) 12 (48%) 4 (66.7%) 6 (75%)
Total 31 25 6 8 0.105
Recurrences 
After first therapy, 37 patients (50.7%) developed recurrent lesions in just more than one 
year (median 14 months; range 1-168) (table 3). Twelve patients had 1 recurrence (16.4%), 
16 patients had 2 recurrences (21.9%), 4 patients 3 recurrences (5.5%), and in 5 patients 
(6.8%) 4 or more recurrences of uVIN were diagnosed. At time of diagnosis 76.5% of patients 
presented with symptoms, 11% had no complaints and of 5 patients it was not known. Of the 
patients with recurrent disease, 16 had prior excision (47%), 14 laser therapy (41.1%), 1 was 
treated with imiquimod (2.9%) and 6 patients were treated with laser and excision (17.6%). 
Recurrent disease was associated with multifocal lesions (p=0.008) in a univariate analysis 
irrespective of time to recurrence (table 3). Median time to recurrence was not significantly 
longer in patients with negative borders (n=2) compared to patients with positive borders 
(n=12) (79 vs. 30 months, p=0.189). Patients who were treated by excision however, had a 
significant longer median time until recurrence of 41.5 months, laser therapy of 7.5 months, 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Considering time to recurrence, a univariate Cox regression analysis of recurrence free 
survival was performed. RFS after diagnosis was associated with multifocal disease (p=0.006, 
HR 2.77, 95% CI 1.30-5.89). RFS after first therapy in univariate Cox regression analysis 
revealed a longer recurrence free survival between different treatment modalities in favor 
of excision and imiquimod therapy (p=0.010, HR 5.5, 95% CI 1.94-15.63 (laser and excision 
compared to excision)). RFS was not associated with immunosuppressive medication 
(p=0.490), smoking (p=0.083), positive margins (p=0.383), concomitant disease (p=0.319), 
local corticosteroid use (p=0.613), or HPV type (p=0.752). Multifocal disease remained an 
independent prognostic factor for a decreased RFS in multivariate Cox analysis corrected for 
multifocal disease, smoking, HPV state, immune compromised patients and BMI (p=0.027) 
whereas excision as first therapy was no longer associated with a longer recurrence free 
survival (p=0.142) (figure 1A+1B). 














































































































Figure 1: Cox regression analyses survival curves of recurrence free survival (RFS) and progression free survival (PFS)  
A: Multivariate regression curve of VIN lesion type and RFS, B: Multivariate regression curve of rst therapy and RFS, C: Univariate curve of HPV type 
and PFS, D: Univariate curve of immunocompromised state and PFS.
Figure 1 
A+B Multiv ri te Cox-based adjusted curves of recurrence free survival (RFS) of multifocal VIN lesions and first 
treatment type corrected for smoking, HPV type, first treatment modality, BMI, immunocompromised patients 
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Progressive disease 
In 11 patients (15.1%) an invasive carcinoma developed during follow up with a median of 
71.5 months after first diagnosis (range 9-259 months) (table 3). Progression of uVIN into 
carcinoma of a persistent lesion occurred in 2 patients (2.7%), in 9 patients a carcinoma 
was diagnosed after successful therapy of uVIN without residual lesions. In 7 patients a 
micro invasive carcinoma (≤1mm invasion) and in 4 patients a macro invasive carcinoma 
(>1mm invasion) was diagnosed. 4 of 11 patients were immune compromised with a median 
time of progression of 54 months (range 9-62 months). Type of first treatment showed 
no differences in progression free survival in univariate Cox analysis (p=0.200). HPV type 
16 compared to 33 was not associated with progression of uVIN into invasive carcinoma 
(p=0.300) and despite the shorter time to progression in immune compromised patients this 
resulted not in a significant shorter PFS (p=0.091, HR 4.744, 95% CI 0.78-28.85) in univariate 
Cox analyses (figure 1C+1D). 
Discussion 
In this study, higher recurrence rates for uVIN were only correlated with multifocality of 
lesions. First treatment by excision or imiquimod therapy as well as unifocal lesions were 
associated with increased recurrence free survival. Immune compromised patients showed 
a trend towards a shorter progression free survival. HPV type, smoking, multicentric disease, 
use of topical steroids, and positive surgical borders were not associated with a shorter 
recurrence free survival. 
After standard treatment, recurrence rates for uVIN are high, and most recurrences occur 
within 3 years of follow-up13,15,28-30. This was confirmed in our study. Higher recurrences 
rates have previously been associated with positive surgical margins and multifocal disease; 
although other studies showed that positive surgical margins were not associated with 
recurrent disease 13,15,29,30. In addition, the margin status of resected uVIN lesions has not 
shown to be associated with progression to invasive cancer 13,31. In our study, positive 
surgical margins were not associated with recurrent disease: 12 of 29 patients with positive 
margins developed recurrent disease, whereas 17 patients did not (41.3% vs. 58.6%, 
respectively) (table 3). Histological positive margins can be regarded as minimal residual 
disease, a condition where the immune system might be more effective in comparison 
to situations with large tumor burden. For example, results from our vaccination trial in 
patients with HPV16-positive uVIN have shown that smaller lesions were more likely to 
regress in response to vaccine-induced HPV16-specific immunity 22,32. In addition, surgical 
removal of primary tumors was shown to restore cell-mediated immune responses even 









































Clinical prognostic factors in usual VIN  |  81
removal of lesions or reduction of lesion size can lead to the restoration of adaptive immune 
responses which may prevent recurrent disease.
Patients treated with excision were found to have lower recurrence rates compared 
to patients treated with laser or combined laser and excision in our cohort. This finding 
might be explained by the fact that patients with large lesions and/ or multifocal disease 
were selected for combination therapy with excision and laser (our study: 2 unifocal vs. 
6 multifocal lesions). Recently, the same observation was done by Wallbillich et al., who 
showed an association between a decreased RFS and treatment of excision and laser30. 
Another study by Brown et al showed that after local excision followed by laser treatment 
of the excision margins, the recurrence rate was decreased in patients with uVIN34. When 
interpreting these findings, it should be kept in mind that a simple comparison for efficacy 
between different treatments is very difficult because the choice of treatment depends on 
several factors, for example uni- or multifocality of lesions and patient related factors. 
Treatment with the immune response modifier imiquimod is more and more used since the 
publication of a large randomized controlled trial in patients with uVIN in 200824. In this study, 
a reduction of >25% in lesion diameter was observed in 80% of the treated patients, with 
a complete disappearance of the lesions in 35% of the patients. HPV clearance occurred in 
60% of patients24. Recurrences after imiquimod are established at approximately 20.5% vs. 
53.5% after surgical therapies35,36. The small number of patients treated with imiquimod in 
our group, however show comparable results to excision regarding RFS in univariate analyses 
(figure 1). In this small cohort a complete response was achieved in one of six (16.7%) of 
patients primarily treated with imiquimod, the other patients with residual lesions were 
secondarily treated with laser therapy. Interestingly, clinical responses after imiquimod 
treatment in uVIN have been shown to be associated with normalization of immune cells in 
the lesions, and also with the presence of circulating HPV-specific T cells11,24,35. 
Other factors which have been associated with recurrence are smoking30, HIV infection37, 
use of immunosuppressive drugs28 and p53 gene mutation2,38. We found no association 
between smoking and increased risk for recurrences in contrast to Wallbillich et al.30 This 
may be related to the high number of smokers in our cohort, since only 8 patients never 
smoked or by longer median time of follow up in our group (21 months vs. 49 months). 
Other studies found no association of smoking and recurrences of uVIN either28,29. Smoking 
is however clearly associated with the development of uVIN and we feel that patients should 
be counseled to stop smoking during follow up visits since it is well known that smoking 
results in a decreased local immune response which makes it easier for the HPV virus to 
invade and persist6,7,15. 
In our cohort the number of progressive disease is 15.1% of which 60% are micro-invasive 
carcinomas (≤1mm), that are known to have excellent survival after wide local excision 
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4 were immune compromised. These patients are known to have an increased risk of 
multiple HPV induced anogenital lesions: over 80% of immune compromised uVIN patients 
were shown to have a history of CIN or developed CIN during follow-up in one study8,39,40. 
Importantly the immune compromised patients had an increased risk (27.3% vs. 12.9%) 
of progression into vulvar carcinoma and displayed a relatively faster (54 vs. 71.5 months) 
development of cancer compared to non immune compromised patients. A 50-fold increase 
in the risk to develop vulvar carcinoma in immune compromised patients was demonstrated 
before, and yearly cervical screening in combination with vulvar, vaginal and anal inspection 
is advised16. We could not detect an increased risk for recurrences; however, patient 
numbers were small. 
Multicentric HPV-associated disease has been described in patients with cervical 
intraepithelial neoplasia (CIN) and uVIN41,42. Other studies have shown that 71% of uVIN 
patients had previous, concurrent or subsequent vaginal intraepithelial neoplasia (VAIN), 
(peri-)anal intraepithelial neoplasia ((P)AIN), CIN or cervical carcinoma41,42. This was 
confirmed in our study, in which 75% of patients were diagnosed previously or concurrent 
with cervical dysplasia or VAIN. Other studies showed that multicentric disease was 
associated with a higher risk of progression compared to isolated uVIN43. We could not 
confirm these data although 7 of 11 patients with progressive disease displayed multicentric 
HPV lesions. Multicentric disease may be a reflection of a higher susceptibility for HPV 
infections and not able to clear the infections which are able to induce transformation (e.g. 
HPV type 16)40,42. HPV testing of multicentric anogenital HPV induced neoplasias revealed 
an identical HPV infection in 46% of cases (most often HPV 16 in 69%, followed by HPV 33 
in 13%). Most uVIN lesions are induced by HPV16 and HPV33, the types most often found 
in multicentric disease, explaining why these patients are at risk for HPV-induced disease 
affecting the cervix, vagina, and/or the anus. From these data it follows that patients with 
uVIN must be carefully screened for cervical dysplasia, in particular when they are immune 
compromised. 
An important limitation of our study, and also from other studies on clinical characteristics 
in VIN patients, is that patient numbers are relatively small because of the rarity of the 
disease. This means that non-significant results, for example for the surgical margin status 
or type of treatment may relate to small patient numbers rather than being no clinical 
difference. Therefore, for the translation into clinical practice, larger prospective, eventually 
multicenter studies are needed in patients with uVIN.
In summary, our data indicate that multicentric disease is highly common in patients with 
uVIN. Recurrences after treatment are high and are only associated with multifocal lesions. 
No other clinical characteristics are correlated with a higher recurrence- or progression rate. 
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From this study and data from others it is clear that the immune system plays a crucial role 
in the development of and course of disease in patients with HPV-induced lesions. Future 
research should be aimed at a detailed analysis of the local immune environment in relation 
to the clinical outcomes of disease in patients with uVIN. Furthermore, the strengthening of 
the systemic and local immune immunity to HPV by (adjuvant) immunotherapies may assist 
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Abstract 
Immunotherapy of uVIN is promising however many patients still fail to show clinical 
responses, which could be explained by an immune escape through alterations in HLA 
expression. Therefore, we analysed a cohort of patients with a primary (n=43) and 
subsequent recurrent uVIN lesion (n=20), vaccine treated uVIN patients (n=12), patients 
with HPV-induced vulvar carcinoma (n=21) and healthy controls (n=26) for the expression of 
classical HLA-class I/II and non-classical HLA-E/-G and MICA. HLA-class I was downregulated 
in 70% of uVIN patients, including patients with a clinical response to immunotherapy. 
Downregulation of HLA-class I is probably reversible, as only 15% of the uVIN cases displayed 
loss of heterozygosity (LOH) and HLA-class I could be upregulated in uVIN keratinocyte 
cultures by IFNγ. HLA-class I downregulation is more frequently associated with LOH in 
vulvar carcinomas (25-55.5%). HLA-class II was found to be focally expressed in 65% of uVIN 
patients. Of the non-classical molecules, MICA was downregulated in 80% of uVIN whereas 
HLA-E and -G were expressed in a minority of cases. Their expression was more prominent 
in vulvar carcinoma. No differences were found between the alterations observed in paired 
primary and recurrent uVIN. Importantly downregulation of HLA-B/C in primary uVIN 
lesions was associated with the development of recurrences and progression to cancer. We 
conclude that downregulation of HLA is frequently observed in premalignant HPV-induced 
lesions, including clinical responders to immunotherapy, and is associated with worse 
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Introduction 
Usual vulvar intraepithelial neoplasia (uVIN) is a chronic premalignant skin condition, with 
an increasing incidence mainly in young women, which is caused by a persistent high risk 
human papilloma virus (HPV) infection in over 90% of cases.1,2 uVIN causes complaints of 
severe and long-lasting pruritis, pain and sexual dysfunction and has a malignant potential of 
3-4% in treated and of 9% of untreated patients. 1,3 Since conventional treatments for uVIN 
are characterised by high recurrence rates of 20-40% and psychosexual problems, there is a 
need for alternative therapies.4-6 Failure of the immune system to induce a strong and effective 
immune response to HPV is known to cause viral persistence and development of these 
premalignant anogenital lesions.7-9 The microenvironment of uVIN lesions is characterised by 
high numbers of infiltrating CD4+ T cells as well as regulatory T cells (Tregs) and low numbers 
of cytotoxic CD8+ T cells (CTLs) compared to controls.10-12 Immunotherapy aims to overcome 
the inertia of the immune system and is therefore considered a possible effective treatment 
option for uVIN.13-17 Immunotherapy by imiquimod (Aldara®,), photodynamic therapy (PDT) 
and/or therapeutic vaccination, in both standard and experimental settings, are nowadays 
widely used as an alternative to conventional treatments, and have shown promising results 
in uVIN.13-17 Imiquimod is a topical immune response modulator which activates dendritic cells 
and induces proinflammatory cytokine expression and T cell activation.14 PDT leads to tumor 
directed cell death and induces local inflammation which activates antigen presenting cells 
and induces effector T cells.17 Therapeutic vaccines are designed to reinforce HPV specific 
CD4+ and CD8+ T cell responses, and particularly the protein peptide TA-CIN in combination 
with imiquimod and the HPV 16 synthetic long peptide (SLP) vaccine have met with clinical 
success.13,15 Application of imiquimod, PDT and therapeutic vaccination or a combination of 
these therapies are all associated with an increase in intralesional CD4+ and CD8+ T cells. 
Clearance of HPV is associated with a normalization of immune cell infiltration.12,15,16 Lack of 
efficacy of immunotherapy was shown to be associated with the presence and increase of 
Tregs.11,15,16,18
The majority of vulvar carcinomas and about 30% of VIN were shown to display down-
regulation of human leukocyte antigen (HLA) class I in a single study.12 This suggests that 
alterations in the expression of classical, and potentially also non-classical HLA-molecules 
may result in escape from a specific T cell response, as well as recurrence/progression of the 
lesions, or unresponsiveness to immunotherapy. Loss of HLA-class I was previously shown to 
be associated with non-responsiveness to PDT.12 In analogy, in HPV-induced cervical cancer 
loss of HLA-A was associated with poor survival.19 Alterations in HLA-class I expression 
are caused by a variety of mechanisms and these alterations may be reversible (‘soft’) or 
irreversible (‘hard’), in case of molecular defects as loss of heterozygosity (LOH) or beta-2 
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classical MHC class I chain related molecule A (MICA), which interacts with the co-stimulatory 
natural killer cell lectin-like receptor (NKG2)D receptor on natural killer (NK) cells and T cells24, 
is observed in cervical cancer where it is associated with a decreased survival when analysed 
in the context of the CTL/Treg ratio and the expression of classical HLA molecules.19 Elevated 
expression of HLA-class II and that of the non-classical molecules HLA-E and HLA-G has also 
been observed in HPV-induced cervical cancers.25-29 HLA-E hampers the efficacy of NK and 
T cells by binding to the inhibitory CD94/NKG2A receptors expressed on tumor infiltrating 
lymphocytes (TILs). While the expression of HLA-E was associated with poor survival in 
ovarian cancer it’s effect was limited in cervical squamous cell carcinoma and associated 
with better survival in cervical adenocarcinoma.27,28 HLA-G inhibits the function of NK cells, T 
cells and antigen presenting cells (APCs) and induces Tregs and myeloid derived suppressor 
cells by direct binding to the inhibitory receptors immunoglobulin like transcripts ILT-2 and 
ILT-4 and the killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4).30 The expression of 
HLA-G was preferentially expressed in cervical cancers with high number of TILs and may 
have caused T cell dysfunction.29
Based on these data in HPV-induced cervical cancer, as well as on the fact that HLA 
downregulation has also been found in vulvar carcinoma, we postulated that similar 
mechanisms may also play a role in premalignant HPV-induced vulvar neoplasia governing 
their progression to vulvar carcinoma and non-responsiveness to immunotherapy. 
Therefore, we analysed the expression of classical and non-classical HLA molecules in 
the lesions of patients with HPV-induced non-recurrent and recurrent uVIN, and vulvar 
carcinoma by immunohistochemistry and compared the results to healthy control tissue. 
Furthermore, the lesions of 12 patients, treated by HPV 16 SLP vaccination with or without 
clinical success, were analysed to determine the influence of HLA expression alteration on 
clinical responsiveness. Moreover, we studied whether HLA-class I downregulation could 
be regarded as ‘hard’ or ‘soft’ by LOH analysis and by comparing HLA expression on freshly 
isolated HPV-infected and non-infected keratinocytes after interferon (IFN)γ stimulation in 
vitro. 
Material and Methods 
Patient characteristics and material 
All patients treated for uVIN in the LUMC between 1990 and July 2012 of whom archival 
formalin-fixed, paraffin embedded tissue of the first uVIN lesion was available, were selected 
and included in this study (N=43, age: mean 47.26 years; range 19-84). Of 20 patients 
recurrent uVIN lesions were also included. Recurrence free survival was determined as 
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visit in case of no recurrent disease. Tissues from a cohort of HPV induced micro invasive- 
(<1mm infiltration) (N=8) and macro invasive vulvar carcinoma (>1mm infiltration) patients 
(N=13) were included as well to evaluate HLA expression in progressive vulvar neoplasia 
(age: mean 69.14 years; range 49-95). Samples from elective reductions of the labia minora, 
which were HPV negative (N=26), served as healthy controls (age: mean 32.96 years; range 
16-54). All samples included in this study were typed for HPV by HPV 16 polymerase chain 
reaction (PCR) with a HPV 16 specific primer set followed by HPV genotyping using the 
INNO-LiPA HPV genotyping Extra line probe assay (Innogenetics, Ghent, Belgium) in case of 
HPV 16 negativity.31,32 Histologic examination of all controls revealed no dysplasia or other 
abnormalities. Paraffin embedded uVIN biopsies of patients included in the HPV 16 SLP 
vaccination trial taken before vaccination were evaluated for tissue availability for HLA-class 
I immunofluorescent staining (N=12, of which 6 patients with and 6 patients without clinical 
response measured as lesion reduction).13 The Leiden University Medical Ethic Committee 
approved this study on prospective collection of healthy control tissue and for keratinocyte 
isolation patients were enrolled in the Circle study which investigates cellular immunity 
against HPV induced neoplasia. Furthermore archival formalin-fixed paraffin embedded 
patients samples were handled according to the medical ethical guidelines described in 
the code of conduct for proper secondary use of human tissue of the Dutch federation of 
Biomedical Scientific Societies. 
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were stained according to standard 
protocols as described previously27 with mouse monoclonal HLA-DR (anti HLA-DR clone 
TAL.1B5; DAKO (1:400)), mouse monoclonal HLA-DRDQDP (anti HLA-DRDQDPQ clone 
CD3/43; DAKO (1:2000)) which recognises all HLA class II molecules HLA-DR, -DQ and 
-DP, rabbit polyclonal MICA (anti MICA LS-B1377; Lifespan BioSciences (1:100)), mouse 
monoclonal HLA-E (anti HLA-E clone MEM-E/02; Serotec (1:200)) and mouse monoclonal 
HLA-G (anti HLA-G clone 4H84; Lifespan BioSciences (1:100)). Brown membrane and 
cytoplasm staining of epithelial cells was indicated positive for HLA expression. In case of 
no basal membrane staining and only cytoplasm staining this was scored as negative for 
HLA expression. Stromal and immune cells served as internal positive control and an extra 
section was stained without primary antibody as a negative control. 
Immunofluorescence 
Simultaneous detection of HLA-class I was performed by three color fluorescence staining 
according to standard procedure27 using mouse monoclonal HCA-2 and HC-10 (anti HLA-A and 
anti HLA-B/C; kindly provided by Prof. J. Neefjes, Netherlands Cancer Institute, Amsterdam, 
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DAKO (1:4000)). HLA-B/C antibody recognises all HLA-B and HLA-C molecules. Staining of 
lymphocytes was performed by use of rabbit polyclonal CD3 (anti CD3 clone ab828; Abcam 
(1:100)) and secondary antibodies were all goat anti mouse isotype specific antibodies with 
Alexa Fluorchromes; Alexa Fluor 488, 546, and 647 (Molecular Probes; 1:200) Five randomly 
selected representative images were captured using a confocal scanning microscope 
(LSM510, Zeiss) in a multitrack setting with a 25x/0.80 Plan-NEOFluar objective. Expression 
of the HLA molecules on the basal membrane was scored and stromal immune cells served 
as an internal positive control. Two additional sections were stained without primary or 
secondary antibody as a negative control. 
Evaluation of HLA expression and lymphocyte infiltrate 
HLA expression patterns were scored according to the scoring system by Ruiter et al.33 
Staining intensity of HLA at the basal membrane was scored as negative, weak, moderate 
or strong (0 to 3) (Supporting Information Fig.S1) and the percentage of positive cells was 
scored as: absent (<1%), sporadic (1-5%), local (6-25%), occasional (26-50%), majority (51-
75%) or large majority (>75%). Final scores of both the intensity and the percentage were 
categorized into three groups: 0-1 (negative), 2-6 (weak/moderate) and 7-8 (strong). The 
slides were scored independently by two researchers (EvE and VB or EJ and MT) without prior 
knowledge of clinical or histopathological parameters. In case of discrepancies consensus 
was reached or a third researcher was consulted. Intraepithelial and stromal lymphocyte 
counts were represented as the number of cells per mm2 for each slide (average of five 250x 
image slides) and were manually counted using the LSM 5 Image Examiner software. 
LOH 
DNA was extracted from micro dissected material (to obtain at least 70% of uVIN DNA) of 
14 uVIN, 9 uVIN adjacent to micro invasive carcinoma, 13 HPV positive vulvar carcinoma 
cases and from the uVIN- and healthy control material from which primary keratinocytes 
were cultured (see below). DNA was extracted and analysed for LOH on chromosome 6p21, 
with a minimal input of 10ng DNA/PCR, by PCR amplification using the D6S273 and D6S265 
microsatellite markers as previously described.22 Definitions of thresholds for LOH >1.7, 
retention of heterozygosity (ROH) 0.76-1.3 and allelic imbalance (“grey area”) 0.58-0.75 
were used accordingly.22
Keratinocyte culture and IFNγ stimulation
Primary keratinocytes were isolated from biopsies or excisions from women undergoing 
surgery for uVIN, HPV induced vulvar carcinomas or elective reduction of the labia minora 
and cultured in E-medium in presence of irradiated 3T3J2 mouse fibroblasts and 5-10μM 
Rho-associated kinase (ROCK) inhibitor (Y-27632). The addition of ROCK inhibitor has proven 









































Alterations in HLA expression in usual VIN  |  93
transduction of exogenous viral or cellular genes.34,35 In case of successful culture the cells 
were adapted to keratinocyte serum-free medium (K-SFM; Medium 154 supplemented 
with HKGS kit, Invitrogen, Breda, The Netherlands) for one passage, after which they were 
stimulated with 0 or 100IU/ml IFNγ for 48 hours. HLA expression was analysed by flow 
cytometry. Details are given in Supplemental Information Materials and Methods. 3T3J2 
mouse fibroblasts were cultured in Dulbecco’s modified Eagle’s medium supplemented with 
8% fetal bovine serum, 2mM l-glutamine and 1% penicillin-streptomycin (complete DMEM 
medium) (Gibco-BRL, Invitrogen).
Statistical analysis
For data analysis the statistical software package SPSS 20.0 (SPSS Inc., Chicago, IL) was used. 
Group comparisons of categorical data were performed by χ2 test, and the Fishers exact test 
in case of small groups. The non-parametric Mann-Whitney U test was used for continuous 
variables. The paired McNemars categorical test or the paired Wilcoxon Signed Rank test for 
continuous variables were used to determine differences in primary and secondary lesions. 
The Spearman correlation coefficient was used to detect correlation in the non-parametric 
data and in case of normality Pearson correlation coefficient was used. The Shapiro-Wilk 
test was used to determine a normal distribution. The Bonferroni correction was applied for 
multiple testing revealing a P-value of <0.004 as significant. Both univariate and multivariate 
analysis, corrected for multifocality of uVIN, were performed by a Cox proportional hazard 
model for recurrence-free survival analysis (RFS) and progression free survival (PFS). Two 
sided P-values <0.05 were considered significant. GraphPad Prism 5.04 (Graphpad Software 
Inc., LA Jolla, CA, USA) was used to illustrate the data by graphs and figures. 
Results 
Patients 
The clinical characteristics of the patient cohort are shown in Table 1. In 79% of uVIN patients 
HPV type 16 was detected, in the other uVIN samples HPV 33 (12%), HPV 73 (2%) or multiple 
high risk HPV infections (7%) were detected. First lesions were unifocal in 58.1% of cases and 
therapy consisted of excision in 51.2% (N=22), laser therapy in 30.2% (N=13), imiquimod 
in 7% (N=3) and a combination of laser and excision in 11.6% (N=5) of patients. Use of 
immunosuppressive medication was reported in 7 (16%) of patients and 80% of the patients 
were smokers.36 The majority of patients with HPV-induced vulvar carcinomas had a low 
stage of disease according to the International Federation of Obstetrics and Gynaecologists 
(FIGO) and only 1 patient was diagnosed with a lymph node metastasis in the groins. None 
of these patients died in follow up and in 3 patients (14%) a recurrent vulvar carcinoma 
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Table 1: Patient Characteristics 
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HLA expression in progressive course of disease 
Expression of classical and non-classical HLA molecules at different stages of disease are 
depicted in Fig. 1 and Supporting Information Fig.S2. Partial downregulation of HLA-class I 
was found in 72% of uVIN lesions, in 88% of uVIN adjacent to micro invasive carcinoma, in 
84% of vulvar carcinomas and in 8% of the controls. Total loss of HLA-A was detected in 9.3% 
of uVIN lesions and in 13% of uVIN lesions adjacent to microinvasive carcinoma. Total loss of 
HLA-B/C was found in 9% of uVIN lesions and in 38% uVIN lesions adjacent to micro invasive 
carcinoma whereas total loss of β2M was seen in 7% of uVIN, 13% of uVIN adjacent to micro 
invasive carcinoma and in 8.3% of vulvar carcinomas. Downregulation of β2M was more 
prominent in 83% - 100% of vulvar carcinoma compared with 58% of uVIN lesions (p=0.030).
HLA-class II expression, determined by either HLA-DR or HLA-DRDQDP positivity, was focal 
in areas of the basal layer in 65% of uVIN, in 75% of micro invasive carcinomas, in 46% of 
the vulvar carcinomas and was absent in the controls. In 7% of uVIN lesions HLA-class II 
expression was limited to the expression of HLA-DQDP. The expression of the non-classical 
molecules HLA-E (14%) and HLA-G (16%) in uVIN lesions was low but increased with the 
progressive course of vulvar neoplasia. Both HLA-E and -G were expressed in 25% of micro 
invasive carcinoma and in 54% (p=0.041) and 46% (p=0.133), respectively of the macro 
invasive vulvar carcinomas. MICA was downregulated in approximately 80% of uVIN lesions, 
in a comparable number of the micro- and macro invasive vulvar carcinomas (100% and 
92%, respectively) and in 7.7% of control tissues. 
HLA expression in recurrent uVIN and recurrence free survival 
We analysed 20 pairs of a primary uVIN lesions and the corresponding lesion that recurred 
after primary treatment. Analysis of the alterations in classical and non-classical HLA 
molecules revealed no overt differences between primary and subsequent recurrent 
lesions (Fig. 2). There was a clear correlation between the downregulation of HLA-B/C and 
the recurrences of uVIN lesions (p=0.029) as well as progression to carcinoma (p=0.016). 
Furthermore, our data suggest that the combination of HLA-class I and MICA downregulation 
was also associated with lesion recurrence (p=0.023) albeit that there was no difference in 
the risk of progression to cancer (Supporting Information Table S1). Expression of the other 
classical and non-classical HLA molecules was not predictive for recurrent uVIN lesions or 
progressive course of disease. Considering the time until recurrence or progression, the 
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Figure 1: Classical HLA-class I, HLA-class II, HLA-E, -G and MICA expression in the progressive course 
of HPV induced vulvar neoplasia
Paraffin embedded tissues of healthy controls (n=26), high grade uVIN lesions (n=43), microinvasive- (n=8) and 
macroinvasive vulvar carcinomas (n=13) were stained by immunohistochemistry for the indicated HLA molecules. 
A: membranous expression of HLA class I was evaluated by use of antibodies to β2M, HLA-A (HCA-2 antibody) and 
HLA-B/C (HC-10 antibody). Weak HLA-class I expression was indicated in case of weak to moderate HLA-A and/or 
HLA-B/C membrane expression compared to stromal expression. No expression was indicated in case of total loss 
of β2M, HLA-A and HLA-B/C on the membrane of basal epithelial layer. B: expression of membranous HLA class 
II was evaluated by use of weak, moderate or strong membrane expression compared to stromal expression of 
HLA-DR or HLA-DRDQDP and healthy controls. Membranous expression of HLA-E (C), HLA-G (D), and MICA (E) was 
considered positive in case of moderate or strong expression. The expression of these molecules was considered 
downregulated in case of none or weak expression. 
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Figure 2: Classical and non-classical HLA expression in primary and recurrent uVIN lesions for each 
individual patient.
Primary lesions of high grade uVIN lesions (n=43) and concomitant secondary recurrent uVIN lesions (n=20) were 
analysed by immunohistochemistry for HLA-class I expression as described in figure 1. Depicted are the expression 
levels of all indicated molecules for each patient in the primary and the concomitant recurrent uVIN lesion showing 
that there are no distinct differences in alterations of classical and non-classical HLA molecules between the 
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Hard and soft wired downregulation of HLA-class I in uVIN and vulvar carcinoma
In order to determine whether the observed downregulation of HLA by immunohistochemistry 
was ‘hard’- or ‘soft’-wired we selected 14 uVIN lesions based on tissue availability, 9 uVIN 
lesions adjacent to HPV positive micro invasive carcinomas and 12 HPV-positive macro invasive 
carcinomas for LOH evaluation (Supplemental Table 2). For 13 of the 14 uVIN lesions and for all 
carcinomas selected for LOH analysis, reliable results were obtained. Immunohistochemistry 
revealed downregulation of HLA-class I in 85% of these uVIN patients, in 100% of the micro 
invasive carcinomas and in 92% of the macro invasive carcinomas. The frequency of LOH 
was low (2 of 13; 15%) in the uVIN patients. In uVIN adjacent to micro invasive carcinoma 
LOH was found in 5 out of 9 cases (55.5%) and in 3 out of 12 (25%) of the macro invasive 
carcinomas LOH could be detected. In most cases the results of immunohistochemistry and 
LOH were concurrent. However, in 1 uVIN case LOH was found while immunohistochemistry 
revealed a strong expression of HLA-A, -B/C and β2M. The high percentage of partial HLA 
downregulation in uVIN lesions as detected by immunohistochemistry without concurrent 
detection of LOH suggests that the observed HLA-class I downregulation in uVIN is ‘soft’ 
wired and therefore, may be restored upon exposure to proinflammatory cytokines. To 
test this, we isolated keratinocytes from 3 healthy controls, 4 uVIN lesions and 2 vulvar 
carcinomas and analysed the expression of HLA-class I directly or after stimulation with 
IFNγ. The cultured keratinocytes of vulvar neoplasia patients displayed a lower expression 
of HLA-class I compared to controls (p=0.018; mean fluorescence 31.6 ± 19.1 vs. 66.1 ± 
14.4) but stimulation with IFNγ resulted in an upregulation of HLA-class I expression in all 
samples (p=0.842; mean fluorescence index 143.7 ± 85.8 vs. 131.8 ± 25.8) (Fig. 3a). The 
expression level detected by in vitro analysis corresponded to the expression of HLA-class 
I obtained by immunohistochemistry on uVIN lesions of these patients (Fig. 4). In 2 cases, 
the cultured keratinocytes showed LOH and IFNγ	stimulation revealed upregulation of HLA-
class I expression in both cases. This is probably explained by the upregulation of HLA-class 
I expression based on the one allele that was still present (Fig. 3a). As a positive control the 
IFNγ-mediated upregulation of HLA-DRDQDP expression was analysed. The expression of 
HLA-class II was upregulated in all cases and the expression levels did not differ (p=0.382; 
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Figure 3: HLA-class I (A) and HLA-DRDQDP (B) expression on cultured patient-derived keratinocytes 
before and after 48h of IFNy stimulation. 
Primary keratinocytes were isolated from biopsies or excisions of the vulva from women undergoing surgery for 
labia reduction, uVIN or HPV induced vulvar carcinomas. Keratinocytes were cultured in E-medium in presence of 
irradiated 3T3J2 mouse fibroblasts and 5-10μM Rho-associated kinase (ROCK) inhibitor (Y-27632). When cells grew 
out they were adapted to keratinocyte serum-free medium for one passage, after which they were stimulated with 
0 or 100IU/ml IFNy for 48 hours. HLA expression was analysed by flow cytometry and the Geomean Index was used 
to depict the intensity of HLA-class I or - II staining. The cultured keratinocytes of vulvar neoplasia patients display 
lower expression of HLA-class I compared to controls whereas stimulation with IFNy results in an upregulation 
of HLA-class I expression in all samples. As a positive control the levels and IFNy mediated upregulation of HLA-
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Figure 4: Immunofluorescent staining of HLA-class I in paraffin-embedded tissue and the effect of 
IFNy stimulation on HLA expression on corresponding isolated keratinocytes
From a number of patients with uVIN lesion we obtained fresh tissue for keratinocyte culture and paraffin embedded 
tissue of the same lesion used for histology. (left) Immunohistochemistry of HLA-B/C (blue), HLA-A (green) and β2M 
(red) staining of the paraffin embedded biopsy is shown. (right) Flow cytometry histograms representing HLA-class I 
expression (using the W6-32 antibody) of the keratinocytes from corresponding lesions with or without stimulation 
with 1000 IU/ml IFNy for 48 hours. Unstained is the background fluorescence of keratinocytes. The expression 
level (low, high) detected by in vitro analysis of keratinocyte cultures corresponded to the expression of HLA-class 
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Lymphocyte infiltrates 
Higher numbers of T cells, identified by the expression of CD3, were found in the stroma 
(p=<0.01) but not in the epithelium of uVIN and vulvar carcinoma lesions when compared to 
control tissues (Fig. 5). No correlations were found between CD3+ T cell infiltrates in stroma 
or epithelium and recurrent or progressive uVIN lesions (Supporting Information Table S1) 
neither was there an association with recurrence- or progression free survival (data not 
shown). Moreover the number of CD3+ cells did not correlate to the upregulation of HLA-
class II, HLA-E or HLA-G or to the downregulation of HLA-class I, HLA-A, HLA-B/C or MICA. 
HLA expression in uVIN biopsies of patients treated by HPV 16 SLP vaccination.
Evaluation of HLA expression in 12 uVIN biopsies taken before inclusion in a HPV 16 SLP 
vaccination trial13 revealed that both clinical responders (n=6; ID 206, 207, 210, 216, 227, 229) 
and non-responders (n=6; ID 201, 202, 203, 212, 222, 228) showed partial downregulation of 
HLA-class I. Overall 75% of uVIN biopsies revealed partial downregulation. In 3 of the 6 non-
responders a strong expression of HLA-class I could be observed whereas all 6 tested clinical 
responders revealed partial downregulation of HLA-class I. Of the clinical responders four 
patients displayed partial downregulation of HLA-A and –B/C whereas 2 patients displayed 
partial downregulation of HLA-A alone. 
Figure 5: CD3 infiltrates in progressive course of HPV induced vulvar neoplasia 
Paraffin embedded tissues of healthy controls (n=26), high grade uVIN lesions (n=43), microinvasive vulvar 
carcinomas (n=8) and macroinvasive vulvar carcinomas (n=13) were analysed for lymphocyte infiltration as 
identified by the expression of CD3 in both the epithelium (A) and stroma (B). An increased number of CD3+ T cells 
were found in the stroma (p=<0.01) but not in the epithelium of uVIN and vulvar carcinoma lesions when compared 
to healthy control tissues.
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Discussion 
This study shows that alterations in classical and non-classical HLA molecules is not limited 
to HPV-induced cancers but can already be observed at the premalignant stage of HPV-
induced vulvar neoplasia. HLA-class I is partially downregulated in over 70% of uVIN lesions 
and in 80% of HPV-induced vulvar carcinomas. Loss of either one allele of HLA-A or HLA-B/C 
was found in only 9% of uVIN lesions and total HLA loss of both alleles in only 2 (5%) of uVIN 
lesions. These results do not completely correspond to the previously reported total loss in 
19%, and partial downregulation of HLA-class I (allelic loss 9%) in uVIN lesions, probably due 
to the inclusion of HPV negative uVIN lesions in the previous study.12 Importantly, our study 
revealed that both HLA-class I and MICA downregulation is an early event in the immune 
escape mechanism of HPV-induced premalignant uVIN lesions. HLA-B/C downregulation 
and possibly also the combined downregulation of HLA-class I and MICA are associated 
with the recurrence of uVIN after treatment. These data once again show the impact of the 
immune system in HPV-induced diseases as downregulation of HLA-class I and MICA are a 
well-documented events in both HPV-induced cervical intraepithelial neoplasia (CIN) and 
cervical cancer and both weak HLA-A and MICA expression are an independent prognostic 
factor for a decreased 5-year survival rate.19,22,26,37 Alterations in the other HLA molecules 
(-class II, -E and -G) have no influence on recurrent or progressive course of uVIN lesions, 
and neither is the expression of both classical and non-classical HLA molecules altered from 
primary to recurrent uVIN lesions. 
The high frequency of HLA-class I downregulation in uVIN may compromise the efficacy of 
immunotherapy because HPV peptides are insufficiently presented to T cells. However, in 
contrast to the vulvar carcinomas tested in this study, the majority of uVIN lesions display 
downregulation of HLA-class I expression that is not associated with LOH suggesting that 
HLA-class I downregulation is soft-wired and that expression can be restored upon changes 
in the microenvironment. Indeed, we were able to show that the lower expression of HLA-
class I by HPV-infected keratinocytes freshly isolated from uVIN lesions could be increased by 
stimulation with IFNγ. Note that we only assessed general HLA-class I expression (by the W6-
32 antibody) which may obscure subtle allele specific alterations. The reversible nature of the 
HLA-class I downregulation, however, may form an explanation for the lack of clinical impact 
of partial downregulation of HLA-class I in patients responding to HPV 16 SLP vaccination 
since for instance vaccine-induced HPV 16-specific type helper T cells infiltrating the lesion 
can provide IFNγ in the microenvironment.13,18 The lack of overt differences in alterations of 
the expression of HLA between primary uVIN and the corresponding recurrent uVIN lesions 
suggests that the same possibility exists to restore HLA expression in recurrent uVIN lesions, 
however, maybe the recurrent lesions more often express LOH as we detected LOH in 55% 
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CIN adjacent to carcinoma (75%) and in cervical cancer (50%).22,23 We did not assess if there 
was a structural loss of β2M expression as total loss of HLA-class I expression was found in 
only 2 uVIN lesions. It will be important to test this as hard-wired HLA downregulation may 
directly affect the ability of lesions to regress. For instance, in melanoma it was the type of 
HLA-class I downregulation that determined the difference between regressing (soft-wired) 
and progressing (hard-wired) metastatic melanoma lesions.38 Moreover in cervical cancer 
patients complete loss of HLA-class I was associated with a failure to induce systemic HPV-
specific T cell responses as measured by CD4+ T cell responses.25 This may indirectly cause 
a failure of HPV-specific T cell response induction since cancer cells with normal HLA-class 
I expression will be more efficiently destroyed by CTLs, resulting in an enhanced antigen 
uptake and presentation by HLA-class II on APCs that can stimulate the CD4+ T cells required 
for the maintenance and functions of CTLs. 
The upregulation of HLA-class II is an early event in the carcinogenesis of vulvar neoplasia. 
HLA-class II is not expressed on non-dysplastic epithelium whereas in 65% of uVIN lesions 
and in 46-75% of vulvar carcinomas the expression is upregulated, corresponding to 
previous data on cervical cancer and 28% upregulation in uVIN (in a single study of only 
7 cases).25,26,39 The expression in uVIN is mainly focal (43.5% of cases <10% upregulation) 
and corresponds to high stromal infiltrates adjacent to the epithelium suggesting that 
upregulation is potentially related to cytokines in the local inflammatory environment. The 
effect of HLA-class II upregulation is unclear and may on one hand elicit activation of CD4+ 
T cells and enhance recruitment of CTLs but on the other hand it may as well hamper the 
immune response by induction or activation of Tregs.24,40
The expression of the non-classical molecules HLA-E and-G increases with the progressive 
course of HPV-induced vulvar neoplasia. These data are corresponding to cervical neoplasia 
where HLA-E expression gradually increases from CIN towards cancer and in cervical cancer 
was correlated to a large tumor size and lymph node metastasis.27,28,41 HLA-E, expressed in 
56-83% of cervical cancers and in 69% of cervical adenocarcinomas, is able to induce tumor 
tolerance by binding to its ligand CD94/NKG2A expressed on both NK and CTLs.27,28,42 CD94/
NKG2A expression can be induced by the cytokines interleukin (IL)-15 and tumor growth 
factor (TGF)-β present in the microenvironment of tumors.43,44 Apart from its immune 
inhibitory function HLA-E can also bind to the immune stimulatory molecule NKG2C, which 
is expressed on the majority of NK cells and on some CTLs.27 However the number of 
infiltrating NK cells in the microenvironment of both uVIN lesions and cervical cancer is 
low.27
HLA-G may induce immune evasion by inhibition of T cells, NK cells and APCs as well as 
by stimulating the production of Th2 cytokines.45,46 Upregulation of HLA-G in tumor cells 
may be induced by IFNγ in the anti-tumor elimination phase, by epigenetic alterations of 
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10.47 HLA-G expression was previously shown to be associated with progression of cervical 
lesions29,41,48,49 and other types of cancer.47 In addition, lack of HLA-G expression was an 
independent prognostic indicator of prolonged survival in patients with colorectal cancer.50 
These studies indicate that the increased expression of HLA-E and HLA-G in progressing 
lesions can contribute to escape from the immune system as well as form a barrier to 
successful immunotherapeutic approaches, although their rare expression in uVIN suggests 
that they are not able to mediate these effects during immunotherapy of uVIN.
In summary, alterations in classical HLA-class I and -II and non-classical MICA expression 
are already present in premalignant uVIN lesions and therefore of potential influence on 
immunotherapy in these lesions whereas expression of the non-classical HLA-E and -G 
are limited to the progressive course of disease. Remarkably, all evaluated uVIN patients 
who showed good clinical responses upon HPV SLP vaccination had partial HLA-class I 
downregulation indicating the potential reversibility of downregulation in premalignant 
uVIN upon proinflammatory cytokine response. These premalignant uVIN lesions may 
indeed be regarded as ‘soft’ lesions, considering the low percentage of LOH in uVIN and the 
reversible HLA-class I downregulation upon IFNγ stimulation in HPV infected keratinocytes. 
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Abstract 
Human papillomavirus induced usual vulvar intraepithelial neoplasia (uVIN) are infiltrated 
by immune cells but apparently not cleared. A potential explanation for this is an impaired 
T cell effector function by an immunesuppressive milieu, co-infiltrating regulatory T cells 
or the expression of co-inhibitory molecules. Here, the role of these potential inhibitory 
mechanisms was evaluated by a detailed immunohistochemical analysis of T cell infiltration 
in the context of FoxP3, Tbet, IDO, PD1, TIM3, NKG2A and Galectins-1, -3 and -9. Paraffin-
embedded tissues of primary uVIN lesions (n=43), recurrent uVIN lesions (n=20), vulvar 
carcinoma (n=21) and healthy vulvar tissue (n=26) were studied. We show that the 
vulva constitutes an area intensely surveyed by CD8+, CD4+, Tbet+ and regulatory T cell 
populations, parts of which express the examined co-inhibitory molecules. In uVIN especially, 
the number of regulatory T cells and TIM3+ T cells increased. The expression of the co-
inhibitory markers TIM3 and NKG2A probably reflected a higher degree of T cell activation 
as a dense infiltration with stromal CD8+TIM3+ T cells and CD3+NKG2A+ T cells was related 
to the absence of recurrences and/or a prolonged recurrence free survival. A dense co-
infiltrate with regulatory T cells was negatively associated with the time to recurrence, most 
dominantly when the stromal CD8+TIM3+ infiltration was limited. This notion was sustained 
in vulvar carcinoma’s where the numbers of regulatory T cells progressively increased to 
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Introduction 
Usual type vulvar intraepithelial neoplasia (uVIN) is caused by a persistent high risk HPV 
(hrHPV) infection, mainly type 16.1 The lifetime risk of an HPV infection is approximately 
80% and around 40% of female adolescents become infected at least once with an hrHPV.2-4 
HPV infections proceed asymptomatically in 90% of cases if the immune system is capable 
to clear the infection within two years.2-4 Spontaneous regression and clearance of HPV is 
associated with systemic HPV-specific CD4+ and CD8+ T cell responses.5,6 uVIN lesions have 
a malignant potential in 10% of untreated and 3-4% of treated patients and recurrence rates 
are high after conventional treatments.7,8 Treatment for uVIN includes potential disfiguring 
interventions associated with psychosexual consequences.7-9 Currently, conventional surgical 
treatments as local excision and laser therapy are increasingly replaced by immunotherapy, 
both in standardised (imiquimod) and experimental settings (photodynamic therapy (PDT) 
and therapeutic vaccination). Topical applied imiquimod induces T cell activation and 
proinflammatory cytokine release while therapeutic vaccines aim to reinforce HPV specific 
CD4+ and CD8+ T cell responses. Both immunotherapeutic approaches are promising and 
associated with clinical success however some patients are refractory to these therapies.10-15 
Although a few studies suggest that failure to respond to immunotherapy is related to a local 
immunosuppressive microenvironment10,13-17, knowledge on the uVIN microenvironment 
is limited. The epidermis of uVIN is characterised by a decreased number of CD8+ T cells 
and increase of immature dendritic cells (DCs) and Langerhans cells (LCs) while the dermis 
underlying the lesion displays an influx of mature DCs, natural killer (NK) cells and both 
CD4+ and CD8+ T cells.17,18 Moreover, some uVIN lesions are infiltrated by high numbers of 
regulatory T cells (Tregs).10,14-17 Tregs may induce expression of Indoleamine 2,3-dioxygenase 
(IDO) by dendritic cells and IDO can induce an immunosuppressive microenvironment by 
suppression of effector T cell and NK cell function and enhance the function of Tregs.19 
Clinical response to immunotherapy in uVIN is associated with an increase in intralesional 
CD8+ T cells as well to low numbers of Tregs.14-16,20 
The immune system prevents uncontrolled inflammation by expression of negative regulatory 
molecules, including Cytotoxic T-lymphocyte Antigen-4 (CTLA-4), T cell immunoglobulin 
mucin-3 (TIM3) and programmed cell death-1 (PD1), suppressing T cell function (reviewed 
in 21,22). The ligands of PD1 are programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2), 
which are induced upon exposure to inflammatory cytokines (e.g. IFNγ, IL-12, GM-CSF 
and IL-4) and can be expressed by resting B cells, T cells, macrophages, DCs and tumor 
epithelium.23,24 The interaction between PD1 and PD-L1 impairs T cell function through 
downregulation of proinflammatory cytokine production or apoptosis.23,24 Monoclonal 
antibodies blocking the co-inhibitory molecules PD1 or PD-L1 resulted in an improved clinical 
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only upregulated by differentiated T cells that produce IFNγ; CD4+ T helper-1 and CD8+ 
cytotoxic T cells.22 CD4+ and CD8+ T cells expressing TIM3, especially in combination with 
PD1, are highly dysfunctional and produce less IFNγ, TNFα and IL-2.27-29 TIM3 can suppress 
T cells following an interaction with Galectin-9.30-32 Galectins (Gal) are a family of lectins 
expressed in a variety of solid tumors, and in particular Gal-1, Gal-3 and Gal-9 are known to 
play a pivotal role in tumor development.33-35 Galectin-9 expression is upregulated by cells 
in response to proinflammatory cytokines in the microenvironment or upon activation via 
toll like receptors.32,36 Gal-1 and -3 can suppress the local immune response via inhibition of 
CD8+ T cell responses, induction of tolerogenic antigen presenting cells (APCs), promotion 
of Tregs and stimulation of an IL-10 associated Th2 cytokine response (reviewed in 33-35,37). 
Furthermore, activated T cells can express the CD94/NKG2A receptor which upon interaction 
with its ligand HLA-E inhibit T cell functionality.38,39
In order to assess the local immune suppressive microenvironment of uVIN we studied the 
infiltrating immune cells in the context of PD1, TIM3, NKG2A, Galectins 1, -3, and -9, IDO, 
and HLA-E in primary and recurrent uVIN lesions and their impact on clinical outcome. The 
results of this study highlight the pivotal role of uVIN-infiltrating activated T cells, reflected 
by the expression of TIM3 and NKG2A, in the protection against recurrent disease. 
Material and Methods 
Patient characteristics and material 
Formalin-fixed, paraffin embedded tissue blocks from 43 patients treated for uVIN in the 
LUMC between 1990 and July 2012 were used. In case of recurrent disease (n= 20 patients), 
defined as diagnosis of uVIN after successful treatment without residual disease, the recurrent 
uVIN lesions were also included. In addition, tissues from patients with HPV-related micro 
invasive (≤1mm infiltration) (n=8) and macro invasive vulvar carcinoma (>1mm infiltration) 
patients (n=13) were included to evaluate TIM3 and NKG2A expression in relation to HLA-E 
expression in progressive vulvar neoplasia (mean 69.14 years; range 49-95).40 Vulvar tissue 
from 26 healthy women undergoing labial reduction surgery served as healthy controls 
(mean 32.96 years; range 16-54). The Leiden University Medical Ethic Committee approved 
this study on prospective collection of healthy controls and use of archival FFPE blocks was 
according to Dutch Federation of Medical Research Association guidelines and histological 
analysis was performed by an experienced gynaecologic pathologist and classified according 
to the International Society for the Study of Vulvovaginal diseases (ISSVD) guidelines.41 All 
samples included in this study were typed for HPV by HPV16 PCR with a HPV16 specific 
primer set followed by HPV genotyping using the INNO-LiPA HPV genotypine Extra line probe 
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All controls were HPV negative and histologic examination revealed no dysplasia and no 
other abnormalities. 
Immunohistochemistry
For the analysis of Tbet, IDO, and NKp46 immunohistochemistry was used (Supplementary 
Fig. S1). Formalin-fixed, paraffin-embedded tissue blocks were cut into 4-µm thick sections 
and were deparaffinised in xylene and dehydrated using graded concentrations of ethanol 
to distilled water. Endogenous peroxidase activity was blocked with 0.3% H2O2/MeOH 
solution for 20 minutes. Antigen retrieval was achieved in boiling citrate (pH 6.0) buffer 
for 10 minutes for IDO and for Tbet and NKp46 EDTA buffer was used. Tissue sections were 
incubated with the primary antibody diluted in phosphate-buffered saline (PBS) containing 
1% bovine serum albumin (BSA) at room temperature overnight in a humidified box. 
Subsequently the tissue sections were incubated at room temperature with BrightVision 
poly-HRP anti mouse, rabbit and rat IgG (ImmunoLogic BV, Duiven, the Netherlands) for 30 
minutes. Slides were washed with PBS between incubation of antibodies for three times five 
minutes. The antigen-antibody reaction was visualized with 0.05M Tris-HCL buffer (pH 7.6) 
with 0.05% of 3,3’-diaminobenzidine and H2O2 for 10 minutes. Sections were counterstained 
with hematoxylin. The following primary antibodies were used: Tbet (anti-Tbet, rabbit, 
clone H210; Santa Cruz 1:400), IDO (anti-Indoleamine 2,3-dioxygenase, mouse-IgG3, clone 
10.1; Millipore 1:400), and NKp46 (anti-NKp46, mouse IgG2b, clone 195314; R&D 1:400). 
Cells positive for Tbet and NKp46 displayed brown nuclair staining. Cytoplasmic staining of 
epithelial cells was indicated positive for IDO expression. Cervical cancer and tonsil were 
used as positive controls and a section stained without primary antibody served as negative 
control. Nuclear staining of Tbet was counted automatically by calculation of area and pixel 
value by Image J. The number of NKp46 cells was limited and therefore counted manually. 
IDO expression was scored by EE and EJ as expression intensity in stroma and cytoplasmic 
staining of the epithelium. 
Immunofluorescence 
Simultaneous detection of lymphocytes and co-inhibitory molecules was carried out by 
double or triple fluorescent staining and confocal microscopy (Fig. 1). In brief, sections were 
deparaffinised and antigen retrieval was performed in citrate buffer or EDTA as described 
above. Incubation with primary antibodies was overnight at room temperature and secondary 
antibodies were all isotype specific antibodies with Alexa Fluorchromes Alexa Fluor 488, 546, 
and 647 (Molecular Probes; 1:200 diluted in PBS/BSA 1%). Primary antibodies were used 
in the following combinations: CD3+CD8+FoxP3+ staining; CD3+ (anti-CD3+, rabbit, clone 
ab828; Abcam 1:100), CD8+ (anti-CD8+, mouse-IgG2b, clone 4B11; Novusbiologicals 1:200), 
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CD3+ (anti-CD3+, rabbit, clone ab828; Abcam 1:100), PD1 (anti-CD279, goat, clone AF1086; 
R&D 1:50), FoxP3 (anti-FoxP3, mouse-IgG1, clone 236A/E7; Abcam 1:200), CD3+CD8+TIM3+ 
staining; CD3+ (anti-CD3+, rabbit, clone ab828; Abcam 1:100), CD8+ (anti-CD8+, mouse-
IgG2b, clone 4B11; Novusbiologicals 1:200), TIM3 (anti-HAVCR2, goat, clone AF2365; R&D 
systems 1:100), CD3+NKG2A+ staining; CD3+ (anti-CD3+, rabbit, clone ab828; Abcam 
1:100), NKG2A (anti-NKG2A, goat, clone N19; Santa Cruz 1:50), Galectin 1, -3, -9 staining; 
Gal-1 (anti-Lgals1, rabbit, clone 25138; Abcam 1:1000), Gal-3 (anti-Lgals 3, rat, clone M3/38; 
Biolegend 1:50), Gal-9 (anti-Lgals 9, goat, clone AF2045; R&D 1:200). Five randomly selected 
representative images were captured using a confocal scanning microscope (LSM510, Zeiss) 
in a multitrack setting with a 25x/0.80 Plan-NEOFluar objective. Stromal and immune cells 
were used as internal positive control and two extra sections were stained without primary 
or secondary antibody as a negative control. Epithelium and stromal cells were manually 
counted using the LSM 5 Image Examiner software and represented as the number of cells 
per mm2 for each slide (average of five 250x image slides).
Data analysis
The statistical software package SPSS 20.0 (SPSS Inc., Chicago, IL) was used and the Shapiro-
Wilk test was applied to determine a normal distribution. All variables were non-parametric 
and subsequently the Mann-Whitney U test was performed to compare continuous variables 
between patient groups. The paired Wilcoxon Signed Rank test was used to determine 
differences in paired primary and secondary recurrent lesions of the same patient. The 
Spearman correlation coefficient was used to detect correlation in the non-parametric data. 
Recurrence free survival (RFS) was determined as the interval between first therapy and 
diagnosis of recurrent disease or the last follow up visit. Patients were divided into groups 
based on the median of infiltrating cells and a univariate Log Rank (Kaplan Meier) analysis 
for recurrence-free survival was performed. Subsequently multivariate analysis, corrected 
for multifocality of uVIN lesion, was performed by a Cox proportional hazard model since 
multifocality was previously identified as prognostic markerin our study cohort.42 Two sided 
p values <0.05 were considered statistical significant. GraphPad Prism 5.04 (Graphpad 
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Figure 1: Examples of triple or double immunofluorescent confocal microscopy of T cell infiltrates 
and co-inhibitory molecules PD1, TIM3, NKG2A and immunosuppressive Galactins 1, -3 and -9
Paraffin-embedded tissue of healthy controls (n=26), primary uVIN lesions (n=43), recurrent uVIN lesions (n=20) 
and vulvar carcinoma (n=21) were analysed by triple or double fluorescent confocal microscopy with antibodies 
against: A: CD8+ (green), CD3+ (red) and FoxP3 (blue): double staining results in CD3+CD8+ (yellow), CD3+FoxP3+ 
(red with blue nuclei), B: PD1 (green), CD3+ (red), FoxP3+ (blue): double staining results in CD3+PD1+ (yellow), 
CD3+PD1+FoxP3+ (yellow with blue nuclei), CD3+FoxP3+ (red with blue nuclei), C: CD8+ (green), TIM3+ (red), CD3+ 
(blue): double staining results in CD3+TIM3+ (purple), CD3+CD8+TIM3+ (white), CD3+CD8+ (light blue), D: Galectin 
3 (green), Galectin 9 (red), Galectin 1 (blue): double staining results in Galectin 1+3+ (light blue), Galectin 1+9+ 
(purple), Galectin 3+9+ (yellow), triple staining in Galectin 1+3+9+ (white), E: NKG2A+ (green), CD3+ (red): double 
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Results 
Patients 
The clinical characteristics of the patient cohort are shown in Supplementary Table S1. The 
clinical prognostic factors were previously described in detail.40,42 HPV type 16 was detected 
in 79% of first uVIN lesions and 58.1% of uVIN lesions were unifocal. First therapy consisted 
of excision (51.2%), laser therapy (30.2%), imiquimod (7%) and a combination of laser and 
excision (11.6%). Use of immunosuppressive medication was reported in 7 patients which 
revealed no overt differences in immune infiltration as compared to the rest of the group 
of uVIN patients (data not shown). In 20 patients a recurrence occurred in a median time of 
19.5 months (range 0-199). Patients with HPV-induced vulvar carcinomas had a low stage of 
disease according to the International Federation of Obstetrics and Gynaecologists (FIGO), 
except for one. None of these patients died during follow up and in 3 patients a recurrent 
vulvar carcinoma occurred after a median time of 7 months (range 6-46). 
The microenvironment in uVIN is functionally different from healthy controls 
Examples of the immunohistological stainings used to quantify the number of cells per 
square millimetre of vulvar tissue are shown in Fig. 1 and Supplementary Fig. S1. Substantial 
numbers of intraepithelial and stromal CD4+ and CD8+ T cells were found in healthy control 
tissue, uVIN and HPV related vulvar cancer (Table 1; Fig. 2), indicating that the vulvar skin is 
intensely surveyed by T cells. NK cells (NKp46+) were rare in both the dermis and epidermis 
of uVIN and controls (Supplementary Table S2).
Overall the intraepithelial CD3+ T cell infiltration (Table 1; Fig. 2) did not differ between 
healthy controls (range 36-592 cells/mm2) and uVIN (range 54-763 cells/mm2). In both 
cases, approximately 40% of these CD3+ cells were CD4+ and 60% were CD8+ (Fig.3). A 
closer look, combining T cell infiltration with the expression of functional markers, revealed 
that especially the number of CD4+FoxP3+ regulatory T cells (Table 1; Fig. 2) as well as 
that of intraepithelial CD3+, CD4+TIM3+, and CD8+ TIM3+ T cells was higher uVIN lesions 
than in healthy control tissue (Table 1; Fig.2; Fig.3). Moreover, the relative contribution 
of CD4+Foxp3+ T cells within the whole infiltrating T cell population increased (Fig.3). In 
contrast, the percentage of T cells expressing PD-1 or NKG2A was higher in controls than in 
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In general, the stroma of uVIN was more densely infiltrated with CD3+ T cells (range 28-2180 
cells/mm2) than control tissue (range 34-976 cells/mm2), albeit that the CD4+ (60-65%) and 
CD8+ (35-40%) composition was not different (Table 1, Fig.2; Fig.3). Analysis of T cell marker 
expression revealed that a much higher percentage of stromal uVIN-infiltrating CD4+ T cells 
expressed FoxP3 (80% vs 20% in healthy controls). In addition, Tbet was expressed in a higher 
number and percentage of cells (Table 1, Fig.2; Fig.3). The numbers and percentages of 
TIM3-positive CD3+, CD4+ and CD8+ T cells were much higher in uVIN lesions than controls 
(Table 1, Fig.2; Fig.3), however as indicated by the ratio’s between TIM3+ and TIM3- T cells 
(<1), each lesion comprised more TIM3- T cells than TIM3+ T cells (Supplementary Table 
S2). Notably, the ratios between these cells were higher in uVIN lesions than in controls, 
indicating that uVIN lesions comprised both absolutely and relatively more infiltrating 
TIM3+ T cells than controls (Supplementary Table S2). 
The number of stromal CD3+PD1+ T cells was higher in uVIN lesions than in controls but 
in both cases the CD3+PD1+ were outnumbered by the CD3+PD1- T cells as indicated by 
their ratios (Supplementary Table S2). Furthermore, the CD3+PD1- to CD3+PD1+ ratio was 
significantly higher for uVIN lesions than controls, suggesting that the uVIN lesions were 
infiltrated by higher numbers of CD3+PD1- T cells (Supplementary Table S2). Finally, stromal 
CD3+NKG2A+ T cells were scarce and did not differ (Table 1; Fig.2; Fig.3). 
In 20 patients, the primary lesion as well as the recurrent lesion were analysed for the 
expression of inhibitory markers. Overall, there were no overt differences in the number of 
intraepithelial and stromal infiltrating immune cells between the primary and the recurrent 
lesions (Supplementary Table S3). In recurrent uVIN lesions a slightly higher number 
of intraepithelial CD3+PD1+FoxP3+ T cells and a lower number of stromal CD3+NKG2A+ 
T cells and a higher ratio of CD4+TIM3+/CD4+TIM3- T cells were seen reflecting a more 
immunotolerant microenvironment (Supplementary Table S3). 
In summary, these data show that HPV-induced uVIN lesions display a T cell infiltrate 
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Figure 3: The relative distribution of T cell subsets within the infiltrating CD3+ T cell population 
Bar graph representing the composition of the infiltrating T cells and the expression of co-inhibitory molecules 
FoxP3, PD1, TIM3 and NKG2A as a percentage (%) of the total amount of infiltrating CD3+ T cells, both in the 
epithelium and stroma of healthy controls, uVIN and vulvarcarcinoma. NE (not evaluated) 
Higher numbers of stromal galectin-1 and/or - 9 expressing immune cells in uVIN.
As Gal-1, Gal-3 and Gal-9 are all involved in tumour development 33-35 their expression was 
also analyzed in uVIN lesions. Gal-9 expression by the uVIN epithelium itself was found in 
some uVIN patients but the expression was less intense compared to what was seen for 
keratinocytes in control tissue (Supplementary Table S2). Galectins can be expressed by 
virtually all immune cells 33-35, but based on the morphology of cells expressing Gal-9 in 
the microenvironment of uVIN and the number of infiltrating T cells (Fig.2), the majority 
of these cells were most likely myeloid cells. Whereas no differences were found in the 
intraepithelial immune cells expressing Gal-9, the total number of stromal Gal-9 expressing 
immune cells was increased in uVIN (Table 1 and Supplementary Table S2). Similarly, 
the number of stromal Gal-1 and Gal-3 positive immune cells was higher in uVIN than in 
controls (Table 1 and Supplementary Table S2). No difference was found in the number 
of intraepithelial Gal-1 expressing immune cells and due to the strong expression of Gal-3 
by the keratinocytes in healthy controls, evaluation of Gal-3+ infiltrating immune cells was 
not possible (Supplementary Table S2). Gal-1 was not or weakly expressed by keratinocytes 
albeit the expression of Gal-1 by the HPV infected keratinocytes of recurrent uVIN lesions 
was increased (38.1%) compared to primary lesions (14.3%) (Supplementary Table S3). IDO 
was not expressed in epithelium of uVIN (Supplementary Table S2). Since PD-1 expression 
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The presence of TIM3+and/or NKG2A+ T cells is associated with the absence of recurrences 
and a longer recurrence free survival
Twenty of the 43 uVIN patients developed recurrent lesions. A comparison of the data 
between the primary lesions of the non-recurrent and recurrent uVIN patients revealed 
that the primary lesions of non-recurrent uVIN lesions displayed a denser infiltration with 
intraepithelial CD3+TIM3+ T cells and Gal-9+ immune cells (Supplementary Table S4). Since 
Gal-9 is expressed upon exposure to proinflammatory mediators36 and expression of the other 
galectins is more likely to be associated with neoplastic cell changes33, the better outcome 
associated with intraepithelial Gal-9 expressing cells may in fact reflect the beneficial action 
of locally active proinflammatory T cells. Indeed, the number of intraepithelial Tbet+ (IFNγ) 
cells was positively associated with the total number of intraepithelial Gal-9+ cells (p= 0.028) 
as well as with the number of intraepithelial CD8+TIM3+ T cells (p=0.042) and in particular 
with a higher ratio of intraepithelial TIM3+ to TIM3- CD8+ T cells (p= 0.005) Altogether, this 
suggests a protective role for TIM3+ T cells against recurrence. 
To sustain this notion we evaluated the time to recurrence of uVIN lesions in the context of 
the different immune infiltrates in uVIN by multivariate Cox analyses. The data were corrected 
for multifocality of uVIN lesions since this was a clinically prognostic factor for recurrence in 
this cohort42 (Fig.4 and Supplementary Table S4). No differences in the time to recurrence 
were found when the intraepithelial populations of T cells were analysed (Supplementary 
Table S4). Analysis of the time to recurrence for cells in the stroma revealed that there 
were no direct associations with T cell functional type (CD4, CD8, Tbet, FoxP3), albeit that 
a low ratio of CD8+/Tregs in the stroma of uVIN, reflecting a relative high infiltrate with 
Tregs, is associated with a decreased RFS (Fig. 4a; p=0.016 HR 0.280). However, when the 
T cells were analysed in the context of their co-inhibitory marker expression, the presence 
of high numbers of absolute stromal CD3+TIM3+ or CD8+TIM3+ T cells (p=0.058 HR 0.377 
and p=0.015 HR 0.282, respectively; Fig. 4b), or relative to their stromal CD8+TIM3-negative 
counterparts (p=0.015 HR 0.287; Fig. 4c), in the uVIN were associated with an improved 
RFS (Supplementary Table S4). Again, the infiltration of CD8+TIM3+ cells and that of Tbet 
(IFNγ) cells was associated with clinical benefit as a combined strong stromal infiltration 
with CD8+TIM3+ cells and Tbet+ cells was associated with a longer RFS (Supplementary Fig. 
S2a). Because of the association between proinflammatory cytokines and Gal-9 expression 
we also analysed the numbers of stromal TIM3+ cells in the context of Gal-9. Notably, a 
strong stromal infiltrate with CD3+TIM3+, and especially CD8+TIM3+ combined with high 
single expression of Gal-9 was associated with a much better recurrence free survival than 
when there were low numbers of these types of T cells and high single Gal-9 expression in a 
multivariate analysis (high vs low CD8+TIM3+: p=0.009 HR 53; Supplementary Fig. S2b and 
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Our data suggest that the expression of TIM3 by CD8+ T cells reflects a greater degree of 
T cell activation in uVIN. In order to understand if in a number of cases this is effectively 
counteracted by co-infiltrating Tregs we analysed their association with recurrence free 
survival by grouping the patients in 4 categories based on the median stromal CD8+TIM3+ and 
median stromal Treg number. This revealed no difference in RFS in epithelial compartment 
(Fig. 4d) and neither between patients displaying a low or high stromal infiltration with 
Tregs when the number of co-infiltrating stromal CD8+TIM3+ T cells was above the median 
(Fig. 4e). However, Tregs were indirectly associated with a worse RFS in case the numbers of 
stromal CD8+TIM3+ were lower than the median (Fig. 4e). 
While, as expected based on our expression data, there was no association between T 
cell expressed PD1 and RFS, surprisingly a high ratio of CD3+NKG2A+ /CD3+NKG2A- was 
also associated with a prolonged RFS (p=0.001 HR 6.36) indicating that the presence of 
CD3+NKG2A+ T cells in stroma is favourable (Supplementary Fig. S2c and Supplementary 
Table S4). 
Altogether these data suggest that patients with a better RFS display increased numbers 
of lesion infiltrating TIM3+ and/or NKG2A+ T cells as well as a more IFNγ-associated 
microenvironment. 
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Figure 4 continued: The impact of TIM3 and NKG2A expressing T cells on recurrence free survival 
(RFS) in uVIN 
Immune cell infiltrates in the microenvironment of uVIN expressing co-inhibitory molecules were grouped based on 
the median number of cells and analysed by Kaplan Meier (Log Rank) survival curves and *multivariate Cox analysis 
to determine the influence on the recurrence free survival of usual VIN lesions. Depicted are A: Ratio CD8+/Treg in 
stroma, B: CD8+TIM3+ in stroma, C: Ratio CD8+TIM3-/CD8+TIM3+ in stroma, D: Combination of CD8+TIM3+ and 
Tregs in epithelium and E: Combination of CD8+TIM3+ and Tregs cells in stroma.
T cells expressing Foxp3, TIM3, Tbet or NKG2a in HPV induced vulvar carcinomas 
The number of stromal CD8+TIM3+ T cells, the combination of stromal CD8+ TIM3+ cells and 
T cells expressing Tbet, as well as the ratio’s between stromal CD8+ T cells/Tregs and stromal 
CD3+NKG2A+/CD3+NKG2A- cells were all associated with protection against recurrence of 
uVIN. Therefore, we extended our study to determine the number of these T cells in a group 
of HPV-induced vulvar carcinomas (n=21). In comparison to uVIN lesions, these HPV induced 
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even stronger CD4+FoxP3+ T cells infiltration (Fig. 2;Fig.3; Supplementary Table S5). There 
was a strong reduction in the ratios of intraepithelial CD8+/Tregs, CD4/Tregs and Tbet+/
Tregs. These ratios were also reduced in the vulva carcinomas stromal compartment albeit 
that the reductions were mild (Supplementary Table S5). Moreover the relative number of 
Tbet + effector T cells was decreased in stroma of vulvar carcinoma reflected by a higher ratio 
of CD8+/Tbet. Both the number of stromal NKG2A+ T cells and that of stromal CD8+TIM3+ T 
cells increased in vulva carcinomas in line with the increases seen for total CD3+ T cells and 
CD8+ T cells, but not as much as was seen for Tregs. While the relative number of stromal 
NKG2A+ to NKG2A- T cells showed a decrease in vulvar carcinoma, the relative numbers 
of stromal TIM3+ CD8+ T cells was enhanced (Supplementary Table S5). Interestingly, the 
number of NKG2A+ T cells was especially low in tumors expressing the NKG2A ligand, HLA-E 
(Supplementary Fig.S3). 
Altogether, the progressive course of vulvar neoplasia is characterised by a more immune 
suppressed microenvironment where there is a marked increase in the number of regulatory 
T cells that readily outnumber the numbers of TIM3+ or NKG2A+ lymphocytes. 
Discussion 
Here we present a comprehensive study on the presence of T cells and expression of several 
immune inhibitory molecules in the microenvironment of primary and recurrent uVIN lesions, 
HPV-induced vulvar carcinoma, and in healthy controls. The results of our study clearly show 
that a stronger infiltration by T cells expressing the co-inhibitory markers TIM3 and NKG2A 
and relatively low numbers of regulatory T cells in primary uVIN lesions is associated with 
a longer recurrence free survival and the absence of recurrences. T cells expressing co-
inhibitory markers are often regarded as exhausted T cells with impaired ability to become 
activated and exert their function.21,22 It is beyond doubt that these T cells are vulnerable 
to suppression in case their ligands are expressed and that blocking of the receptor-ligand 
interactions (e.g. PD1-PD-L1) can stimulate tumor-specific T cell immunity.25,26 However, the 
expression of these receptors by activated T cells has been shown to primarily reflect T cell 
differentiation and activation.43-45 Based on their positive association with RFS, the increased 
expression of the co-inhibitory markers TIM3 and NKG2A by T cells in uVIN also is more likely 
to reflect a greater degree of T cell activation. 
TIM3 is associated with exhaustion of T cells in several types of carcinoma and is expressed 
on terminally differentiated CD4+Th1+ 31, Th17 and CD8+ T cells.36,46 In uVIN the numbers 
of both CD4+ and CD8+ T cells expressing TIM3 were increased when compared to healthy 
tissue. TIM3 expressed on CD4+ T cells did not bear any impact on clinical outcome, 
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later development of recurrence in uVIN lesions. CD4+TIM3+ and TIM3 co-expressed on 
CD8+PD1+ T cells are associated with impaired T cell function resulting in less IFNγ, TNFα 
and IL-2 production in cancer.27,29 In tumor bearing mice the administration of Gal-9 induced 
the apoptosis of CD4+ T cells while it increased the number of IFNγ producing CD8+TIM3+ 
T cells and CD86+TIM3+ DCs and prolonged their survival47 while in vitro, Gal-9 exposed 
immature DCs become activated and produce IL-12.35,47,48 Furthermore, treatment of PBMCs 
from healthy donors with Gal-9 induces apoptosis in 60% of T cells but the remaining cells 
expand and differentiate into central memory and IFNγ producing T cells.49 Thus Gal-9 can 
mediate positive effects on CD8+TIM3+ T cells as long as they do not express PD1, and 
impair activated Th1 T cells.31,49 In view of these data, the positive relation between IFNγ 
(Tbet), Gal-9 and TIM3 on CD4+ and CD8+ T cells in uVIN, in combination with a lower 
PD1 expression can explain the positive impact of (the presence of) CD8+ TIM3+ T cells on 
recurrences. Furthermore, it also helps to explain why the CD4+ TIM3+ T cells do not bear 
any impact.
It is likely that the T cells expressing the co-inhibitory markers in the presence of their 
ligands are functionally impaired and as such they will not be able to contribute in the 
antitumor response. This effect, however, may go unnoticed if their presence simultaneously 
indicates that overall there is much more effective stimulation of T cells within a highly 
active microenvironment. Then, the association between non-recurrence and RFS and 
the expression of these markers is highly likely a reflection of an effective local immune 
response, which one can envisage may even lead to regression when in addition such co-
inhibitory molecules on the T cells are blocked. 
Previous studies suggested that the stromal compartment of uVIN is the immunologically 
active area in uVIN.16,17 Our data confirm that uVIN are intensely surveyed by the immune 
system as an abundant number of activated proinflammatory IFNγ-producing T cells, 
reflected by T cells expressing Tbet, TIM3 and/or NKG2A, and Gal-9 expressing immune 
cells were detected in the stroma. Moreover, our study reveals the importance of this 
stromal immunological activity by the association of such an activity with favourable 
clinical outcome. The stromal compartment in vulvar carcinomas show signs of immune 
suppression as reflected by the relative decrease in the number of stromal Tbet + effector T 
cells and a strong increase in the numbers of Tregs outnumbering stromal TIM3+ or NKG2A+ 
lymphocytes. 
The epithelium in uVIN was considered to be in immunosuppressed state.14-17,20 This fits with 
the data on myeloid cells and Tregs in our cohort of uVIN patients showing that a dense 
intraepithelial CD14+ cell infiltration was associated with high numbers of intraepithelial 
CD4+ Tregs but also with lower numbers of stromal CD8+TIM3+ T cells.50 In vulvar 
carcinomas this was even more pronounced as evidenced by a strong reduction in the ratios 
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immunological landscape is associated with the activation of a local IFNγ-associated T cell 
response. If the local response is less active (lower numbers of CD8+TIM3+ and NKG2A+ 
T cells; higher numbers of macrophages) recurrences are likely to appear more rapidly. 
Immunotherapy may strengthen the pre-existent activation of the local immune system and 
immunologically active primary lesions may be more likely to respond to immunotherapy, 
also because these lesions are characterised by lower numbers of regulatory T cells 
subsets, which have previously been shown to be associated with non-responsiveness 
to immunotherapy.10,14,15 Along these lines, we expect that less immunologically active 
uVIN lesions, recurrent lesions and vulvar carcinoma may form a greater challenge for 
immunotherapy. We will now evaluate the expression of these potential biomarkers in the 
lesions of uVIN patients vaccinated with our HPV16-SLP vaccine combined with imiquimod 
applied at the vaccination site (manuscript in preparation), to explore their potential role in 
relation to the clinical response to vaccination.
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Abstract 
Human papilloma virus (HPV) induced usual type vulvar intraepithelial neoplasia (uVIN) is 
infiltrated by myeloid cells but the type and role of these cells is unclear. We used triple 
immunofluorescent confocal microscopy to locate, identify and quantify myeloid cells 
based on their staining pattern for CD14, CD33 and CD163 in a cohort of 43 primary and 
20 recurrent uVIN lesions, 21 carcinomas and 26 normal vulvar tissues. The progressive 
course of uVIN is characterised by an increase in both intraepithelial and stromal mature M1 
and M2 macrophages. While the M2 macrophages outnumber M1 macrophages in healthy 
controls and uVIN, they are matched in number by M1 macrophages in cancer. Importantly, 
uVIN patients with a dense intraepithelial infiltration with mature CD14+ macrophages 
(irrespective of M1 or M2 type) displayed approximately a six times higher risk to develop a 
recurrence and a high number of these cells constituted an independent prognostic factor 
for recurrence. In addition, a dense intraepithelial CD14+ cell infiltration was associated 
with high numbers of intraepithelial CD4+ Tregs and low numbers of stromal CD8+TIM3+ T 
cells. Patients with low numbers of intraepithelial CD14+ cells and high numbers of stromal 
CD8+TIM3+ cells showed the best recurrence free survival. These data clearly show the 
importance of the local immune response in HPV-induced vulvar neoplasia and may be of 
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Introduction 
Usual vulvar intraepithelial neoplasia (uVIN) lesions are caused by a persistent high risk 
human papilloma virus (HPV) infection (mainly HPV 16) and are characterised by high 
recurrences, a low spontaneous regression rate of 1.5% and a malignant potential of 3-4% 
in treated patients.1-3 Treatment of uVIN lesions is indispensable since 80% of patients 
suffer from symptoms as pruritis and pain.2-4 Conventional treatment consistent of potential 
disfiguring surgical interventions is associated with psychosexual problems and is increasingly 
replaced by either standardised immunotherapy with imiquimod or immunotherapy in 
experimental setting by therapeutic vaccination or photodynamic therapy, with promising 
clinical successes.2-8 
The incidence of hrHPV-induced dysplasia is increased in immunocompromised patients 
highlighting the essential role of the immune system in viral clearance.9,10 Spontaneous 
regression of HPV is associated with systemic HPV specific CD4+ and CD8+ immune 
responses, however in most of the patients with uVIN these T cell responses are either weak 
or absent.11,12 In addition, the local innate immune cell environment is known to influence 
innate and adaptive immune responses in tumors.13,14 Monocytes are innate immune 
cells which can differentiate into dendritic cells (DCs) or macrophages in response to local 
factors.13 DCs process and present antigens to T cells, stimulate cytotoxicity of NK cells and 
initiate the adaptive immune response.15 Studies of the microenvironment in uVIN revealed 
that it is characterised by especially dermal immune activity as higher numbers of innate and 
adaptive immune cells are found in the stroma when compared to healthy control tissue.16,17 
In contrast, the epidermis shows reduced numbers of CD8+ T cells, CD1a+ mature Langerhans 
cells (LCs) and immature CD207+ LCs, while the number of intraepithelial macrophages 
is increased in uVIN.16,17 Intralesional macrophages are derived from tissue immigrating 
monocytes and are generally categorised into tumor suppressive type 1 macrophages (M1) 
which produce IL-12 and TNFα and tumor promoting type 2 macrophages (M2) which are 
known to produce anti-inflammatory cytokines.13,18,19 High numbers of tumor-associated 
macrophages (TAMs) induce tumor growth, progression and poor survival rates (reviewed 
in 13). Interestingly, in HPV-induced cervical cancer the intraepithelial infiltration with high 
numbers of M1 macrophages is an independent prognostic factor for a favourable survival.20 
The type of myeloid cells infiltrate could influence the uVIN microenvironment and as such 
may also influence the outcome of immunotherapeutic approaches for HPV induced vulvar 
neoplasia.5-8,21 Current knowledge of the character of uVIN infiltrating myeloid cells is limited. 
In this study we aimed to characterise intraepithelial and stromal (im)mature myeloid cells 
in uVIN lesions, HPV induced vulvar carcinoma and healthy vulvar tissue and determine 
their influence on the clinical course of disease. We analysed myeloid cell infiltrates in the 
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performed in cervical cancer.20 CD14 is a marker for monocytes/macrophages and expressed 
as well on a subset of DCs14,20,22,23, CD33 expression is lost along the differentiation pathway 
of myeloid cells and is expressed by immature monocytes, macrophages and myeloid 
DCs.24 CD163 is a monocyte/macrophage specific marker that is mainly expressed on M2 
macrophages as well as on immune suppressive DCs.14,25-28 Our results demonstrate that 
under healthy conditions, intraepithelial myeloid cells are absent whereas in the stroma M2 
macrophages dominate. The changes to vulvar dysplasia are characterised by an increase 
in both intraepithelial and stromal mature CD14+ M1 and M2 macrophages. The increase 
of intraepithelial mature CD14+ cells is an independent negative prognostic factor for 
recurrence free survival in uVIN.
Material and Methods 
Patient material 
Analysis of myeloid cell infiltrates in the microenvironment of vulvar neoplasia was 
performed on formalin-fixed, paraffin embedded tissue (FFPE) blocks from 43 first lesions 
of uVIN, 20 recurrent uVIN lesions, 21 HPV positive vulvar carcinomas and 26 HPV negative 
healthy controls who underwent labial reduction surgery. Selected uVIN patients were 
treated in the Leiden University Medical Center (LUMC) between 1996 and July 2012 
and histological analysis was performed by an experienced gynaecologic pathologist and 
classified according to the International Society for the Study of Vulvovaginal Diseases (ISSVD) 
guidelines.29 Patient selection and characteristics have been described previously.30,31 The 
Leiden University Medical Ethic Committee approved the study on prospective collection 
of healthy controls and use of archival FFPE blocks was according to Dutch Federation of 
Medical Research Association guidelines. On all FFPE tissue from uVIN lesions HPV typing 
was performed by HPV16 PCR with a HPV16 specific primer set followed by HPV genotyping 
using the INNO-LiPA HPV genotypine Extra line probe assay (Innogenetics, Ghent, Belgium) 
in case of HPV16 negativity.32,33 
Triple immunofluorescent confocal microscopy 
Simultaneous detection of monocytes was carried out by triple fluorescent staining and 
confocal microscopy as described previously.20 In brief, sections were deparaffinezed and 
antigen retrieval was performed in pre-heated Tris-EDTA buffer pH 9.0. Primary antibodies: 
CD14 (anti-CD14, mouse IgG2a, clone 7; Novocastra 1:50), CD33 (anti-CD33, mouse IgG2b, 
clone PWS44; Novocastra (1:100) and CD163 (anti-CD163, mouse IgG1, clone 10D6; Novocastra 
1:1600). Secondary antibodies were all isotype specific antibodies with Alexa Fluorchromes 
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1:200). Five randomly selected representative images of immunofluorescent stained tissue 
sections were captured using a confocal scanning microscope (LSM510, Zeiss) in a multitrack 
setting with a 25x/0.80 Plan-NEOFluar objective. Cervical cancer tissue was used as a positive 
control and two extra sections were stained without primary or secondary antibody as a 
negative control. Epithelium and stromal cells were manually counted using the LSM 5 Image 
Examiner software and represented as the number of cells per mm2 for each slide (average 
of five 250x images). By use of overlapping colors the following infiltrating myeloid cells were 
distinguished; CD14+CD33-CD163- (green), CD14-CD33+CD163- (red), CD14-CD33-CD163+ 
(blue), CD14+CD33+CD163- (yellow), CD14+CD33-CD163+ (light-blue), CD14-CD33+CD163+ 
(purple), CD14+CD33+CD163+ (white) (Fig. 1). These cells were prior to analysis categorized 
into total CD14+, CD33+ or CD163+ positives, M1 macrophages (CD14+CD33-CD163- and 
CD14+CD33+CD163-), M2 macrophages (CD14+CD33+CD163+ and CD14+CD33-CD163+) 
and non-macrophage M2-like cells (CD14-CD163+). 
Data analysis
For data analysis the statistical software package SPSS 20.0 (SPSS Inc., Chicago, IL) was used. 
Non-parametric Mann-Whitney test was used to compare continuous variables between 
patient groups and group comparisons of categorical data were performed by χ2 test, and 
the Fishers exact test in case of small groups. The Shapiro-Wilk test was used to determine a 
normal distribution and revealed that all data on myeloid cell counts were non-parametric. 
The paired Wilcoxon Signed Rank test was used to compare primary and secondary 
lesions. The Spearman correlation coefficient was used to detect correlation in the non-
parametric data. The Bonferroni correction was applied for multiple testing considering 12 
variables (Supplementary Table S1), revealing a P-value of <0.004 as significant. Patients 
were divided into groups based on the median of infiltrating cells and both an univariate 
(Log Rank) and multivariate analysis corrected for multifocality of uVIN (Cox proportional 
hazard model) were performed for recurrence-free survival (RFS) analysis, since this was 
previously identified as prognostic marker in our study cohort34. Two sided P-values <0.05 
were considered statistical significant. GraphPad Prism 5.04 (Graphpad Software Inc, LA 
Jolla, CA, USA) was used to illustrate the data by graphs and figures. 
Results 
Patient characteristics 
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The progressive course of vulvar neoplasia is characterised by an increase in mature CD14+ 
and CD14+CD163+ myeloid cells 
Triple immunofluorescent confocal microscopy of CD14, CD33 and CD163 revealed several 
different combinations of myeloid cells staining patterns (Fig. 1). The stroma of HPV induced 
vulvar neoplasia is abundantly infiltrated with CD14+, CD163+ and CD14+CD163+ myeloid 
cells. Approximately four times more M2 macrophages compared to M1 macrophages are 
present in the stroma of uVIN and healthy controls. Vulvar carcinomas are characterised 
by increased numbers of CD14+ cells and especially the single positive CD14+ cells and M1 
macrophages reach the level of the number of stromal M2 macrophages (reflected in the 
M1/M2 ratio; Fig. 2). The total number of CD33+ immature myeloid cells and CD163+ cells 
as well as the non-macrophage M2-like cells (CD14-CD163+) are increased in uVIN but in 
vulvar carcinoma they are back at the same level found in controls. The number of immature 
(CD33+) M2 macrophages in carcinoma is very low when compared to controls and uVIN 
lesions, suggesting only matured macrophages are present in the tumor microenvironment. 
Figure 1: Immunofluorescent staining of uVIN, vulvar carcinoma and control tissue with antibodies 
against CD14+ CD33+ and CD163+ 
Epithelial (E) and stromal (S) infiltrates of myeloid cells in the progressive course of vulvar neoplasia 
were analysed with antibodies against CD14 (green), CD33 (red) and CD163 (blue). Representative 
examples of a healthy control, uVIN and vulvar carcinoma section are depicted. Of note: the vulvar 
carcinoma only tumorepithelium is depicted. In the enlarged section single positive cells of CD33 (red) 
and CD163 (blue) can be distinguished as well as a triple positive CD14+CD33+CD163+ (white) and a 
double positive CD33+CD163+ (purple) myeloid cell. In the picture of uVIN CD14+CD33+ (yellow) and 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the epithelia of healthy tissue, myeloid cells were virtually absent (median 0.00 cells/
mm2 for all types). However, these cells were clearly present in uVIN and vulvar carcinoma. 
Specifically a rise in the number of intraepithelial CD14+, single CD14+, CD163+, single 
CD163+ and CD14+(CD33-)CD163+ myeloid cells was found in uVIN and vulvar carcinoma 
(Table 2 and Fig. 2). In addition, a gradual increase in M1 macrophages, M2 macrophages 
and non-macrophage M2 like cells (CD14-CD163+) was observed from controls to uVIN 
to carcinoma. The increase in the numbers of the different intraepithelial myeloid cell 
subclasses (e.g. M1 and M2) was mutually correlated (Supplementary Table S1). The ratio 
between M1 and M2 macrophages in uVIN was still much lower than 1 indicating that the 
number of intraepithelial M2 macrophages still dominated. 
A sharp increase in all the mentioned myeloid subsets marked the difference between uVIN 
and vulvar carcinoma. The great majority of CD14+ cells were CD163-negative indicative 
for a M1 type of infiltrating macrophages. Furthermore, these cells were mainly CD33- 
representing mature myeloid cells. This is also indicated by the CD33-/CD33+ cell ratio which 
is higher in vulvar carcinoma than in uVIN (data not shown p=0.002). Moreover, the ratio 
between intraepithelial M1 and M2 macrophages and the ratio between M1 macrophages 
and CD163+ cells was well above 1 indicating that in vulvar carcinoma the number of M1 
macrophages was equal to or dominated M2 macrophages. 
Overall, changes in the intraepithelial infiltration from healthy tissue to carcinoma reflected 
changes in the stromal compartment. Furthermore, uVIN and vulvar carcinoma display 
increased numbers in both stromal and epithelial myeloid cell populations when compared 
to healthy tissue. Whereas in uVIN the CD163+ (M2 and M2-like cells) cell populations still 
dominate, vulvar carcinoma is specifically characterised by yet an higher increase in myeloid 
cells infiltration and specifically an increased M1 infiltrate in comparable or higher numbers 
than the M2 population. A few patients presented with immunological disorders but they 
did not show overt difference in immune infiltration as compared to the rest of the group of 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Intraepithelial CD14+ macrophage infiltration of uVIN is an independent prognostic factor 
for decreased recurrence free survival 
The most prominent findings are the increase of CD14+ cells, CD163+ cells and CD14+CD163+ 
cells in the epithelium with a relative stronger increase of M1 cells over CD163+ cells at 
advanced stages of disease. To test if these myeloid cell populations contribute to the 
clinical course of uVIN we first analysed the myeloid cell infiltrates of the paired primary 
and recurrent lesions in a group of 20 patients. This analysis revealed no differences in the 
general myeloid cell infiltrates (Supplementary Table S2). Subsequently, we assessed if there 
were overt differences in the myeloid cell infiltration of the primary lesions when the patients 
with uVIN were divided into a group with or without recurrence. No gross differences were 
found between the two groups of patients based on the absolute numbers of infiltrating 
cells (Mann-Whitney U test) or based on the median cell count (χ2 test) (Supplementary 
Table S3 for χ2 analysis and data not shown of Mann-Whitney U test). Then we analysed 
the recurrence free survival of the patients in the context of these myeloid cells. This 
revealed that if the number of intraepithelial CD14+ macrophages (irrespective of M1 or 
M2 type) was high, patients more rapidly developed a recurrence. Moreover, the number 
of intraepithelial CD14+ macrophages formed an independent prognostic factor for a short 
recurrence free survival. Patients with a dense intraepithelial infiltration of CD14+ cells in 
the primary lesion had approximately a six times higher hazard ratio to rapidly develop a 
recurrence (HR 5.94; 95% CI 1.76-20.09). The influx of CD14+ M1 macrophages appeared to 
be the most important factor as a higher ratio of M1 cells over CD163+ cells was associated 
with a rapid development of an recurrence (Supplementary Table S3 and Fig. 3). Thus, while 
differences in the intraepithelial CD14+ cell infiltrate of the primary lesion is associated with 
a decreased recurrence free survival time and forms an independent prognostic factor, the 
immune infiltration of the primary and recurrent lesions within each individual patient with 
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Figure 3: Influence of intraepithelial CD14+ and ratio M1/CD163+ infiltrates on recurrence free 
survival
Myeloid cell infiltrates in the epithelium and stroma of uVIN lesions were divided based on the 
median number of cells and analysed for their influence on the recurrence free survival (RFS) of the 
uVIN patients by univariate (Log Rank) and *multivariate Cox analysis. Depicted are Kaplan-Meir 
survival curves of RFS for; A: total intraepithelial CD14+ infiltrate, suggesting that low numbers are 
an independent favourable prognostic marker, B: the ratio of intraepithelial M1 monocytes and total 
CD163+ cells, indicating that relatively more numbers of intraepithelial M1 macrophages is associated 
with a decreased RFS. 
Intraepithelial macrophage infiltration is correlated to a high number of regulatory T cells 
and low numbers of activated CD8+ stromal T cells 
In parallel, we had analysed this patient cohort with respect to T cell infiltration and the 
expression of co-inhibitory molecules in the microenvironment of uVIN.30 The outcomes of 
that study were then used to determine how changes in myeloid cell infiltration correlated 
with changes in uVIN-infiltrating T cells. Correlations of myeloid cell infiltrates to lymphocyte 
infiltrate and the expressed co-inhibitory markers are described in Supplementary Table 
S1. Regardless of the type of myeloid infiltrate, higher numbers of intraepithelial myeloid 
cells were correlated with the presence of intraepithelial regulatory T cells, represented 
by CD4+FoxP3+, CD3+PD1+FoxP3+ or CD4+TIM3+ T cells.35 Moreover a high number 
of intraepithelial myeloid cells was strongly associated with lower numbers of stromal 
CD8+TIM3+ cells, a T cell population for which we previously showed to be associated 
with improved recurrence free survival.30 The relation between stromal myeloid cells and 
different types of T cells was less clear. 
In view of the independent prognostic effects of intraepithelial CD14+ myeloid cells (this 
study) and stromal CD8TIM3+ cells30 their combined effects on recurrence free survival 
were examined. This revealed that patients with low numbers of intraepithelial CD14+ cells 
and high numbers of stromal CD8+TIM3+ cells have a much better recurrence free survival 
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T cells (Fig. 4a). Furthermore, since there was a direct association between the numbers of 
intraepithelial myeloid cells and that of intraepithelial Tregs, the latter of which we showed 
that they do not as a single entity impact RFS30, we also analysed the RFS on basis of the 
combined intraepithelial CD14+ cell and Treg number in our patient cohort. This analysis 
revealed that patients with high numbers of intraepithelial CD14+ macrophages and 
intraepithelial Tregs more rapidly displayed recurrences (Fig. 4b). 
Figure 4: Combinatorial analysis of intraepithelial CD14+ macrophages and stromal CD8+ TIM3+ T 
cells or intraepithelial regulatory T cells 
Based on the median number of innate and adaptive immune cells, combinatorial data of the 
importance of innate and adaptive immune infiltrates were analysed for their influence on recurrence 
free survival by univariate (Log Rank) and *multivariate Cox analysis. Kaplan-Meir survival curves of 
RFS are depicted for; A: total of intraepithelial CD14+ cells combined with stromal CD8+TIM3+ T cells, 
suggesting that uVIN lesions with low numbers of intraepithelial CD14+ cells and high numbers of 
stromal CD8+TIM3+ T cells have the best prognosis. B: low intraepithelial CD14+ cells are correlated 
with a low intraepithelial numbers of regulatory T cells, these patients have the best recurrence free 
survival. 
Discussion 
This is the first study on the presence and clinical impact of different myeloid cell populations 
in patients with HPV-induced non-recurrent and recurrent uVIN as well as HPV induced 
vulvar carcinoma. It demonstrates that under healthy conditions, intraepithelial myeloid 
cells are absent whereas in the normal stroma M2 macrophages dominate. The change 
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in both intraepithelial and stromal mature M1 and M2 macrophages. Vulvar carcinoma, 
however, is associated with a strong increase in especially mature CD14+ M1 macrophages. 
Whereas in the stroma of healthy controls and uVIN the M2 macrophages outnumber M1 
macrophages, in vulvar carcinoma these M1 macrophages level up and generally dominate 
M2 macrophages. Importantly, the number of intraepithelial mature CD14+ cell infiltrate 
forms an independent negative prognostic factor for recurrence free survival in uVIN. 
Importantly, we detected no difference in the number and composition of the myeloid cell 
infiltrate between paired primary and secondary lesions of patients, suggesting that after 
treatment the patients may display a similar recurrence free period before a third lesion 
appears. 
Recently, a study of the effects of imiquimod on the local immune signature also showed 
that the number of intraepithelial CD14+ cells was higher in uVIN when compared to 
healthy controls.16 Although there was no significant difference between responding and 
non-responding patients, the non-responding group on average had the highest number of 
intraepithelial CD14+ cells suggesting that these non-responding patients immunologically 
were more similar to the recurrent uVIN and vulvar cancer patients. It might be perceived 
that the intraepithelial CD14+ or single CD14+ cell population, thus is unfavourable. However, 
this contradicts the finding that single CD14+ cells are related to a pro-inflammatory anti-
tumor immune microenvironment13,18,19, as well as previous findings that this intraepithelial 
CD14+ single cell population was related to an improved survival in patients with HPV-
induced cervical cancer.20 Other studies also showed a positive relationship between M1 
infiltration and survival.36-40 Notably, HPV induced vulvar carcinomas are known for their 
good overall prognosis and survival rate of approximately 80%.41,42 In the current study, the 
increased presence of single CD14+ cells, representative for M1 macrophages, was related 
to a decreased RFS but so was the number of all intraepithelial CD14+ cells, comprising 
both M1 and M2 macrophages. Most notably, in uVIN the increase of one myeloid cell 
population coincided with the increase in all other myeloid populations (Supplementary 
Table S1) as well as with intraepithelial CD4+ regulatory T cells. Tregs are known to regulate 
monocyte differentiation and stimulate M2 macrophages.13 We showed that in uVIN the 
population of (stromal and intraepithelial) M2 macrophages outnumber M1 macrophages 
by a factor 4 at least (M1/M2 ratio; Table 2), suggesting that in the epithelium of uVIN 
not the M1 macrophages but other immune suppressive immune cells prevail. This is in 
line with previous studies, the focus of which was mainly on T cell infiltrates and LCs/DCs 
in uVIN in relation to responses to immunotherapy.5,7,8,16,17,21,43,44 From these studies it was 
concluded that the epithelium of uVIN lesions was suppressed as it lacked a strong CD8+ 
infiltration and displayed lower numbers of Langerhans cells.16,17,21 In contrast, the dermis of 
uVIN lesions was thought to be the most active region as there was abundant infiltration of 
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T cells expressing TIM3 reflected activated T cells, the presence of which was associated 
with local IFNγ production and an increased RFS.30 Notably, in case of abundant Treg 
infiltration, the effect of CD8+ T cells on RFS in uVIN diminished.30 In the current study, we 
found a clear inverse association between the number of these stromal CD8+TIM3+ T cells 
and intraepithelial macrophages. If the enhanced intraepithelial M1 and M2 macrophage 
infiltrate is considered to reflect, rather than cause, a process in uVIN associated with an 
unfavourable course of the disease, one can envisage that an active uVIN-resistant stromal 
immune response (e.g. more CD8+TIM3+ cells and less Tregs) prevents this process and thus 
the accumulation of intraepithelial macrophages. 
Irrespective of their actual role in the prevention or stimulation of uVIN recurrences, an 
estimation of the number of intraepithelial macrophages may thus be of help in determining 
the prognosis of patients diagnosed with uVIN. Previously, we had identified multifocality 
of uVIN lesions, most often found in relation to larger lesions, as the only clinical prognostic 
factor for recurrence in this cohort.34 A larger lesion size was found associated with a 
lower capacity to respond to therapeutic vaccination.6 Potentially, intraepithelial myeloid 
cell infiltration may also influence the outcome of immunotherapeutic approaches since 
CD14+ and CD68+ cells were also higher in patients that failed to clear their VIN lesion after 
imiquimod treatment.16 Hence, imiquimod or vaccination reinforced T cell responses5-8,44 
might be locally suppressed by the microenvironment associated with the dense 
intraepithelial CD14+ cell infiltration. Our combined analysis of the stromal infiltration with 
activated CD8+ T cells (CD8+TIM3+) and intraepithelial CD14+ cells suggests that lesions 
more rapidly occur when low CD8+ T cell infiltration is paralleled by a dense intraepithelial 
CD14+ infiltrate (Fig. 4). New studies on the innate and adaptive immune cell infiltrate of 
uVIN in pre-treatment samples should determine their relevance for the clinical responses 
to immunotherapy. 
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Abstract
Different topical or systemic immunotherapies have shown partial clinical success in the 
treatment of human papillomavirus (HPV)-induced usual vulvar intraepithelial neoplasia 
(uVIN). The clinical response of patients with HPV16-induced uVIN to HPV type 16 synthetic 
long peptide (SLP) vaccination was associated with a stronger HPV16-specific T-cell response 
and a distinct peak in cytokine levels directly after the first vaccination. This suggested that 
differences in capacity to respond to HPV16-SLP vaccination are related to the immune status 
of patients before therapeutic intervention. Because cytokines and co-inhibitory molecules 
are important regulators of the immune response, circulating myeloid and lymphoid cells of 
uVIN patients were phenotyped and their phosphorylation of signal transduction activators 
of transcription (STAT) proteins (pSTAT1, pSTAT3, pSTAT5 and pSTAT6) upon stimulation 
with different cytokines were analysed. A decreased number of circulating dendritic cells 
(DCs) and higher numbers of immature DCs and type 2 monocytes are related to recurrent 
disease. Increased frequencies of CD4+CD94+ and CD4+CD94+NKG2a+ T cells and lower 
numbers of CD8+TIM3+ T cells were related to the absence of recurrent disease. No 
differences were found in pSTAT response upon stimulation with IFNγ, IL-2, IL-4, IL-5, IL-6, 
IL-7 and IL-10. However, the CD14+CD33+ monocytes of uVIN patients responded differently 
when stimulated with IFNα and GM-CSF, specifically with respect to the response rate or 
levels of pSTAT5 and total pSTAT induction, suggesting that there are differences in the 
capacity of these immature immune cells to induce pro-inflammatory cytokine responses. 
Interestingly, the CD14+CD33+ cells of uVIN patients, who responded with a distinct peak in 
IFNγ upon HPV 16 SLP vaccination, displayed a stronger pSTAT1 response to IFNα stimulation. 
Altogether, our data suggest that the circulating myeloid cell population is phenotypically 
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Introduction 
Human papilloma virus (HPV) induced usual vulvar intraepithelial neoplasia (uVIN) is caused 
by a failure of the immune system to clear a persistent HPV infection and is related to the 
majority of uVIN lesions1. The incidence of uVIN is higher in immunocompromised patients, 
indicating the pivotal role of the immune system in viral clearance and lesion regression2-5. 
Indeed, the presence of HPV-specific T-cell reactivity is associated with protection against 
development and progression of HPV-induced neoplasia, but is lacking in most uVIN 
patients6-9. In addition, treatment of uVIN with immunotherapy aimed at the reinforcement 
of the immune response against HPV, shows promising clinical successes although the 
number of complete clinical responses varies up to 50%10-13. Furthermore, local immunity is 
associated with clinical outcome. The epithelium of uVIN lesions is characterised by lower 
numbers of infiltrating CD8+ T cells, a reduction of Langerhans cells (LCs) and an increase in 
CD14+ macrophages14,15 and CD4+ regulatory T cells (Tregs)12-16. Importantly, a high number 
of intraepithelial macrophages are an independent prognostic factor for rapid recurrences16 
and high Treg numbers are related to non-responsiveness to immunotherapy11-13. 
Furthermore, a dense stromal infiltration by dendritic cells (DCs) and Tbet+, CD8+TIM3+ and 
CD3+NKG2a+ T cells as well as low numbers of Tregs are associated with the prevention of 
recurrences14,15,17. T-cell function has been related to expression of co-inhibitory molecules 
as CTLA-4, PD1, TIM3 and NKG2a after interaction with their ligands18-21. Monocytes and 
macrophages are important antigen presenting cells and mediate the innate immune 
responses by phagocytosis and activate and polarise the adaptive immune response 
depending upon cytokine production22-24. 
We recently showed that a high number of HPV16-positive uVIN patients clinically responded 
to treatment with a HPV16-SLP vaccine and that these clinical responses were strongly 
correlated with the strength of HPV16-specific proliferative T-cell responses characterised 
by high amounts of interferon gamma (IFNγ) and interleukin-5 (IL-5)10,25. The HPV-specific 
T-cell response in the clinical complete responders was characteristically accompanied by 
a distinct peak in cytokine levels three weeks after the first vaccination10,25, suggesting that 
already before treatment a difference in the patients’ capacity to respond to therapeutic 
vaccination may determine final outcome. Cytokines are well-known important immune 
regulators and the cytokine milieu plays an essential role in the functional differentiation 
of immune cells, including T cells and antigen presenting cells 22,26,27. Binding of cytokines 
to their receptor triggers distinct signal transduction activators of transcription (STAT) 
pathways 28-30. Phosphorylation of STAT (pSTAT) within cells modulates their activity and 
phosphorylation either leads to the activation of the protein, and triggers downstream 
activation of different regulatory pathways as NF-kB, MAP kinases and PI3K/Act31 involved 
in differentiation, proliferation and apoptosis32. The JAK/STAT pathway is facing different 
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function to maintenance of immune tolerance and protection against cancer (reviewed 
in33). Therefore, measurement of cytokine-induced pSTAT may form a method to analyse 
differences in responsiveness of the immune system between subjects. Due to the 
many different cell types involved in the immune response, the evaluation of changes in 
responsiveness requires quantification of phosphorylation events in individual cells by flow 
cytometry29. 
We hypothesized that differences in patients with respect to the response of immune cells 
to cytokines may offer an explanation for the observed difference in vaccine responses and 
associated clinical outcome. Because cytokines and co-inhibitory molecules are important 
regulators of the immune response we phenotyped circulating myeloid and lymphoid cells 
in uVIN patients and healthy controls as well as analysed the phosphorylation of STAT 
proteins (pSTAT1, pSTAT3, pSTAT5 and pSTAT6) in these immune cells upon stimulation with 
different cytokines. 
Our data suggest that the circulating myeloid cell population is phenotypically and 
functionally altered in uVIN patients and that the measurement of circulating type 2 
monocytes is related to recurrent disease, which is similar to our previous finding on the 
association between recurrences and type 2 macrophages in the local microenvironment.
Materials and Methods
Patient material 
Patients presenting with histologically proven high-grade uVIN at the Leiden University 
Medical Center (LUMC) were enrolled in the Circle study, which is approved by the medical 
ethical committee of the LUMC and investigates cellular immunity against HPV-induced 
neoplasia. After meaningful signed informed consent was obtained, venous heparinized 
blood (60 mL) was collected prior to the therapeutic intervention and peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll gradient centrifugation, cryopreserved 
at 10 million cells per vial and stored in the vapour phase of liquid nitrogen according 
to standard operating procedures (SOPs) in the laboratory of the Department of Clinical 
Oncology. Serum was collected in a clotting tube and frozen at -20oC until use. 
Patient characteristics are summarized in Table 1. Fourteen patients with high-grade uVIN 
were included in this study (mean age at inclusion 51.1 year ± 49.5) of whom in 3 cases 
a micro-invasive carcinoma (<1mm invasion) was diagnosed after therapy. In 7 cases a 
recurrence of uVIN was diagnosed after Circle inclusion of which 2 patients were excluded 
from recurrence analysis because of a persistent uVIN lesion despite therapy. In the 
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The patient characteristics of the subsequent groups are given: the healthy controls, uVIN patients 
included in the Circle study and the uVIN patients who participated in the HPV 16 SLP ISA101 
vaccination trial. 
*Of the overall inclusions of the vaccination trial only 3 patients progressed, in this cohort however 
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Analyses were performed according to the occurrence of a recurrent uVIN lesion after Circle 
inclusion. The Circle patients were compared to a cohort of age-matched healthy controls 
(mean age at inclusion 46.4 year ± 13.1) with no known HPV medical history. 
In order to analyse effects of STAT phosphorylation in patients who received therapeutic 
vaccination, an additional uVIN patient cohort was selected which included a cohort of 10 
HPV16-positive uVIN patients who received 4 vaccinations with HPV16-SLP (ISA101) with or 
without application of imiquimod on the vaccination site. Pre-vaccination PBMC samples of 
3 patients, who displayed a distinct peak of IFNγ production after the first vaccination and 
5 patients without an IFNγ peak upon the first vaccination (determined by a median IFNγ 
production above 1000pg/ml in the cytokine bead array) were analysed34,35.
HPV typing 
HPV typing was performed on formalin-fixed, paraffin embedded tissue, resected during 
surgery or on a biopsy taken at enrolment in the vaccination study by HPV16 PCR with a 
HPV16-specific primer set followed by HPV genotyping using the INNO-LiPA HPV genotyping 
Extra line probe assay (Innogenetics, Ghent, Belgium) in case of HPV16 negativity36,37. 
Notably, at the same time the blood samples were collected.
Cell proliferation assay
The overall capacity of the T cells to proliferate upon mitogenic stimuli (i.e. 
phytohaemagglutinin (PHA), HA 16 Remel, Murex Biotech, Dartford, UK) was tested 
in a 3-days proliferation assay where the PBMC samples of uVIN patients and healthy 
controls were analysed against medium (Iscove’s Modified Dulbecco Medium (IMDM, Life 
Technologies, Bleiswijk, the Netherlands) +10% Human AB serum (HAB, Greiner, Alphen a.d. 
Rijn, the Netherlands)) only (negative control) or after PHA stimulation (0.5 µg/mL), using a 
previously described method which was slightly modified38. The proliferation of PBMCs were 
measured in quadruplicate wells (50.000 cells/well) after 3 days of incubation by adding 
3H-thymidine for the last 16-18 hours of the incubation period after which its incorporation 
(expressed as counts per minute (cpm)) is measured. A cut-off was calculated by mean cpm 
of the 4 wells with unstimulated PBMCs (medium only) plus 3 times standard deviation (SD). 
The stimulation index (SI) was calculated by the ratio of the mean cpm of 4 wells with PHA 
stimulated PBMCs divided by the mean cpm of the 4 wells containing unstimulated PBMCs. 
A SI ≥3 plus mean cpm of the PHA stimulated wells above cut-off is considered a positive 
response. 
Antigen presenting capacity of antigen presenting cells 
The antigen-presenting capacity of antigen-presenting cells (APC) was tested in a mixed 
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10%HAB were irradiated at 3000 rad to prevent proliferation of these cells. Thereafter, 
the cells were centrifuged, the supernatant removed and the cells resuspended in 1.5 
mL IMDM-10%HAB. The irradiated patient’s PBMCs were independently co-cultured with 
PBMCs obtained from two different healthy donors (differently from the healthy subjects) in 
quadruplicate wells (100.000 cells/well). Cells were incubated for 6 days at 37oC, 5% CO2 in 
a humified incubator before supernatants (100 uL/well pooled) were harvested and stored 
at -20oC until cytokine level determination by the Th1/Th2 cytometric bead array kit (CBA, 
BD Biosciences, Breda, the Netherlands). Cells were pulsed with 3H-thymidine for 16-18 
hours and the proliferation was measured by 3H-thymidine incorporation. The proliferative 
capacity of the two individual healthy donors co-cultured with the irradiated patients 
PBMCs is a measure for the APC quality of the patient. The SI was calculated by the ratio of 
the mean cpm of irradiated patient’s PBMCs co-cultured with PBMCs of one healthy donor 
divided by the mean cpm of that particular healthy donor unstimulated PBMCs and a SI ≥3 
is considered positive.
Phenotyping of PBMCs for macrophages, myeloid-derived suppressor cells and co-
inhibitory molecule expression by flow cytometry analysis
The composition of the immune cells in the Circle and healthy control PBMC samples was 
determined by phenotyping for macrophages (macrophages set), myeloid-derived suppressor 
cells (MDSC set) and expression of co-inhibitory molecules on T cells (inhibitory T-cell set). 
Three sets of antibodies (10-11 antibodies per set) directed to specific surface markers for 
myeloid cells and T cells were used to stain these cells, which were thereafter analysed 
by multiparameter flow cytometry (LSR Fortessa, BD Biosciences). Thawed PBMCs were 
washed two times with Phosphate Buffered Saline (PBS)/0.5% Bovine Serum Albumin (BSA) 
and incubated on ice with PBS/0.5%BSA/10% Fetal Bovine Serum (FBS). Thereafter, PMBCs 
were stained for 30 minutes in the dark on ice with the 3 different antibody sets, washed 
two times with PBS/0.5%BSA and fixed with 1% paraformaldehyde (PA). Compensation 
beads were made for the different fluorchromes according to the protocol of BD Biosciences 
to optimize fluorescence compensation settings of the flow cytometer. Surface stainings 
were analysed using FACSDivaTM Software (BD Biosciences) after identification of the life 
gate in single cells.
Flow cytometry for analysis of macrophages 
The following antibodies were used: anti-CD1a-FITC (Clone HI149, BD Biosciences), anti-
CD3-Pacific Blue (PB;Clone UCHT1, DAKO), anti-CD11b-PE (Clone D12, BD Biosciences), anti-
CD11c-Alexa Fluor (AF) 700 (Clone B-ly6, BD Biosciences), anti-CD14-PE-Cy7 (Clone M5E2, 
BD Biosciences), anti-CD16-PE-CF594 (Clone 3G8, BD Biosciences), anti-CD19-Brillian Violet 
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anti-CD163-APC (Clone 215927, R&D systems), anti-CD206-APC-Cy7 (Clone 15-2, Biolegend) 
and anti-HLA-DR-Horizon (H) V500 (Clone L234, BD Biosciences). In the analysis singlet cells 
and subsequently those in the life gate and CD45+ cell gate were plotted for CD3 and CD19. 
The CD45+CD3-CD19- were selected and further gated as HLA-DR+ cells. This population was 
divided upon differential expression of CD14 and CD11b, which reveals five subpopulations 
of myeloid cells in the CD45+HLA-DR+ population; activated monocytes (CD14Int+CD11b+ 
or CD14high+CD11b+), immature DCs/early differentiating monocytes (CD14-CD11b-), 
activated DCs or monocytes with loss of CD14 (CD14-CD11b+) and non-activated DCs or 
monocytes (CD14+CD11b-). Within these subcategories CD163, CD16, CD206 and CD11c 
were plotted for each of the populations to distinguish phenotypes (Supplementary Fig. S1). 
Differentiation markers used are CD16339, CD11b (a monocyte activation marker40), CD11c 
(a marker of dendritic cells41), CD16 (macrophage Fcγ-Receptor III)42 and CD206 (a mannose 
receptor)42. CD16 is expressed on IL-6 and IL-10 polarized CD14+ macrophages in co-
expression of CD163+43,44. CD206 is an early marker for differentiation of monocytes into 
macrophages45 and is expressed on IL-4 polarized macrophages where CD14 and CD163 are 
downregulated and CD200R upregulated43,44. Type 2 macrophages are mainly associated with 
Th2 responses and divided into four sub-categories; M2a macrophages (CD206+) induced 
by IL-4 and IL-13 associated with allergy and parasitic infections; M2b immunoregulatory 
macrophages (CD16+) induced by TLR activation and M2c (CD163+) regulatory macrophages 
induced by IL-10 and M2d macrophages46-49. Activation of macrophages may as well result 
in loss of CD14, CD163 and CD16 expression42,50. To compare these data between different 
patients the numbers of events were calculated as percentage of CD45+ cells. If percentages 
were below 0.05% these cell populations and differences were considered as irrelevant.
Flow cytometry for analysis of MDSCs
Next to terminally differentiated myeloid cells such as macrophages and DCs, myeloid-
derived suppressor cells (MDSCs) were stained and acquired, these immature myeloid cells 
counteract the anti-tumor immune response (reviewed in 22,51). Two main MDSC phenotypes 
have been described: the monocytic (mMDSC) and polymorphonucleair MDSCs (granulocytic 
MDSC, gMDSC) 22,51, which were analysed using the following antibodies: anti-CD3-PB (Clone 
UCHT1, DAKO), anti-CD11b-FITC (Clone CBRM1/5, Biolegend), anti-CD14-AF700 (Clone 
M5E2, BD Biosciences), anti-CD15-PE-CF594 (Clone W6D3, BD Biosciences), anti-CD19-
BV605 (Clone SJ25C1, BD Biosciences), anti-CD33-PE-Cy7 (Clone P67.6, BD Biosciences), anti-
CD34-APC (Clone 581, BD Biosciences), anti-CD45-PerCP-Cy5.5 (Clone 2D1, BD Biosciences), 
anti-CD124-PE (Clone HiL4R-M57, BD Biosciences) and anti-HLA-DR-HV500 (Clone L234, BD 
Biosciences). In the MDSC antibody set CD45+ CD3- CD19-HLA-DR- singlet and viable cells 
were isolated and herein the CD14+ and CD15+ populations identified. Subsequently CD11b, 
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We have evaluated these cell types upon CD45 and HLA-DR negative cells for expression of 
CD14+ and CD15- (mMDSC) and CD14- and CD15+ (gMDSC)51. Subsequently, hematopoietic 
progenitor markers CD33+ and CD34+ in combination with CD11b+ and CD124+ (IL-4Rα) 
were analysed (reviewed in51). Myeloid differentiation of the hematopoietic progenitor cells 
is characterised by loss of CD34 and expression of CD3352. The numbers of events were 
calculated as the percentage of the CD45+ cells. If percentages were below 0.05% these cell 
populations and differences were considered as irrelevant. 
Flow cytometry for analysis of co-inhibitory molecules on T cells 
Expression of co-inhibitory receptors on T cells were analysed by the following antibodies: 
anti-CD3-PB (Clone UCHT1, DAKO), anti-CD4-PE-CF594 (Clone RPA-T4, BD Biosciences), 
anti-CD8-APC-Cy7 (Clone SK1, BD Biosciences), anti-TIM3-PE (Clone F38-2E2, Biolegend), 
anti-NKG2a-AF700 (Clone 131114, R&D Systems), anti-CTLA-4 (CD152)-PE-Cy5 (Clone BNI3, 
BD Biosciences), anti-CD94-FITC (Clone 131412, R&D Systems) and anti-PD1-BV605 (Clone 
EH12.2H7, Biolegend). After identification of the singlets and life gate the CD4+ and CD8+ 
cells were selected within the CD3+ cells. CD94, TIM3, NKG2a, CD152 and PD1 were plotted 
in these populations (Supplementary Fig. S3). The numbers of events were calculated as 
percentage of the CD3+ cells. If percentages were below 0.05% these cell populations and 
differences were considered as irrelevant. 
Flow cytometry analysis of STAT phosphorylation in PBMCs 
Phosphorylation of signalling proteins within cells modulates their activity and leads 
to activation of the protein (MAP kinases and STAT transcription factors), whereas in 
some cases the phosphorylation leaves the proteins in an inactive state. To determine 
the activation state of PBMCs, intracellular phosphorylation of STAT1, -3, -5 and -6 were 
measured in CD3+, CD4+ and CD8+ lymphocytes and in CD14+CD33+ and CD14-CD33dim 
monocytes, after individual stimulation with eight different cytokines (IL-2, IL-4, IL-5, IL-
6, IL-7, IL-10, IFNγ) or adjuvant immune modulators (IFNα and GM-CSF). PBMCs of uVIN 
Circle patients, healthy controls and pre-vaccination samples of HPV16-SLP treated uVIN 
patients were analysed using this phosphorylation cytometry assay. The protocol was 
adopted from G.P. Nolan (Stanford University, Stanford California)29 and A. Cesano (Nodality, 
South San Francisco)53. Thawed PBMCs were resuspended in serum-free (SF) IMDM at a 
concentration of 1-1.5 x106/ml and incubated at 37oC for 1 hour to rest. Then, the PBMCs 
in SF medium were stimulated for 15 minutes at 37oC with the following cytokines and 
adjuvant immune modulators: IFNγ (20 ng/mL; Immunotools, Friesoythe, Germany), IL-10 
(50 ng/mL; Immunotools), IL-2 (50 ng/mL; Aldusleukin 18x106IE, Novartis Pharma, Arnhem, 
the Netherlands), IL-5 (50 ng/mL; Immunotools), IL-6 (100 ng/mL; Immunotools), IL-4 (50 
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IFNα (1000 IU/mL Roferon A, Roche, Woerden, the Netherlands), GM-CSF (4 ng/mL; 
Immunotools). These concentrations were first determined by titration assays (data not 
shown). After the stimulation the cells were immediately fixed in 1.5% paraformaldehyde 
(PA, pharmacy LUMC) for 10 minutes at room temperature (RT) and after centrifugation 
resuspended in 100 uL phosphate buffered saline (PBS, B. Braun, Melsungen, Germany)/0.5% 
bovine serum albumin (BSA; Sigma, St Louis, USA)/1.5% PA, and transferred into wells of a 
V-bottom 96-wells plate (Costar). After another wash step in 100 uL PBS/0.5% BSA the cell 
surface staining was performed for 30 minutes in the dark on ice with anti-CD3-PB (Clone 
UCHT, DAKO, Heverlee, Belgium), anti-CD4-HV500 (Clone RPA-T4, BD Biosciences), anti-CD8-
APC-Cy7 (Clone SK1, BD Biosciences), anti-CD14-FITC (Clone M5E2, BD Biosciences) and 
anti-CD33-AF700 (Clone WM53, BD Biosciences). Then, the cells were washed two times 
with 100 uL PBS/0.5% BSA and permeabilized by adding 100 uL cold 100% Methanol (Sigma) 
for 10 minutes on ice. Thereafter, cells were washed again two times with 100 uL PBS/0.5% 
BSA and subsequently the intracellular staining was performed for 30 minutes in the dark 
at RT again with anti-CD33-AF700 (Clone WM53, BD Biosciences) and with anti-pSTAT1 
(Clone 4a, BD Biosciences), anti-pSTAT3 (Clone 49-p-STAT3, BD Biosciences), anti-pSTAT5 
(Clone 47, BD Biosciences), anti-pSTAT6 (Clone 18-p-STAT6, BD Biosciences) either coupled 
to fluorochromes PE or AF647. After this intracellular staining the cells were washed for two 
times with 100 uL PBS/0.5% BSA and fixated in 1% PA. Compensation beads were prepared 
for all the fluorochromes according to the protocol of BD Biosciences to properly set up the 
fluorescence compensation settings for the multicolour flow cytometric analyses by use of 
LSR Fortessa (BD Biosciences). Phosphorylation data were analyzed using FlowJo software 
(TreeStar Inc, Ashland, USA, version 7.6.5). The life gate was identified and subsequently 
CD3+ and CD3-negative populations were selected to distinguish between CD4+ and CD8+ 
T cells within the CD3+ population and single positive CD14 or CD33 or double positive 
(CD14+CD33+) myeloid cells within the CD3-negative population (Supplementary Fig. S4). 
The levels of pSTATs were analyzed as mean fluorescence intensity (MFI) and a fluorescence 
index (mean of stimulated sample divided by mean of unstimulated control sample) was 
calculated. A fluorescence index ≥ 2 was considered as a distinct upregulation of pSTAT after 
stimulation with the cytokine whereas an index between 1.5 and 2 was considered as a 
small up-regulation. Downregulation was defined as an index ≤ 0.5 or small downregulation 
when the index was between 0.5 – 0.7. Values between 0.7 and 1.5 were considered as no 
difference. 
Statistical analysis
The non-parametric Mann-Whitney U test was used to compare continuous variables 
between patient groups and the χ2 test was used to compare categorical data with the 









































Phenotyping and STAT phosphorylation of systemic immune cells in uVIN patients  |  161
coefficient was used to detect correlation in the non-parametric data. Patients were divided 
into groups based on the median of infiltrating cells and a univariate (Log Rank) analysis was 
performed for recurrence-free survival (RFS) analysis. Because of the small study population 
no multivariate analysis was performed. Two sided P values <0.05 were considered statistical 
significant. GraphPad Prism 5.04 (Graphpad Software Inc, LA Jolla, CA, USA) was used to 
illustrate the data by graphs and figures and for statistics in the total pSTAT induction. 
Results
Antigen presenting capacity of APCs and T-cell proliferation of lymphocytes in uVIN 
patients and healthy donors 
The antigen presenting capacity of blood-derived APCs from uVIN patients and healthy 
controls was tested by mixing them with lymphocytes of two unrelated healthy donors. In 
addition, the capacity of T cells to proliferate upon PHA stimulation was tested. No differences 
were observed between patients with uVIN and healthy controls (Supplementary Fig. S5), 
indicating that there are no overt general defects in the immune reactivity of patients with 
uVIN that may explain differences in response to immunotherapy. 
Circulating myeloid cells and MDSCs in uVIN patients and healthy controls 
An extensive panel of markers was used to distinguish monocytes/macrophages, dendritic 
cells and MDSC. The major populations of myeloid cells consisted of activated CD14+CD11b+ 
monocytes and account in total for approximately 15% of myeloid cells in both uVIN patients 
and healthy controls (Supplementary Table S1). The other three remaining populations 
represent minor categories of circulating myeloid cells and consist of immature DCs/early 
differentiating monocytes (CD14-CD11b-), activated DCs or monocytes with loss of CD14 
(CD14-CD11b+)42,50 and non-activated DCs or monocytes (CD14+CD11b-) accounting for <1% 
of CD45+HLA-DR+ cells. 
Comparison of the different subpopulations between uVIN patients and healthy controls 
revealed no differences in the great proportion of activated CD14+ monocytes. Analysis of 
the smaller myeloid cell groups revealed that the frequency of circulating immature DCs/
early differentiating monocytes (CD14-CD11b-, p=0.03) and type 2a and 2c monocytes 
(CD14-CD11b+CD206+CD16-, p=0.01 and CD14-CD11b+CD163+CD206-, p=0.02) were 
lower in uVIN patients than in healthy controls (Supplementary Table S1). The frequency 
of circulating MDSC populations was estimated below 0.05% and therefore not further 
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,
Figure 1: Influence of systemic DCs and type 2 macrophages on recurrence free survival 
Differences in circulating myeloid cell types between recurrent and non-recurrent uVIN patients were 
divided based on the median percentage of cells and analysed by univariate Log Rank for their influence 
on recurrent free survival (RFS). Kaplan-Meir survival curves for activated DCs and type 2 macrophages 
on RFS are depicted. In A and B a high number of activated DCs (CD14-CD11b+CD11c+CD16+(A) and 
CD14-CD11b+CD11c+CD163-(B)) is related to an increased RFS and in C and D a high number of type 
2a macrophages (CD14-CD11b+CD206+CD16+(C)) and type 2c macrophages (CD14-CD11b+CD11c-
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Previously we observed that the number of CD14+ intraepithelial myeloid cells had a 
prognostic value with respect to the recurrence and progression of uVIN lesions16. Therefore, 
we evaluated the frequency of circulating myeloid cells in this context. Recurrent uVIN 
patients have a lower, albeit not significant, percentage of circulating CD14High+CD11b+ 
activated monocytes compared to non-recurrent uVIN patients (9.5% vs 16.5%). Analysis of 
DCs by CD11c+ in this CD14High+CD11b+ monocyte population revealed that more DCs are 
present in non-recurrent uVIN patients, albeit not significant, probably due to the small group 
of patients analysed. Furthermore, patients with recurrent uVIN lesions displayed increased 
frequencies of type 2a and 2c monocytes/macrophages (CD14-CD11b+CD206+CD16+, 
p=0.01, CD14-CD11b+CD163+CD206-, p=0.01, and CD14-CD11b+CD11c-CD163+, p=0.01) 
and a lower number of activated DCs (CD14-CD11b+CD11c+CD16+, p=0.02 and CD14-
CD11b+CD11c+CD163-, p=0.00). Moreover, a high number of activated DCs was associated 
with a prolonged recurrence free survival (Fig. 1a+b p=0.02/0.01) whereas a high frequency 
of type 2a and 2c monocytes/macrophages are associated with a decreased recurrence free 
survival (Fig. 1c+d p=0.01).
Expression of co-inhibitory molecules on PBMC from uVIN patients and healthy controls 
In Table 2 the percentage of CD3+ lymphocytes of CD4+, CD8+ and expression of co-inhibitory 
molecules are represented. The majority of circulating lymphocytes is CD4+ (approximately 
70%) and hardly express one of the tested co-inhibitory molecules on their surface, except 
for PD1 which was expressed in over 4% of CD4+ T cells and in approximately 3% of CD8+ 
T cells. TIM3 and NKG2a are expressed only by small proportions (<1%) of lymphocytes. 
Surface CTLA-4 (CD152) expression is scarce (< 0.05% of CD4+ and CD8+ T cells) and was 
therefore not analysed in detail. Thus, the differences in expression of the co-inhibitory 
molecules on T cells between healthy controls and uVIN patients are based on small cell 
populations. In the CD4+ T-cell populations the number of CD4+NKG2a+, either with or 
without co-expression of TIM3 and/or PD1, T cells is higher in uVIN patients(Supplementary 
Table S3). There were no differences in co-inhibitory molecule expression on CD8+ T cells 
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Table 2: Expression of co-inhibitory molecules on CD3+ lymphoid cells in healthy controls and uVIN 
patients









































In the microenvironment of the uVIN lesion, stromal expression of CD8+TIM3 and 
CD3+NKG2a+ T cells was related to an improved clinical outcome in uVIN patients17. Hence, 
we analysed the co-inhibitory molecule expression on lymphocytes in the context of 
recurrent disease. The main finding was that the frequency of CD4+ T cells expressing CD94+ 
was higher in patients who did not display a recurrent uVIN lesion. Moreover, a relatively 
higher number of circulating CD4+CD94+ T cells was associated with a longer recurrence 
free survival. This was not the case when patients were divided on basis of CD3+CD94+ 
and CD8+CD94+ T-cell frequencies (Fig. 2a+b+c). Expression of CD94 is related to the NKG2 
family of receptors (e.g. NKG2a, -c, -d, -e and -h) by formation of heterodimers with either 
an activating or inhibitory function and are therefore always co-expressed54,55. Our study 
on the local immune infiltrate revealed that the expression of NKG2a was associated with 
an increased recurrence free survival (RFS). Therefore, we analysed RFS in the context 
of CD94+NKG2a+ T cells. The frequency of CD3+CD94+NKG2a+ and CD8+CD94+NKG2a+ 
T cells was not associated with differences in RFS while relatively higher numbers of 
CD4+CD94+NKG2a+ T cells were associated to no recurrences (Supplementary Table S3 
+ Fig. 2d-f). Because the CD3+CD94+NKG2a+/CD3+CD94+NKG2a- cell ratio in the uVIN 
microenvironment was associated with better clinical performance17, we also analysed 
this ratio for cells in the circulation, but this lacked clinical significance (Supplementary 
Table S3 + Fig. 2g). The expression of TIM3 on circulating T cells was higher in patients with 
recurrent uVIN lesions albeit not directly related to RFS (Supplementary Table S3 and Fig. 
2h-j). However, a relative higher number of circulating CD8+TIM3+ T cells was related to the 
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No differences in STAT phosphorylation levels upon stimulation with cytokines 
Since pathogens can reprogram intracellular immune-related signalling networks, potentially 
hindering immune activation, we set out to study the response of APCs and lymphocytes to 
various cytokines. In Figure 3 an example of STAT phosphorylation (pSTAT) upon cytokine 
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Figure 3: STAT phosphorylation upon stimulation with various cytokines or immune modulators in 
an example of one patient with uVIN 
Intracellular phosphorylation of STAT1, -3, -5 and -6 were measured in CD3+, CD4+ and CD8+ 
lymphocytes and in CD14+CD33+ and CD14-CD33dim monocytes, after individual stimulation with 
eight different cytokines (IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IFNγ) or adjuvant immune modulators (IFNα 
and GM-CSF) to determine the activation state of PBMCs of uVIN patients and healthy controls. 
After identification of the lifegate in the CD3+ populations CD4+ and CD8+ T cells were distinguished 
whereas in the CD3- population either single or double CD14+ and CD33+ cells were identified. The 
levels of pSTATs were analyzed as mean fluorescence intensity (MFI) and a fluorescence index (mean 
of stimulated sample divided by mean of unstimulated control sample) was calculated. A fluorescence 
index ≥ 2 was considered as a distinct upregulation of pSTAT after stimulation with the cytokine whereas 
an index between 1.5 and 2 was considered as a small up-regulation. Downregulation was defined as 
an index ≤ 0.5 or small downregulation when the index was between 0.5 – 0.7. Values between 0.7 
and 1.5 were considered as no difference. The differences in pSTAT induction in different immune cell 
populations upon cytokine stimulation are illustrated by use of FlowJo software (TreeStar Inc, Ashland, 
USA, version 7.6.5). The results for Il-2, IL-5 and IL-10 are depicted in Supplementary Fig. S7. 
IFNγ is expected to induce a high increase in the levels of pSTAT1 in monocytes and 
somewhat lower levels in T cells53. Indeed, a strong pSTAT1 increase was uniformly detected 
in CD14+CD33+ monocytes and in 37.5% of CD4+ T cells in all uVIN patients and healthy 
controls. In addition, IFNγ induced increased levels of pSTAT5 in CD14+CD33+ monocytes in 
approximately half of patients and control subjects (Fig. 4 and Supplementary Fig. S7). IL-2 
hardly showed an effect on STAT phosphorylation, except for the upregulation of pSTAT5 in 
3 individuals (2 patients and a healthy donor). IL-4 is known to mediate its signals via pSTAT6 
56,57. Indeed IL-4 stimulation resulted in a strong increase of pSTAT6 in both myeloid cells and 
T cells of uVIN patients as well as healthy controls (Fig. 4 and Supplementary Fig. S7). IL-5 
is known for pSTAT5 induction57, but this was not observed. IL-6 is both a pro-inflammatory 
as anti-inflammatory cytokine, which is well known for its activation of STAT3. Whereas IL-6 
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expression58, it did not influence pSTAT3 levels in myeloid cells (Fig. 4 and Supplementary 
Fig. S7). Furthermore, IL-6 increased the levels of pSTAT1 and pSTAT5 levels in T cells, albeit 
that pSTAT5 upregulation was more infrequently observed. The upregulation of pSTAT1 
was more pronounced in CD4+ than CD8+ T cells (Fig. 4 and Supplementary Fig. S7). IL-7 is 
known to induce pSTAT557. Indeed CD4+ and CD8+ T cells but not myeloid cells expressed 
pSTAT5 (Fig. 4 and Supplementary Fig. S7). IL-10 is known to induce pSTAT357. Approximately 
half of the uVIN patients and controls displayed increased levels of pSTAT3 in CD4+ and 
CD8+ T cells whereas in 53% of patients and 75% of controls pSTAT3 was increased in the 
CD14+CD33+ monocyte population upon IL-10 stimulation (Fig. 4 and Supplementary Fig. 
S7). Overall, we observed no strong differences in the activation or expression of pSTAT to 
cytokine stimulation in the immune cells between healthy controls and uVIN patients. 
STAT phosphorylation upon stimulation with immune modulators that are used to enhance 
the efficacy of immunotherapy
IFNα and GM-CSF are used in clinical trials as immune modulators to boost and polarize the 
Th1/CTL response to therapeutic vaccination and in some cases as monotherapy59-61. IFNα 
is a well-known potent inducer of various pSTATs and it is known to have a close synergic 
function with IFNγ53,62,63. Indeed all types of tested immune cells responded with increased 
levels of pSTAT1. In T cells the levels of pSTAT5 increased, which was most pronounced for 
CD4+ T cells. Interestingly, pSTAT5 upregulation was more often observed in the CD8+ T-cell 
population of healthy controls than that of uVIN patients (88% controls vs 54% patients 
(p=n.s.)). Moreover, whereas the majority of healthy controls (75%) displayed increased 
pSTAT5 levels in their CD14+CD33+ monocytes, this was only the case in 37.5% of the 
patients (p=0.07). The levels of pSTAT5 expressed by healthy control-derived CD14+CD33+ 
monocytes were increased as well (p= 0.05; Supplementary Fig. S7). IFNα also stimulated 
the increase of pSTAT3 and pSTAT6, especially in the CD4+ T cells and the CD14+CD33+ 
monocytes. The immune modulator GM-CSF only induced an increase in pSTAT5 levels 
in CD14+CD33+ monocytes and in contrast to IFNα this was more often observed in 
CD14+CD33+ monocytes of uVIN patients (83%) than healthy controls (38%). Also the 
absolute levels of pSTAT5 were higher in these cells after stimulation with GM-CSF (p=0.018; 
Fig. 4, Fig. 5 and Supplementary Fig. S7). Comparison of the pSTAT responses to these two 
immune modulators between uVIN patients and healthy controls revealed differences 
only in the response of CD14+CD33+ monocytes. Healthy control-derived CD14+CD33+ 
monocytes displayed a stronger response on the basis of the overall number of pSTATs that 
were increased upon stimulation with IFNα (Fig. 6). In conclusion, comparison of the fold-
increase of pSTATs showed that IFNα induced a stronger increase of pSTAT5 in CD14+CD33+ 
monocytes of healthy subjects while GM-CSF triggered a stronger upregulation of pSTAT5 in 
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Figure 4: Boxplots of pSTAT induction upon stimulation with various cytokines or immune modulators 
in patients with uVIN and healthy donors
The fold increase of different pSTATs upon cytokine stimulation in all immune cell populations are 
depicted for uVIN patients and healthy controls. Significant differences by comparison of absolute fold 
changes of pSTAT in uVIN patients and healthy donors by use of the non-parametric Mann-Whitney U 
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Figure 5: Phosphorylation of pSTAT5 after stimulation with GM-CSF and pSTAT1 and pSTAT5 upon 
IFNα in CD14+CD33+ monocytes in uVIN patients and healthy donors 
The induction of pSTAT1 and pSTAT5 upon stimulation with immunomodulatory agents GM-CSF 
and IFNα. In figure A, a significant increase in pSTAT5 in CD14+CD33+ myeloid cells upon GM-CSF in 
comparison to the fold increase in healthy controls is depicted. In figure B the pSTAT1 and in figure C 
the pSTAT5 induction in CD14+CD33+ myeloid cells upon IFNα is depicted and albeit not significant in 
uVIN patients the fold induction is lower compared to healthy controls. 
STAT phosphorylation of pre-treatment samples of patients treated with HPV-16 SLP ISA 
101 vaccination
We then compared the STAT phosphorylation after stimulation with these immune 
modulators in pre-treatment samples of 3 uVIN patients which responded by a peak in T-cell 
associated IFNγ production upon the first vaccination with HPV16-SLP ISA101 to those (n=5) 
that did not34. The CD14+CD33+ cells of uVIN patients with a peak IFNγ response displayed 
a more pronounced increase in pSTAT1 induction upon IFNα stimulation than the other 
patients. Stimulation with GM-CSF did result in an overt pSTAT5 induction and there were 
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Figure 6: Total pSTAT upregulation in different immune cell types upon stimulation with IFNα, GM-
CSF and IFNγ 
Total pSTAT upregulation was calculated upon an upregulation or downregulation of one or more STATs 
upon stimulation with a specific cytokine. In case of upregulation +1 and in case of downregulation -1 
was scored revealing a maximum score of 4 in case of pSTAT 1, 3, 5 and 6 upregulation and a minimum 
score of -4 for each patient. Subsequent analysis of the total pSTATs was performed by an unpaired T 
test in Graphpad Prism 5. In Figure A the total pSTAT induction upon IFNα is significantly higher in the 
CD14+CD33+ myeloid cell population in healthy controls. Differences in total pSTAT induction upon 
GM-CSF (Fig. B) and IFNγ (Fig. C) can be established albeit that IFNγ reveals a distinct upregulation of 








































172  |  Chapter 7
Figure 7: STAT phosphorylation upon stimulation with IFNα and GM-CSF in CD14+CD33+ myeloid 
cells of patients with and without an IFNγ peak response upon HPV 16 SLP ISA 101 vaccination 
In patients where a distinct peak of IFNγ production upon the first vaccination with HPV 16 SLP ISA 101 
is found, IFNα reveals a higher fold increase in pSTAT1 of CD14+CD33+ monocytes albeit not significant 
(A). Stimulation with GM-CS F does result in an overt increase in pSTAT5 in both peak responders and 
non-responders (B). 
Discussion 
In this study we analysed the type and function of circulating immune cells by an extensive 
phenotypic analysis and a novel technology that allows simultaneous measurements of 
changes in phosphorylation of protein levels of STATs after stimulation29,53. Our study revealed 
no differences in the potential of T cells to proliferate or the capacity of antigen presenting 
cells to stimulate T-cell responses between uVIN patients and healthy subjects. However, 
the frequencies of immature DCs or differentiating macrophages and activated monocytes/
macrophages are lower in uVIN patients compared to healthy controls. Furthermore, 
patients with recurrent uVIN lesions display lower frequencies of DCs and higher frequencies 
of type 2 monocytes/macrophages than patients without recurrent disease. This alteration 
was also observed at the functional level since CD14+CD33+ monocytes/macrophages of 
uVIN patients displayed decreased levels of pSTAT5 upon IFNα stimulation but increased 
pSTAT5 levels when stimulated with GM-CSF when compared to healthy controls. Our data 
on the response of CD14+CD33+ cells from vaccinated patients to IFNα suggest that this may 
also be reflected in their capacity to respond to vaccination, but clearly more patients need 
to be analysed. Importantly, the relation between increased numbers of circulating type 2 
monocytes/macrophages in the blood and a worse RFS is in concordance with our previous 
observation that M2 macrophages are abundantly infiltrating uVIN lesions and associated 
with recurrent disease as well16. 
A higher frequency of circulating CD4+CD94+(NKG2a+) T cells was found to be associated 
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positive for CD94 since CD94 forms a complex with the NKG2 family54,55. In our previous 
study on the expression of co-inhibitory molecules in the uVIN microenvironment we 
studied NKG2a expression in the context of CD3+ T cells and showed that its expression 
was associated with a better RFS17. Unfortunately, we did not distinguish between CD4+ 
and CD8+ T cells expressing NKG2a+ in that study. Our current data suggest that specifically 
the expression of NKG2a on CD4+ T cells is associated with better clinical outcome. New 
studies are required to analyse whether the NKG2a+ cells in the uVIN microenvironment 
are CD4+ or CD8+ and which of the two populations is associated with better RFS. It will be 
extremely important to know if the analysis of both the type 2 monocytes/macrophages 
and the CD4+CD94+NKG2A+ T cells in a blood sample could substitute for measurements 
of these cell types in the tissue as it may allow a relatively simple blood analysis to become 
a biomarker that is associated with local events and prognosis. Therefore, a new study is 
warranted in which both blood and tissue of the same patient population is studied to 
validate our current observations.
In contrast to the similarities between local and systemic NKG2a expression we did not 
observed such a relationship with respect to the presence of CD8+TIM3+ cells. While in the 
uVIN microenvironment the presence of CD8+TIM3+ cells correlated with pro-inflammatory 
T-cell responses, characterised by Tbet and Galectin-9 expression, and was found to be a 
favourable prognostic factor in recurrence free survival, the frequencies of circulating TIM3+ 
T-cell subpopulations were not directly associated. However, a relative higher number of 
circulating CD8+TIM3+ T cells over CD8+TIM3- T cells was found to be associated with 
worse clinical outcome. These opposite data suggest that either there is no reflection of the 
changes in the local environment by those measured in the circulation, or that the context in 
which CD8+TIM3+ cells are analysed is more important as it is expressed both during T-cell 
activation and exhaustion64. Future research should establish the exact role and function of 
these cells in uVIN patients. 
Of interest for future immunotherapeutic studies are our data on the stimulation of 
immune cells with the immune modulators GM-CSF and IFNα. They are both involved in DC 
activation and used as adjuvants for different therapeutic vaccines aiming to enhance a Th1 
polarized T-cell response59-61. The use of mainly IFNα has been proven beneficial to vaccine-
induced T-cell responses, whereas GM-CSF resulted in different outcomes60,61. IFNα can be 
seen as a potent immune modulator revealing mainly pro-inflammatory associated STAT1 
phosphorylation induction in both healthy controls, premalignant and cancer patients and 
it is known to have a close synergic effect with IFNγ62,63. A type I IFN response is essential 
for DC maturation and induction of CD4+ Th1 immunity65. The higher total induction of 
pSTAT in healthy subjects compared to uVIN patients may reflect the reduced potency of 
the precursor cells of patients’ DCs and macrophages (CD14+CD33+) to respond to immune 
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CD14+CD33+ myeloid cells from uVIN patients and healthy controls when stimulated with 
IFNα or GM-CSF. Of note, IL-2 is known to induce pSTAT5 in DCs required for their functional 
maturation66. However, an IL-2 induced increase of pSTAT5 was not observed, potentially 
because the stimulation was for 15 minutes whereas in another study pSTAT5 was shown to 
be detectable in DCs only after 30 minutes of stimulation66. GM-CSF is known to generate 
granulocyte and macrophage populations from myeloid precursor cells and is of importance 
in survival, proliferation and differentiation of monocytes and macrophages by activation of 
JAK2 and STAT5 24. The CD14+CD33+ myeloid cells of uVIN patients responded to GM-CSF 
with higher levels of pSTAT5 but it is unclear how this may impact immunity. In patients 
with a cytomegalovirus (CMV) infection monocyte-derived DCs lack the ability to secrete 
IL-12 and to induce Th1 cell activation and this is associated with an impaired response 
of these monocytes to induce pSTAT5 upon GM-CSF stimulation67, suggesting that GM-CSF 
induced pSTAT5 is required for a good immune response. Interestingly, leukaemia patients 
display an increased pSTAT5 response to GM-CSF stimulation when compared to healthy 
donors. Similar to what we observed in uVIN patients. This response in leukaemia patients 
was classified as hypersensitivity and correlated with high risk disease, higher peripheral 
leukocyte and monocyte count and altered signalling in the Ras pathway68. Signalling via 
STAT5 may result in pro-inflammatory responses but it also essential for the induction of 
peripheral tolerance27. pSTAT5 plays an essential role in Th2 differentiation since pSTAT5 
expression results in IL-4 expression by cells lacking pSTAT6 and pSTAT5 induces IL-4 in T 
cells cultured under Th1 polarizing conditions. Moreover pSTAT5 is involved in regulatory 
FoxP3+ T-cell (Treg) development, induced by IL-2 and pSTAT5, by binding to the FoxP3 
promotor56. The role of an altered pSTAT5 expression in myeloid cells of uVIN patients can 
thus be interpreted along two lines; a tolerance inducing role as well as a pro-inflammatory 
role when pSTAT5 is expressed in combination with pSTAT1. Interestingly, the increased 
expression of pSTAT1 upon stimulation with IFNα in uVIN patients with a peak IFNγ response 
upon vaccination fits this latter role of pSTAT5 well. Unfortunately, it remains difficult to 
unravel the activated interactive pathways in vivo that may explain the difference in the 
patients capacity to respond to immunotherapy by in vitro experiments of phosphorylation 
of STATs upon single cytokine stimulations due to heterodimerization of simultaneous STATs 
and crosstalk among the JAK-STAT pathways occur32,57,62. For example there is cross talk 
between type I and type II IFNs as pre-treatment with IFNγ sensitizes cells to IFNα and pre-
treatment with IFNγ increases the level of pSTAT1 which can enhance the subsequent IFNγ 
response during macrophage activation62,63. Furthermore, IFNs inhibit IL-4 induced STAT6 
expression in human monocytes and IL-10 can inhibit the activity of pro-inflammatory 
cytokines such as IFNα 62,69,70. Potentially, combinations of cytokines to stimulate immune 
cells may better mimic the in vivo reaction upon secretion of multiple cytokines in response 
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In conclusion, our data suggest that the circulating myeloid cell population is phenotypically 
and functionally altered in uVIN patients and that the measurement of circulating type 2 
monocytes is related to recurrent disease. This relationship needs to be confirmed as it may 
serve as a blood biomarker that reflects the local microenvironment and is important for 
prognosis.
Acknowledgements 
We thank all the patients and healthy controls who participated in the Circle study and in 
the therapeutic vaccination trial with HPV16 SLP ISA101 vaccination. Moreover we greatly 
acknowledge A. Cesano and M. Westfall from Nodality Inc, South San Francisco, USA for the 
assistance with their experience in the development of our protocol and E.M. Osse and N. 
ter Haar from the Department of Pathology, LUMC, Leiden, The Netherlands for performing 
the HPV typing. 








































176  |  Chapter 7
References
 1.  van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. Review of squamous premalignant vulvar 
lesions. Crit Rev Oncol Hematol 2008; 68(2):131-156.
 2.  Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and 
in situ vulvar carcinoma. Obstet Gynecol 2006; 107(5):1018-1022.
 3.  Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 
Suppl 1:S16-S24.
 4.  Petry KU, Kochel H, Bode U, Schedel I, Niesert S, Glaubitz M et al. Human papillomavirus is associated 
with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical 
neoplasia among immunocompromised women. Gynecol Oncol 1996; 60(1):30-34.
 5.  Jamieson DJ, Paramsothy P, Cu-Uvin S, Duerr A. Vulvar, vaginal, and perianal intraepithelial neoplasia 
in women with or at risk for human immunodeficiency virus. Obstet Gynecol 2006; 107(5):1023-
1028.
 6.  de Jongt A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A et al. Frequent 
detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 
2002; 62(2):472-479.
 7.  Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S et al. 
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy 
population as witness of previous viral encounter. Cancer Res 2003; 63(3):636-641.
 8.  van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, 
Drijfhout JW et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in 
patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact 
of imiquimod treatment. Clin Cancer Res 2005; 11(14):5273-5280.
 9.  Bourgault Villada I, Moyal BM, Berville S, Bafounta ML, Longvert C, Premel V et al. Human 
papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. 
Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol 2010; 
159(1):45-56.
 10.  Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP et al. 
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 
361(19):1838-1847.
 11.  van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ et al. Treatment of 
vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358(14):1465-1473.
 12.  Winters U, Daayana S, Lear JT, Tomlinson AE, Elkord E, Stern PL et al. Clinical and immunologic results 
of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial 
neoplasia. Clin Cancer Res 2008; 14(16):5292-5299.
 13.  Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL et al. Phase II trial of imiquimod 
and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010; 
102(7):1129-1136.
 14.  van Seters M, Beckmann I, Heijmans-Antonissen C, van Beurden M, Ewing PC, Zijlstra FJ et al. 
Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia. Cancer 
Res 2008; 68(16):6617-6622.
 15.  Terlou A, van Seters M, KleinJan A, Heijmans-Antonissen C, Santegoets LA, Beckmann I et al. 
Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in 
usual type vulvar intraepithelial neoplasia. Int J Cancer 2010; 127(12):2831-2840.
 16.  van Esch EM, van Poelgeest MI, Trimbos JB, Fleuren GJ, Jordanova ES, van der Burg SH. Intraepithelial 
macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive 
course of HPV-induced vulvar neoplasia. Int J Cancer 2015; 136(4):E85-E94.
 17.  van Esch EM, van Poelgeest MI, Kouwenberg S, Osse EM, Trimbos JB, Fleuren GJ et al. Expression of 
coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia 










































Phenotyping and STAT phosphorylation of systemic immune cells in uVIN patients  |  177
 18.  Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 
2013; 13(4):227-242.
 19.  Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012; 
24(2):213-216.
 20.  Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 
2008; 8(6):467-477.
 21.  Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev 
Immunol 2008; 26:677-704.
 22.  Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. 
Nat Rev Immunol 2012; 12(4):253-268.
 23.  Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages 
in human cancers. J Transl Med 2011; 9:216.
 24.  Lehtonen A, Matikainen S, Miettinen M, Julkunen I. Granulocyte-macrophage colony-stimulating 
factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/
macrophage differentiation. J Leukoc Biol 2002; 71(3):511-519.
 25.  Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F 
et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and 
phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010; 107(26):11895-11899.
 26.  Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFNgamma and lymphocytes 
prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 
410(6832):1107-1111.
 27.  O’Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y. Genomic views of STAT function in CD4+ T 
helper cell differentiation. Nat Rev Immunol 2011; 11(4):239-250.
 28.  Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the 
tumour microenvironment. Nat Rev Immunol 2007; 7(1):41-51.
 29.  Lee AW, Sharp ER, O’Mahony A, Rosenberg MG, Israelski DM, Nolan GP et al. Single-cell, 
phosphoepitope-specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/
STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection. J 
Virol 2008; 82(7):3702-3712.
 30.  O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N 
Engl J Med 2013; 368(2):161-170.
 31.  Jenkins BJ. Transcriptional regulation of pattern recognition receptors by Jak/STAT signaling, and the 
implications for disease pathogenesis. J Interferon Cytokine Res 2014; 34(10):750-758.
 32.  Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated 
tumorigenesis. Oncogene 2004; 23(48):8017-8023.
 33.  Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of Jak/STAT Signaling in Immunity and 
Disease. J Immunol 2015; 194(1):21-27.
 34.  van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends- van der Meer TM, et al. 
Therapeutic Vaccination in Vulvar/Vaginal Intraepithelial Neoplasia: a Randomized Controlled Study 
with Imiquimod as Adjuvant. Submitted 2015.
 35.  Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F 
et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and 
phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010; 107(26):11895-11899.
 36.  van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR 
followed by reverse line blot analysis enables rapid and high-throughput identification of human 
papillomavirus genotypes. J Clin Microbiol 2002; 40(3):779-787.
 37.  Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter SJ et al. Development and clinical 
evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and 
identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37(8):2508-2517.
 38.  de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ et al. Human 
papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity 
against early antigens E2 and E6. Cancer Res 2004; 64(15):5449-5455.
 39.  Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential 








































178  |  Chapter 7
 40.  Fink R, Al-Obaidi M, Grewal S, Winter M, Pepper J. Monocyte activation markers during 
cardiopulmonary bypass. Perfusion 2003; 18(2):83-86.
 41.  Amano H, Amano E, Santiago-Raber ML, Moll T, Martinez-Soria E, Fossati-Jimack L et al. Selective 
expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of 
systemic lupus erythematosus. Arthritis Rheum 2005; 52(9):2790-2798.
 42.  Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages 
in human cancers. J Transl Med 2011; 9:216.
 43.  Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TR, Reedquist KA et al. Systematic validation 
of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 
2012; 375(1-2):196-206.
 44.  Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor 
CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J 
Leukoc Biol 2000; 67(1):97-103.
 45.  Kataoka M, Tavassoli M. Development of specific surface receptors recognizing mannose-terminal 
glycoconjugates in cultured monocytes: a possible early marker for differentiation of monocyte into 
macrophage. Exp Hematol 1985; 13(1):44-50.
 46.  Rey-Giraud F, Hafner M, Ries CH. In vitro generation of monocyte-derived macrophages under 
serum-free conditions improves their tumor promoting functions. PLoS One 2012; 7(8):e42656.
 47.  Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 
2008; 8(12):958-969.
 48.  Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in atherosclerosis. Immunol Rev 
2014; 262(1):153-166.
 49.  Ohlsson SM, Linge CP, Gullstrand B, Lood C, Johansson A, Ohlsson S et al. Serum from patients 
with systemic vasculitis induces alternatively activated macrophage M2c polarization. Clin Immunol 
2014; 152(1-2):10-19.
 50.  Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H et al. 
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin 
Cancer Res 2011; 17(17):5668-5673.
 51.  Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived 
suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35(2):107-115.
 52.  Crocker PR, Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol 2001; 22(6):337-342.
 53.  Longo DM, Louie B, Putta S, Evensen E, Ptacek J, Cordeiro J et al. Single-cell network profiling 
of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated 
differences in immune signaling pathway activation. J Immunol 2012; 188(4):1717-1725.
 54.  Borrego F, Masilamani M, Marusina AI, Tang X, Coligan JE. The CD94/NKG2 family of receptors: from 
molecules and cells to clinical relevance. Immunol Res 2006; 35(3):263-278.
 55.  Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH et al. HLA-E expression 
by gynecological cancers restrains tumor-infiltrating CD8 T lymphocytes. Proc Natl Acad Sci U S A 
2011; 108(26):10656-10661.
 56.  Knosp CA, Johnston JA. Regulation of CD4+ T-cell polarization by suppressor of cytokine signalling 
proteins. Immunology 2012; 135(2):101-111.
 57.  Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16:293-322.
 58.  Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter FF, et al. Combining 
carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α 2b 
in patients with recurrent epithelial ovarian cancer. Submitted 2015
 59.  Talebian YM, Keene KR, Hiemstra PS, van der Burg SH. Recent progress in peptide vaccination in 
cancer with a focus on non-small-cell lung cancer. Expert Rev Vaccines 2014; 13(1):87-116.
 60.  Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: 
implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010; 43(3):204-209.
 61.  Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S et al. Use of GM-CSF as an adjuvant 
with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010; 9(5):519-525.










































Phenotyping and STAT phosphorylation of systemic immune cells in uVIN patients  |  179
 63.  Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE et al. Sensitization of IFN-gamma Jak-
STAT signaling during macrophage activation. Nat Immunol 2002; 3(9):859-866.
 64.  Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J 
Immunol 2014; 193(4):1525-1530.
 65.  Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C et al. Dendritic cells require 
a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as 
adjuvant. J Exp Med 2009; 206(7):1589-1602.
 66.  Herr F, Lemoine R, Gouilleux F, Meley D, Kazma I, Heraud A et al. IL-2 phosphorylates STAT5 to drive 
IFN-gamma production and activation of human dendritic cells. J Immunol 2014; 192(12):5660-
5670.
 67.  Carlier J, Martin H, Mariame B, Rauwel B, Mengelle C, Weclawiak H et al. Paracrine inhibition of GM-
CSF signaling by human cytomegalovirus in monocytes differentiating to dendritic cells. Blood 2011; 
118(26):6783-6792.
 68.  Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM et al. GM-CSF-dependent 
pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. 
Blood 2013; 121(25):5068-5077.
 69.  Dickensheets HL, Venkataraman C, Schindler U, Donnelly RP. Interferons inhibit activation of STAT6 
by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci U S A 
1999; 96(19):10800-10805.
 70.  Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP et al. Interleukin-10 inhibits 
expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine 






















































































































































































































































































































































































































































































































































































186  |  Chapter 7
Supplementary Figure S6 - Continued
Overview of pSTAT upregulation in CD4+, CD8+, CD14+CD33+ and CD14-CD33dim immune cells upon stimulation 
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Supplementary Figure S7
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Supplementary Table S1 - Systemic expression of myeloid cells in PBMCs of uVIN patients and 
healthy controls recurrent vs non-recurrent uVIN patients. 
*Non-parametric Mann-Whitney U test was used to determine the differences in expression of 
systemic myeloid cells between healthy controls and uVIN patients and recurrent and non-recurrent 
uVIN patients. p<0.05 is considered significant and in bold the p-values are marked where the cells 
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Supplementary Table S3: Systemic expression of co-inhibitory molecule expression on lymphoid 
cells in PBMCs of uVIN patients and healthy controls recurrent vs non-recurrent uVIN patients. 
*Non-parametric Mann-Whitney U test was used to determine the differences in expression of 
systemic myeloid cells between healthy controls and uVIN patients and recurrent and non-recurrent 
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A diagnosis with usual vulvar intraepithelial neoplasia (uVIN), caused by a persistent 
infection with the human papilloma virus (HPV), has major impact on the patient since 
this chronic skin disease is associated with severe long-lasting complaints as pruritus, high 
recurrence rates, a malignant potency, psychosexual implications and frequent outdoor 
patient clinic follow up visits. The incidence of uVIN is increasing, mainly in young women 
and there is a need for alternative therapies. The immune response clearly plays a role 
in protection against this disease and different immunotherapies are being developed to 
treat the persistent HPV infection and related anogenital neoplasia. In contrast to patients 
with cervical intraepithelial neoplasia (CIN) for whom the conventional loop electrosurgical 
procedure (LEEP) therapy is a relatively simple and uncomplicated therapy, the conventional 
therapies for uVIN are associated with potential mutilation and high recurrence rates. 
Therefore uVIN patients form an exquisite patient group to evaluate the potency of 
immunotherapy in HPV-induced premalignant disease. In the past decade clinical successes 
have been achieved in the treatment of uVIN by different immunotherapeutic approaches, 
albeit that still a notable number of patients does not respond to these therapies. Despite 
the fact that uVIN is the first HPV-induced disease successfully treated by immunotherapy, 
the knowledge of the immune response in uVIN is relatively limited when compared to the 
well-studied CIN and cervical cancer lesions. Through the studies in this thesis we gained 
more knowledge on the local and systemic immune responses. This may help to understand 
the non-responsiveness to immunotherapy of some patients which can be used to optimize 
these therapies and to foster individualised (immune) therapies. 
Local immune cell infiltrates in the microenvironment of uVIN lesions 
The importance of the immune infiltration in protection and regression of uVIN lesions is 
indicated by the normalization of immune cell counts when the lesion is resolved1-4. The 
epithelium of the uVIN lesion has been characterised as immunosuppressive reflected 
by a lower number of CD8+ T cells, the presence of immature DCs and LCs whereas the 
stroma is the immune active compartment with higher numbers of mature DCs, NK 
and T cells1,5,6. Regulatory T cells (Tregs), which are known to suppress induction of pro-
inflammatory Th1 cells required to subsequently attract effector CD8+ T cells to the lesion, 
abundantly infiltrate uVIN lesions and are consistently associated with non-responsiveness 
to immunotherapy 1-3,7-11. Intralesional CD8+ T cells are indispensable as illustrated by the 
decrease in the number of CD8+ T cells in the progression of uVIN as well as in an increase 
of mainly CD8+ lymphocytes in clinical responders to immunotherapy1-4,12. We confirmed 
the abundant expression of CD4+ and CD8+ lymphocytes and regulatory T cells mainly in the 
stroma of uVIN lesions. Moreover a high stromal CD8+/Treg ratio was related to a prolonged 
recurrence free survival rate in uVIN lesions highlighting the importance of intralesional 
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carcinomas the number of regulatory T cells increase and outnumber the CD8+ T cells, as 
reflected by a lower CD8+/Treg ratio (Chapter 5). 
Alterations in HLA expression in uVIN patients 
Alterations in HLA expression (e.g. HLA class I expression) in uVIN might allow these 
premalignant lesions to escape immune surveillance by specific CD8+ T cells because of 
insufficient antigen presentation to T cells. In a previous study downregulation of HLA 
class I was reported in 30% of uVIN lesions and in the majority of vulvar carcinomas. HLA 
class I downregulation was associated with non-responsiveness to photodynamic therapy 
(PDT)2. In Chapter 4 we show that alterations in HLA expression are already present in HPV-
induced uVIN. Over 70% of uVIN lesions and 80% of vulvar carcinomas display (partial) 
downregulation of HLA class I. Total loss of HLA-A and/or HLA-B/C, however, is scarce and 
found only in <10% of uVIN lesions although total loss of HLA B/C increased from 9% in uVIN 
to 38% in uVIN adjacent to micro invasive carcinoma. Downregulation of HLA B/C was related 
to the recurrences and progression of uVIN lesions. The (partial) HLA-class I downregulation 
seems reversible in uVIN since IFNγ stimulation of uVIN keratinocytes in vitro resulted in the 
upregulation of HLA class I. Moreover, only 15% of uVIN cases showed a genetically caused 
downregulation of HLA class I, through loss of heterozygosity (LOH). The reversibility of HLA 
class I downregulation is a potential explanation for the fact that HLA class I downregulation 
showed no clinical impact on the results of our HPV16 SLP vaccination trial, where all clinical 
responders showed partial downregulation of HLA class I and non-responders could still 
fully express HLA class I. Potentially, vaccine induced IFNγ-producing HPV16-specific CD4+ T 
cells that infiltrate the lesion mediate the upregulation of HLA class I in uVIN lesion without 
genetic cause of HLA downregulation. In vulvar carcinomas however LOH was more often 
associated with HLA class I downregulation (25-55.5%) suggesting that more advanced 
stages of HPV induced neoplasia are increasingly difficult to treat by immunotherapy. MICA, 
which serves as a stimulatory molecule for CD8+ T cells and NK cells through interaction 
with NKG2d, was downregulated in 80% of uVIN and carcinomas. A combination of HLA-
class I downregulation and MICA was associated with recurrent disease. The alterations of 
the classical HLA molecules and MICA seem an early event in HPV induced neoplasia which 
may allow lesions to develop. Expression of the non-classical HLA molecules -E and -G was 
associated with the progressive course of vulvar neoplasia, and found in approximately 50% 
of carcinoma cases. Negative feedback through NKG2a, suppressing activated T cells and NK 
cells, may add to the difficulty to treat carcinoma. 
Intralesional infiltration of myeloid cells and characterisation of lymphocytes 
The observed intralesional lymphocytic and myeloid cell infiltrates in uVIN by several 
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This may be caused by an impaired function of those infiltrating immune cells as result of 
an immunosuppressive microenvironment. In Chapter 5 we presented a detailed analysis 
of several immune inhibitory molecules in the uVIN lesions and observed the expression of 
co-inhibitory molecules PD1, TIM3 and NKG2a on a proportion of infiltrating lymphocytes. 
The negative regulatory molecules as CTLA-4, TIM3 and PD1 are expressed to suppress 
T-cell function and prevent uncontrolled inflammation of the immune system14,15. TIM3 is 
upregulated in IFNγ producing CD4+ and CD8+ differentiated T cells whereas CTLA-4, PD1 
and NKG2a can be upregulated on T cells after activation15-17. In our study, the expression 
of TIM3 was correlated with high numbers of infiltrating Tbet positive T cells as well as 
with higher numbers of immune cells expressing its ligand Galectin-9, which is known to be 
upregulated in response to pro-inflammatory cytokines (e.g. IFNγ) or upon activation via 
TLRs18,19. Upon Gal-9 TIM3 interactions, T-cell function can be suppressed18,20,21, but Gal-9 
TIM3 interactions in CD8+ T cell may enhance their function if these cells do not co-express 
PD121,22. Interestingly the expression of the markers TIM3 and NKG2a on lymphocytes in 
uVIN lesions seemed a reflection of T-cell activation rather than inhibition since relatively 
higher numbers of CD8+TIM3+ and CD3+NKG2a+ T cells in the stroma of uVIN lesions 
were related to a prolonged recurrence free survival. However, when co-infiltrating Tregs 
outnumber these CD8+TIM3+ T cells the recurrence free survival is decreased. This is also 
observed in vulvar carcinomas. Unfortunately, we were not able to evaluate CTLA-4 by 
immunohistochemistry due to aspecific staining of different antibodies in paraffin embedded 
tissue but analysis of PD1 showed a number of activated PD1+ T cells in uVIN lesions, the 
presence of which did not seem to have clinical impact. Interestingly, the number of PD1+ 
and NKG2a+ T cells was higher in the epithelium of control tissue compared to uVIN tissue 
suggesting that immune cells in HPV infected tissue are less activated. Although scarcely 
present, stromal NKG2a expression on CD3+ T cells was associated with an improved clinical 
outcome in uVIN lesions. Potentially, because its ligand HLA-E was almost not expressed in 
uVIN lesions23. The expression of NKG2a is thus a potential reflection of an adequate local 
pro-inflammatory T-cell response in uVIN lesions. This notion would fit with the observation 
that in HLA-E expressing vulvar carcinomas the number of stromal CD3+NKG2a+ T cells was 
remarkably lower. 
The progressive course of HPV induced vulvar neoplasia is characterised by an increase in 
both epithelial and stromal Tregs as well as intraepithelial and stromal matured M1 and M2 
macrophages (Chapter 6). In uVIN lesions M2 macrophages outnumber M1 macrophages 
whereas the numbers of M1 level up in vulvar carcinoma. In case of a dense number of 
intraepithelial CD14+ macrophages (irrespective of type M1 or M2) the risk of a recurrence 
is markedly enhanced and this is an independent prognostic factor for recurrent disease. 
The presence of these CD14+ macrophages is associated with an increase in intraepithelial 
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an immunosuppressed microenvironment since the combination of these parameters 
was associated with rapid recurrences (Chapter 6). Interestingly, patients not responding 
to imiquimod display an increased average (not-significant) number of CD14+ and CD68+ 
cells suggesting that macrophage infiltration in uVIN lesions may have impact on clinical 
responses to immunotherapy1. Based on our data we expect that the patients with higher 
numbers of CD14+ and CD68+ macrophages will also display a stronger infiltration with 
regulatory T cells whereas the clinical responders to imiquimod therapy probably will show 
the presence of pro-inflammatory infiltrating T cells. 
Systemic immunity in patients with uVIN lesions 
Systemic cellular HPV specific T-cell responses characterized by relatively robust proliferative 
IFNγ- and IL-5-producing CD4+ T-cell responses against early viral proteins E2, E6 and E7 are 
associated with better control of HPV16 infections24,25. In uVIN patients the systemic HPV 
16-specific IFNγ-associated type 1 T-cell responses against E2, E6 and/or E7 are either weak 
or non-detectable in up to 50% of the patients26-28. Perhaps the patients with detectable 
systemic HPV-specific T-cell responses are also the patients where a pro-inflammatory 
effector T-cell response is detected in the microenvironment. The presence of such 
circulating HPV-specific T-cell responses is unfortunately not associated with spontaneous 
lesion clearance but is associated with a better clinical response to imiquimod or PDT26,29. 
Therapeutic vaccination studies demonstrated the importance of a strong and broad systemic 
HPV specific pro-inflammatory immune response to resolve uVIN3,13,30,31. Interestingly, the 
capacity of patients to respond to therapeutic vaccination differs extensively. Some of the 
patients display relatively weak vaccine-induced responses of limited breadth associated 
with no clinical response, whereas in others the vaccine-induced T-cell response was strong 
and broad and associated with lesion regression. These data suggested that the patients’ 
capacity to respond to the vaccination varies and potentially this depends on their immune 
status. In two hypothesis generating studies we explored the phenotypic (co-inhibitory 
molecule expression) and functional (cytokine stimulated STAT phosphorylation) analysis 
of peripheral circulating lymphocytes as well as the type and number of myeloid cells 
(macrophages, DCs and MDSCs) in uVIN patients in comparison to that of healthy controls. 
Phenotypic analysis of circulating lymphocytes and myeloid cells
The expression of the inhibitory markers on peripheral lymphocytes was limited to a 
small percentage (<1%) of all CD3+ lymphocytes apart for PD1, which is expressed in 
approximately 3-5% of CD4+ or CD8+ T cells in both uVIN patients and healthy controls. 
No overt differences were observed although in uVIN patients the proportion of CD4+PD1+ 
and CD4+TIM3+ T cells was slightly increased compared to healthy controls. Interestingly, 
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compared to patients with a recurrence. In addition, a higher frequency of these cells 
was associated with a prolonged recurrence free survival (Chapter 7). Interestingly, high 
numbers of CD3+NKG2a+ T cells in the microenvironment were also associated with a 
favourable clinical outcome(Chapter 5). Importantly, if a cell is NKG2a+ one can consider 
it positive for CD94+ as well because NKG2a forms a complex with CD94 and cells should 
be positive for CD94 when they express NKG2a17. While we observed that the frequency 
of circulating CD4+CD94+ and CD4+CD94+NKG2a+ T cells were related to non-recurrent 
uVIN and a prolonged recurrence free survival, this was not the case for CD8+ T cells. In 
our analysis of lesion infiltrating lymphocytes we were not able to distinguish between 
CD4+NKG2a+ or CD8+NKG2a+ T cells in the microenvironment but this is an important 
goal for the future analysis since a potential direct correlation between systemic and local 
immunity in relation to clinical outcome would provide a valuable biomarker. Unlike NKG2a+ 
expression, the frequency of local and circulating CD8+TIM3+ T cells was associated with 
opposite clinical outcomes. Circulating CD8+TIM3+ T cells are related to recurrences and 
a decreased recurrence free survival period (Chapter 7). The relation between CD8+TIM3+ 
cells and their opposite relations with clinical outcome based on the origin of the biological 
sample they are measured in requires further investigation. 
Phenotyping of circulating myeloid cells revealed that the frequencies of CD14+CD11b+ 
monocytes are comparable in uVIN patients and controls and account for the largest 
population of myeloid cells. The percentage of CD14highCD11b+ monocytes was lower in 
recurrent uVIN lesions than in non-recurrent lesions (9.5% vs 16.5%) albeit that this percentual 
difference was not significant, probably due to the small group of patients analysed. Minor 
groups are represented by populations of <1% and are formed by CD14+IntCD11b+ mature 
macrophages/DCs, non-activated CD14+CD11b- monocytes and CD14-CD11b+ myeloid 
cells which may be activated DCs or monocytes with loss of CD1432,33. A comparison of the 
myeloid cell populations revealed that patients with recurrences displayed lower frequencies 
of circulating immature DCs/early differentiating monocytes and activated mature DCs 
whereas the proportion of circulating type 2 monocytes/macrophages was increased. This 
is in accordance with the observation that an increased number of lesion-infiltrating M2 
was associated with worse outcome. Patients with relatively higher frequencies of DCs and 
lower frequencies of circulating type 2 monocytes/macrophages show a s favourable clinical 
outcome and prolonged recurrence free survival (Chapter 7). 
Notably, DCs are indispensable in antigen presentation and subsequent regulation of tumor-
specific immune responses34 and their activation is impaired by immunosuppressive tumor 
associated myeloid cells as macrophages35. The immature or non-activated DCs which we 
observed more frequently in PBMCs of recurrent uVIN patients are also frequently observed 
in tumors and they do not contribute to anti-tumor immune responses34. The higher number 
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found to be increased within the lesion (Chapter 6) are probably involved in the impairment 
of DC.
Phosphorylation of signal transduction activators of transcription (STAT) in uVIN patients 
and healthy controls
We analysed the activation of different signal transduction routes in cytokine stimulated 
immune cells as a measure of their immune responsiveness (Chapter 7). We observed no 
differences in the activation rate or expression levels of pSTAT between uVIN patients and 
healthy controls for most of the cytokines tested. The only observations that we made 
were that healthy donor derived CD8+ T cells more often upregulated pSTAT5 upon IFNα 
stimulation when compared to uVIN patients. In an earlier study HPV-specific T cells from 
patients with recurrent respiratory papillomatosis display a reduced IFNγ and IL-2 secretion 
as well as lower STAT5 phosphorylation when compared to healthy controls suggesting that 
the HPV-specific T-cells were anergic. Their function could be restored by IL-2 implying that 
interventions restoring pro-inflammatory cytokine responses could improve clinical outcome 
and reverse T-cell anergy36. In addition, we observed that the CD14+CD33 monocytes of uVIN 
patients displayed lower levels of pSTAT5 upon IFNα stimulation whereas upon stimulation 
with GM-CSF higher levels of pSTAT5 were induced. Potentially, the cytokine signalling in 
these precursor antigen presenting cells has been altered in uVIN patients. 
The data obtained with the immune modulators GM-CSF and IFNα, both involved in DC 
activation, are of interest for future immunotherapeutic studies. They are both used 
as adjuvants to different therapeutic vaccines in order to enhance a Th1 polarized T-cell 
response37-39 but mainly the use of IFNα has been proven beneficial to vaccine induced 
T-cell responses38,39. The use of GM-CSF to enhance T-cell immunity has met with mixed 
outcomes38,39. Our data suggested that IFNα can indeed be regarded as a potent immune 
stimulator. It synergizes with IFNγ and may be a promising immune modulator during 
immunotherapy of uVIN patients. IFNα therapy has already shown promising enhancement 
of immune responses and potentially is related to clinical outcomes37,38,40-42. In a small 
number of vaccinated uVIN patients, with a peak of IFNγ upon the first HPV-16 SLP ISA101 
vaccination, pSTAT1 expression was increased upon stimulation with IFNα as well although 
it is difficult to unravel the activated interactive pathways in vivo that may explain the 
difference in the patients’ capacity to respond to immunotherapy. 
In conclusion, the circulating myeloid cell population is phenotypically and functionally 
altered in uVIN patients and our phenotypical analysis of circulating immune cells revealed 
two potential biomarkers associated with a better clinical outcome. The first is the frequency 
of CD4+CD94+ cells whereas the second is formed by the frequency of certain myeloid cell 
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Future prospects for the immunotherapy of premalignant uVIN lesions
The prerequisites for successful immunotherapy of uVIN consist of adequate T-cell priming 
by APCs, a balance towards effector instead of regulatory T cells, an increase of intralesional 
effector T cells, prevention of immune exhaustion and creating a pro-inflammatory 
microenvironment in which the activated HPV-specific effector T cells can exert their function 
in order to resolve the infection and lesion43,44. Different immunotherapies may act on parts of 
this. For instance, the topical immune modifier imiquimod enhances the migration of effector 
T cells in the lesion but apparently lacks the capacity to induce systemic T-cell activation to 
HPV antigens1,7,26. Therapeutic HPV vaccination results in adequate T-cell priming and pro-
inflammatory T-cell responses and is in two studies related to clinical responses (reviewed 
in 45) of which the TA-HPV results in an increase in intralesional influx of T cells in responders 
if combined with imiquimod3 whereas this remains unknown for the HPV-16 SLP vaccine30,31. 
We recently submitted the results of a vaccination study with HPV16 SLP ISA101, in which 
patients were randomised for vaccination with or without imiquimod application on the 
vaccination sites46. This trial confirmed the clinical efficacy of the vaccine as well as the 
relation of clinical responses to the strength of the vaccine induced pro-inflammatory HPV 
specific T-cell response. PDT may also result in the priming of lesion-specific T cells47, but 
is not likely to be as effective as vaccines. Since the vaccine-induced immune responses in 
the two HPV16 SLP trials are quite strong, one can envisage that meaningful improvements 
of clinical efficacy are not likely to come from further improvements of the vaccine itself 
but need to come from manipulation of the microenvironment where the T cells need to 
execute their function30,46.
We have shown that the premalignant uVIN lesions are actually immune supportive 
compared to progressed vulvar lesions. This is reflected by reversibility of HLA-class I 
downregulation, the infiltration with relative high numbers of activated CD8+ effector T cells 
and IFNγ-producing (Tbet+) T cells as well as relatively low numbers of regulatory T cells 
and intraepithelial CD14+ monocytes, all of which are related to time to recurrence and 
progression of the disease. We hypothesize that for immunotherapy one may best focus 
on this group of patients as, with such a supportive immunological profile of which it is 
likely that they will be responsive. For instance, the lesions of patients within this group 
show no impaired migration of T cells or local immune suppression which may counteract a 
therapeutic vaccine-induced or boosted T-cell response.
The non-responders to current immunotherapies are likely to be among the group of patients 
with lesions that are characterised by loss of HLA expression and show a strong infiltration 
with Treg and CD14+ macrophages. These lesions are more alike to HPV induced vulvar 
cancers. Here one can expect that immunotherapy requires a strategy including methods 
to overcome the different aspects of immunological failure which may come from the 
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imiquimod on the lesion can be used. Imiquimod is a topical immune modifier which acts 
through activation of innate immune cells by binding to TLR7 and 8 on DCs, which induces 
activation of NF-kB and subsequent secretion of multiple pro-inflammatory cytokines and 
activation of DCs, resulting in an influx of immune cells in the vulvar lesions and in increased 
antigen presentation because of LC migration to the draining lymph nodes1,3,4,7,48,49. Recently, 
it was also shown to upregulate the local expression of CXCL9 and CXCL10, chemokines 
involved in recruitment of CD4+ and CD8+ T cells50. Thus imiquimod may be used to change 
the local microenvironment cytokine milieu resulting in M1 polarization of the macrophages 
and a better attraction of CD8+ T cells to a number that outbalances Tregs. Treatment 
does not result in expansion of HPV-specific T cells26 but the combination is very likely to 
be successful as pre-existing HPV-specific immunity is related to better clinical responses 
upon imiquimod therapy26 and data from our clinical vaccination trials show that vaccinated 
patients who were initially not responding to vaccination, but are subsequently treated with 
imiquimod, generally display a complete and durable lesion regression30,46. Furthermore, 
the combination of vaccination and local imiquimod resulted in increased lesion-infiltrating 
immune cells and disease control in an animal model 50 and in uVIN patients3. A similar 
observation was made when imiquimod was combined with PDT3,4. In contrast to the 
combination of PDT and imiquimod, the numbers of intralesional T cells did not return to 
levels before imiquimod application when it was combined with vaccination suggesting that 
the vaccine-induced HPV 16 specific T-cell response resulted in increased T-cell infiltration 
and subsequent higher numbers of clinical responders1-4,31. 
Of note, our associations between immune cell infiltrates and clinical outcome are based 
on a cohort of uVIN patients treated with conventional therapies. It will be of utmost 
importance to estimate and validate these associations in a second patient cohort consisting 
of patients treated with immunotherapies such as imiquimod and therapeutic vaccines, in 
particular with HPV16 SLP vaccination. 
As already established the combination of local imiquimod and systemic immunotherapy to 
increase both intralesional and circulating immune responses promoted the clinical success 
rate3. 
Furthermore depletion of Tregs may be of additional value to enhance cytotoxic T-cell 
mediated responses since we showed the importance of Tregs in the recurrence and 
progression of uVIN and the association of local Treg infiltration in non-responsiveness to 
immunotherapy. Cyclophosphamide is a well-known Treg depleting agent and anti-CD25, 
anti-CTLA-4 and anti-GITR monoclonal antibodies have been used as well51-54. Anti-CTLA4 
has been shown to deplete tumor infiltration regulatory T cells, which express high levels of 
CTLA4, via an Fc dependent mechanism55-59. In a murine model of HPV tumor bearing mice 
a single dose of cyclophosphamide prior to therapeutic HPV-16 DNA vaccination resulted in 
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and increased number of HPV specific CD8+ T cells52. Moreover in patients with genital warts 
administration of cyclophosphamide reduces the number of regulatory T cells and improves 
the microenvironment resulting in prevention of recurrence in patients with large genital 
warts after laser therapy60. In ovarian cancer patients pre-treated with cyclophosphamide 
before p53 SLP vaccination the systemic number of Tregs nor their function was altered but 
induced higher IFNγ specific T cells compared to p53 SLP vaccination although the influence 
on the local regulatory T cell infiltrates was not established61. 
The targets for monoclonal antibodies on either blocking of co-stimulatory or co-
inhibitionary pathways on effector T cells, monocytes/APCs or regulatory T cells to release 
the brake on T-cell proliferation and activation are extensive (reviewed in 14,62-64). Our current 
data do not support the use of such antibodies to improve immunity, however, more specific 
phenotyping of the cells expressing these inhibitory molecules as well as their ligands are 
needed before firm conclusions on this topic can be made.
Another target that should be considered to optimize immunotherapy of uVIN may be the 
depletion or re-programming of macrophages as they were found to be associated with 
recurrent disease and increased numbers of regulatory T cell infiltrates in uVIN lesions. 
In our data the absence of intraepithelial macrophages, irrespective of type 1 or type 2 
macrophages, is favourable. Notably, the CD14+CD163-negative cells that are thought to 
be M1 macrophages may also reflect a population of CD14+CD11c+PDL1+ regulatory DCs 
which have been correlated to Tregs in metastatic lymph nodes of cervical cancer patients65. 
This still needs to be studied in uVIN. If so, depletion of macrophages might be the first 
choice. On the other hand, we found that M2 macrophages strongly outnumber the M1 
macrophages in uVIN lesions which may have masked a potential positive influence of M1 
macrophages. In tumors, M1 macrophages were an independent prognostic factor for 
better clinical outcome32,66. Furthermore, our research group showed that a population 
of inflammatory macrophages was required for vaccine induced regression of tumors67. 
In case M1 macrophages are as essential in uVIN lesions, therapies resulting in a switch 
from M2 to M1 macrophages are required. As production of PGE2 and IL-6 is known to 
induce M2 macrophages and hamper DC differentiation68,69, blocking with anti-IL-6 
(tocilizumab) or COX-inhibition which blocks production of PGE2 (celexocib) can induce re-
polarization of macrophages and may improve clinical outcome68-72. Moreover blockade of 
colony-stimulating factor 1 receptor (CSF1 inhibitors) results in improved anti-tumor T-cell 
responses by decreasing the number of tumor associated macrophages (TAM) but also 
reprogram remaining TAMs to support antigen presentation and include T-cell activation 
revealing reduced local immune suppression and IFNγ responses73-75. Re-differentiation 
of macrophages can as well be induced in response to IFNγ in combination with CD40-
CD40L68 since upon CD40 ligation DCs mature and produce pro-inflammatory cytokines 
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options rely in triggering of TLRs78,79. By triggering of TLR3 by poly I:C in mice tumor supporting 
macrophages were converted into tumor suppressing M1 macrophages rapidly producing 
inflammatory cytokines78. Furthermore blocking of IL-10 by antibodies in combination with 
the TLR9 ligand CpG resulted in a shift from M2 to M1 infiltrating macrophages 79. 
Recently antiviral therapy by cidofovir 1%, which may induce apoptosis of the HPV infected 
cells80, showed comparable results to imiquimod making this a feasible and active alternative 
in treatment of uVIN lesions81. It will be important to establish if the clinical effect of this 
compound relies on the immune system. If so, the effects of this compound may be improved 
by combination with one or more immunotherapeutic agents. 
Last but not least if pre-existing immune infiltrates can function as biomarkers in the 
individual patient to predict the patients’ responsiveness to the suggested therapy we could 
prevent unnecessary side effects of immunotherapy as well as delay in effective therapy 
and prevent potential progression in this period. In the ideal situation combination of 
local immunotherapy, as imiquimod or cidofovir, to induce local inflammation and effector 
T-cell homing, combined with therapeutic vaccination to induce a strong and proliferative 
systemic HPV T-cell response would be combined with an additional immune modulating 
therapy depending on the immune infiltrates profile present in the local environment of the 
patients’ uVIN lesion. 
Final conclusion
All steps achieved in the last decade regarding the knowledge of immune infiltrating 
cells in (pre)malignant lesions as well as steps taken in immunotherapeutic approaches, 
makes that we now know that these high grade HPV uVIN lesion can undergo an immune-
driven regression and we are challenged to further improve the promising established 
immunotherapies. Individualisation of patients therapy based on the immune infiltrates 
prior to therapy requiring for example depletion of immune suppressive macrophages or 
Tregs or enhancement of the pre-existent pro-inflammatory environment should be a goal 
to keep in mind in order to minimize the side effects of therapies and to improve the number 
of responding patients.
The recent introduction of prophylactic HPV vaccination to prevent HPV related (pre)
malignancies is expected to lower the incidence and impact of HPV related disease as 
uVIN in the future82. However it will take a long time until the prophylactic vaccination will 
actually decrease the burden of HPV-induced (pre)malignancies over the general population 
especially since the coverage of HPV vaccination is lower as expected83. These prophylactic 
vaccines are not able to treat already infected HPV women84. Therefore, new strategies to 
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Vulvaire intra-epitheliale neoplasie (VIN) is een relatief weinig voorkomende afwijking 
aan de schaamlippen met vaak een langdurig beloop en recidiverend karakter. VIN is een 
voorstadium van schaamlipkanker. Er zijn twee typen van VIN te onderscheiden; differentiated 
VIN (dVIN) en usual VIN (uVIN). uVIN wordt veroorzaakt door een voortdurende infectie met 
het humaan papilloma virus (HPV) bij patiënten van wie het afweersysteem er niet slaagt om 
de infectie op te ruimen. Door de stijging in het aantal HPV infecties is er ook sprake van een 
toename van uVIN in met name jonge vrouwen. De kans op het spontaan verdwijnen van 
uVIN afwijkingen is met 1.5% laag. De kans dat uVIN zich tot schaamlipkanker ontwikkeld is 
10% als er geen behandeling plaats vindt en als de uVIN afwijking wel wordt behandeld dan 
verminderd de kans naar 3-4%. uVIN geeft bij de meeste vrouwen klachten als jeuk, pijn en/
of branderigheid maar ook psychoseksuele klachten. Indien de uVIN afwijking geen klachten 
geeft en er geen verdenking is dat er kankervorming plaatsvindt, kan er gekozen worden 
voor een afwachtend beleid met regelmatige poliklinische controles. Een behandeling van 
uVIN is in de meerderheid van de patiënten echter wel nodig, omdat ze klachten ervaren. 
Standaard chirurgische behandelingen voor uVIN zijn het chirurgisch verwijderen van de 
afwijking of lasertherapie. Na deze standaard behandelingen komt de afwijking in 20-
40% van de gevallen weer terug. Daarnaast kan een chirurgische behandeling leiden tot 
misvorming van de schaamlippen, wat vaak samen gaat met psychoseksuele klachten. Dit 
is de reden dat er momenteel behandelingen worden ontwikkeld die het afweersysteem 
activeren om zo het HPV virus en de daardoor veroorzaakte uVIN afwijking te bestrijden. 
Sinds de jaren 70 is het bekend dat HPV baarmoederhalskanker veroorzaakt en in 1982 
toonde onderzoek aan dat HPV ook VIN afwijkingen veroorzaakt. HPV is een seksueel 
overdraagbaar virus waarvan er meer dan 100 soorten bekend zijn. Deze zijn onderverdeeld 
in zogenoemde laag risico virussen die bijvoorbeeld wratten kunnen veroorzaken en in 
hoog risico virussen, zoals HPV 16 en 18, die baarmoederhalskanker en ook uVIN kunnen 
veroorzaken. Ongeveer 80% van de mensen wordt in zijn leven besmet met één of meerdere 
HPV infecties. In de meeste gevallen zal het afweersysteem deze infecties binnen 1-2 jaar 
onder controle krijgen zonder dat er klachten ontstaan. Indien het afweersysteem niet in 
staat is om dit virus op te ruimen, wat in ongeveer 10% van de mensen het geval is, dan 
is er sprake van een chronische HPV infectie die afwijkingen in de slijmvliezen van zowel 
het genitale gebied (baarmoederhals, schaamlippen, vagina en anus) als in de hoofd-hals 
regio kan veroorzaken (amandelen). Risicofactoren voor het krijgen van een voortdurende 
HPV infectie zijn het aantal seksuele partners, roken en gebruik van orale anticonceptie. 
Sinds een aantal jaar is er een preventief vaccin beschikbaar tegen de meest vóórkomende 
typen hoog risico HPV 16 en 18, die in 2010 is opgenomen in het rijksvaccinatieprogramma 
voor meisjes. Het doel van deze vaccinatie is om een HPV 16 en 18 infectie te voorkomen 
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jonge meisjes dat gevaccineerd in Nederland lager dan gehoopt (variërend per regio van 31% 
tot 61%). Doordat het een lange tijd duurt voordat een afwijking zich door HPV ontwikkelt, 
zal het ook lang duren voordat men het beschermende effect van het preventieve vaccin 
ziet. Daarom is behandeling en opsporing van HPV veroorzaakte afwijkingen nog steeds van 
groot van belang.
Het afweersysteem is een zeer complex geheel met het doel de mens te beschermen 
tegen indringers van buiten en afwijkingen binnen het lichaam. Het kan globaal worden 
onderverdeeld in het aangeboren afweersysteem en het verworven afweersysteem. 
Het aangeboren afweersysteem kan direct, snel en altijd met dezelfde kracht reageren 
op indringende ziekteverwekkers in de omgeving. Cellen die onderdeel uitmaken van 
het aangeboren afweersysteem zijn onder andere: natural killer (NK) cellen en antigeen 
presenterende cellen (APC) zoals macrofagen en dendritische cellen (DCs). APC’s zijn in staat 
zijn om het verworven afweersysteem activeren. 
Het verworven afweersysteem is heel specifiek en kan tegen delen die uniek zijn voor 
ziekteverwekkers zoals virussen, bacteriën of kanker cellen reageren. Het duurt langer voordat 
een verworven afweerreactie op volle sterkte is, maar de reactie is zeer krachtig en specifiek 
gericht tegen de afzonderlijke ziekteverwekkers. Bovendien zorgt deze afweerreactie ervoor 
dat er een geheugen opgebouwd kan worden tegen deze ziekteverwekkers. Dit geheugen 
zorgt ervoor dat wanneer men dezelfde ziekteverwekker nog een keer tegenkomt, men 
er dan niet meer ziek van wordt. In de verworven afweerreactie spelen vooral de witte 
bloedcellen (lymfocyten) een belangrijke rol. 
Subpopulaties van lymfocyten zijn onder andere B- en T-cellen. B-cellen maken antistoffen 
die de buitenkant van virussen kunnen herkennen en op die manier kunnen voorkomen 
dat het virus het lichaam kan infecteren. De B-cellen zijn belangrijk voor de werking van 
het preventieve HPV vaccin. T-cellen zijn van groot belang in de afweer tegen onder andere 
virale infecties zoals HPV wanneer de infectie al heeft plaatsgevonden. Er zijn verschillende 
soorten T-cellen te onderscheiden: de T-helper cellen (CD4+), cytotoxische T-cellen (CD8+) 
en ook regulatoire T-cellen (Treg). De CD4+ T-helper cellen activeren B cellen, ondersteunen 
de werking van cytotoxische CD8+ T-cellen en kunnen het gewenste type afweerreactie 
stimuleren. Globaal kunnen er twee T-helper afweerreacties onderscheiden worden die het 
afweersysteem sturen: een type 1 en een type 2 afweerreactie. De type 1 reactie resulteert 
in het opruimen van geïnfecteerde cellen door stimulatie van macrofagen en cytotoxische 
T cellen en kenmerkt zich door de productie van signaalstoffen (cytokines) zoals IFNy, 
TNFα en IL-2. De type 2 reactie resulteert activatie van B cellen en is een chronische 
ontstekingsreactie die zich kenmerkt door cytokines zoals IL-4, IL-5 en IL-10. Cytotoxische 
T-cellen kunnen geïnfecteerde cellen en tumorcellen opruimen en zijn van groot belang in 
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staat zijn om de activatie van andere afweercellen te onderdrukken. Dit is belangrijk om 
bijvoorbeeld allergie of autoimmuunziekten te voorkomen, maar ook om te zorgen dat er 
geen lichaamsschade optreed bij een te sterke afweerreactie.
Het is bekend dat in het geval van voortdurende HPV infecties en het ontstaan van 
uVIN zowel de aangeboren als verworven afweerreactie tegen HPV onderdrukt of niet 
geactiveerd is. Het merendeel van de macrofagen in uVIN zijn gericht op het dempen van de 
afweerreactie. Er zijn minder T-cellen gericht tegen HPV terwijl diegene die er zijn minder 
actief zijn. Bovendien worden ze in de uVIN vaak ook vergezeld door grotere aantallen van 
regulatoire T-cellen. 
Aangezien we weten dat het falen van het afweersysteem om HPV te controleren in 
een klein deel van de patiënten tot het ontwikkelen van uVIN leidt, is er de afgelopen 
jaren veel aandacht uitgegaan naar immunotherapie als behandelmethode voor uVIN. 
Immunotherapie heeft als doel om het afweersysteem zodanig te activeren dat de HPV 
infectie en de afwijking ten gevolge van HPV worden opgeruimd. 
Er kunnen twee soorten immunotherapie worden onderscheiden. Lokale immunotherapie 
grijpt direct aan op de afwijking zelf en beoogt de activering van het afweersysteem 
in de uVIN zelf. Een voorbeeld hiervan is het gebruik van imiquimod crème (Aldara®). 
Systemische immunotherapie zorgt voor activatie van het afweersysteem in het hele 
lichaam. Therapeutische HPV vaccinatie is hiervan een voorbeeld. Het vaccin stimuleert de 
lymfocyten van het verworven afweersysteem om tegen delen van het HPV te reageren. 
Deze lymfocyten circuleren door het lichaam om HPV infecties/afwijkingen op te sporen en 
daarna te vernietigen. Therapeutische vaccins bestaan in verscheidene vormen die heden 
ten dage in onderzoekverband worden getest. Eén type vaccin, het HPV 16 synthetic long 
peptide (HPV16 SLP) vaccin, ontwikkeld in het Leids Universitair Medisch Centrum (LUMC), 
geeft een krachtige stimulus aan het verworven afweersysteem wat samen gaat met het 
(deels) verdwijnen van uVIN in een groot aantal patiënten. Zowel de lokale als systemische 
immunotherapie van uVIN heeft geresulteerd in veel belovende resultaten in meer dan de 
helft van alle behandelde patiënten. Een aanzienlijk deel van de patiënten reageert helaas 
(nog) niet op deze therapieën. 
Dit proefschrift richt zich op het lokale en systemische afweersysteem in uVIN patiënten. 
Het doel is om meer inzicht te krijgen in de rol en het falen van het afweersysteem in uVIN 
en hoe dit de reactie op immunotherapie kan beïnvloeden. Hiertoe hebben we bij een 
geselecteerde groep uVIN patiënten uit het LUMC, de patiënt karakteristieken, de lokale en 
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In hoofdstuk 2 van dit proefschrift wordt een gedetailleerd overzicht van de eigenschappen 
van de aangeboren en verworven afweerreactie tegen HPV, en bij uVIN in het bijzonder, 
gegeven. Daarnaast beschrijven we verschillende vormen van immunotherapie voor uVIN en 
wordt er een overzicht gegeven van mogelijke oorzaken van het falen van immunotherapie 
in uVIN. Dit review vormt de basis voor de verschillende studies in dit proefschrift. 
In hoofdstuk 3 beschrijven we de patiënt karakteristieken van onze onderzoeksgroep van 
uVIN patiënten. Hieruit blijkt dat in onze onderzochte populatie alleen het op meerdere 
plekken aanwezig zijn van uVIN afwijkingen een voorspeller is voor het snel terugkomen 
van uVIN nadat deze eerder door een chirurgische behandeling was verwijderd. Eerder 
beschreven voorspellende patiënt karakteristieken als roken en het nog aanwezig zijn 
van uVIN in de randen van het operatiegebied waren in deze groep niet van belang voor 
het verdere beloop van de ziekte. Het multifocaal aanwezig zijn van uVIN als ongunstige 
voorspeller hebben we mee laten wegen in alle volgende onderzoeken over het belang van 
afweercellen in het verdere beloop van de uVIN afwijking. 
Veranderingen in de lokale afweerreactie in uVIN 
uVIN wordt gekenmerkt door een ruime hoeveelheid aan verschillende typen afweercellen die 
zich in de afwijking bevinden. Alhoewel deze afweercellen aanwezig zijn in de uVIN afwijking 
blijken ze toch niet in staat te zijn om de HPV infectie op te ruimen en de uVIN afwijking te 
laten verdwijnen. De functie van deze cellen is dus verminderd of niet van het juiste type 
benodigd voor het opruimen van de uVIN cellen. In een effectieve afweerreactie tegen uVIN 
is de hoeveelheid en verhouding van cytotoxische CD8+T-cellen (die de geïnfecteerde cellen 
op kunnen ruimen) en regulatoire T-cellen (die de afweerreactie onderdrukken) van groot 
belang. Het recidiveren van uVIN, het ontstaan van schaamlipkanker en het niet reageren 
op immunotherapie wordt namelijk gekenmerkt door minder cytotoxische T-cellen en meer 
regulatoire T-cellen (hoofdstuk 5). 
De effectiviteit van T-cellen, maar ook NK cellen,wordt beïnvloedt door de aan- of afwezigheid 
van het zogenoemde humaan leukocyten antigeen (HLA) molecuul op afweercellen. Dit 
molecuul toont aan de buitenkant van de geïnfecteerde cel een klein stukje van het virus 
waardoor de cel herkent kan worden door T-cellen. In hoofdstuk 4 hebben we daarom de 
aanwezigheid van verschillende HLA moleculen bestudeerd. HLA klasse I, dat nodig is voor 
de herkenning van geïnfecteerde cellen door cytotoxische T-cellen, is verminderd aanwezig 
bij de meerderheid van uVIN afwijkingen. Dit verlies aan HLA klasse I lijkt echter geen 
probleem te zijn in de effectiviteit van immunotherapie.. Het verlies aan HLA klasse I in uVIN 
was meestal niet het gevolg van een genetische irreversibele verandering. In reactie op IFNy 
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HLA klasse I op huidcellen van uVIN weer gestimuleerd. In uVIN patiënten die behandeld 
werden met het therapeutische HPV-16 SLP vaccin zagen we bovendien dat patiënten die 
niet reageerden op het vaccin wel HLA klasse I tot expressie te brachten, terwijl patiënten 
die wel reageerden soms minder HLA klasse I hadden. In schaamlipkanker lijkt dit anders 
te zijn. Minder HLA klasse I is hier wel vaak het gevolg van een genetische verandering. 
De niet klassieke HLA moleculen -E en -G, die een remmende werking op T en NK cellen 
hebben, worden niet tot expressie gebracht in uVIN maar wel in ongeveer de helft van de 
patiënten met schaamlipkanker. De combinatie van HLA-E en -G expressie met irreversibele 
genetische veranderingen in HLA klasse I, maakt immunotherapie in schaamlipkanker 
mogelijk moeilijker dan in uVIN. 
De functie en het type van de aanwezige afweercellen in uVIN kunnen beïnvloed zijn. Ze 
kunnen in een uitgeputte of niet functionele staat verkeren waardoor het afweersysteem de 
afwijking niet voldoende aanvalt. In hoofdstuk 5 hebben we daartoe naast het vaststellen 
van de hoeveelheid en verhouding van de verschillende T cellen ook de aanwezigheid van 
zogenoemde co-inhibitie moleculen op T-cellen onderzocht. In hoofdstuk 6 hebben we 
tevens de hoeveelheid en het type macrofagen in uVIN onderzocht waarna we beide datasets 
aan elkaar gekoppeld hebben. Een effectieve afweerreactie in uVIN kenmerkt zich door 
geactiveerde IFNy producerende T-cellen en de relatieve afwezigheid van macrofagen en 
regulatoire T-cellen. Deze combinatie van afweercellen in de uVIN afwijking is geassocieerd 
met het (lang) uitblijven van recidieven. 
In het lokale afweersysteem van uVIN is het dus van belang dat immunotherapie een goede 
activatie van het afweersysteem bewerkstelligd die zich kenmerkt door IFNy productie. 
Een gunstige samenstelling van afweercellen voorafgaand aan immunotherapie zal het 
waarschijnlijk makkelijker maken om de uVIN afwijking te laten verdwijnen. De afweercellen 
zijn immers al aanwezig, ze hoeven niet nog naar de afwijking toe te komen en hebben geen 
verminderde functie. Een boost van de al aanwezige afweerrespons kan dan genoeg zijn, 
terwijl immunotherapie in patiënten met een onderdrukte, niet effectieve afweerrespons, 
lastiger zal zijn. Deze patiënten zullen baat hebben bij een bredere aanpak om zowel de 
functie als het type aanwezige afweercellen te beïnvloeden. 
Veranderingen in de systemische afweerreactie in uVIN 
Systemische HPV specifieke afweer is van belang voor het verdwijnen van HPV afwijkingen. 
In het bloed van uVIN patiënten is deze afweer meestal zwak of niet aanwezig. Het opwekken 
van deze HPV specifieke afweerrespons na therapeutische HPV 16 SLP vaccinatie leidt tot 
het verdwijnen van de uVIN afwijking. Niet alle patiënten blijken in staat tot het opwekken 
van sterke HPV specifieke afweer reactie. Dit duidt erop dat er verschillen bestaan in de 
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In hoofdstuk 7 worden, net als eerder voor het lokale afweersysteem, verschillen in type 
en functie van afweercellen aanwezig in het bloed onderzocht. De functie van T-cellen om 
signaalstoffen uit te scheiden en van macrofagen om afweercellen te activeren, is gelijk in 
gezonde controles. Co-inhibitie moleculen op T-cellen zijn nauwelijks aanwezig. Echter net 
als bij het lokale afweersysteem, zijn IFNγ-producerende T-cellen van belang. In patiënten 
met recidiverende uVIN afwijkingen komen minder van deze actieve T-cellen voor. Naast deze 
actieve T-cellen zijn er in patiënten met recidiverende uVIN afwijkingen minder dendritische 
cellen en meer type 2 (afweer remmende) monocyten. In uVIN patiënten met recidieven 
lijkt er sprake van een verminderde mogelijkheid tot activatie van de HPV specifieke afweer 
door een tolerant, minder effectief afweersysteem. 
De mogelijkheid tot activatie van afweercellen in reactie op signaalstoffen (cytokines) 
en het type afweerreactie hierop hebben we onderzocht met behulp van het meten van 
phosforylatie van signal transduction activators of transcription (STAT). STAT phosforylatie 
in afweercellen is na stimulatie met verschillende cytokines gelijk in uVIN patiënten en 
gezonde controles. Stimulatie met afweer stimulerende stoffen IFNα en GM-CSF resulteerde 
wel in verschillen. In uVIN patiënten lijken de voorloper cellen van antigeen presenterende 
cellen minder in staat om IFNy geassocieerde responsen op te wekken. In de uVIN patiënten 
die behandeld werden met therapeutische HPV 16 SLP vaccinatie bleken de patiënten waar 
het afweersysteem goed reageerde op vaccinatie, ook beter in staat om IFNy geassocieerde 
responsen op te wekken na stimulatie met IFNα. IFNα kan gezien worden als een sterke 
afweer modulator die vooral IFNy geassocieerde responsen opwekt. IFNα zou mogelijk 
aanvullend kunnen zijn op bestaande immunotherapie om hun effecten te versterken. 
Bovenstaande resultaten suggereren dat de systemische myeloide cellen (voorlopers 
van) dendritische cellen en macrofagen) in patiënten met uVIN zowel in type als functie 
veranderd zijn. Het recidiveren van uVIN is gerelateerd aan type 2 monocyten in het bloed 
is en de aanwezigheid van macrofagen in de uVIN afwijking. Nader onderzoek is nodig om te 
kijken of het meten van deze type 2 monocyten kan dienen als bloedmarker. Het meten van 
deze type 2 monocyten is dan mogelijk een reflectie van het lokale afweersysteem en kan 
van belang zijn voor de prognose van de patiënt. 
Discussie en toekomstperspectieven
In hoofdstuk 8 worden de bevindingen van dit proefschrift samengevat en worden mogelijke 
combinaties van immunotherapieën en toekomstige onderzoeksmogelijkheden uitgelicht. 
Een succesvolle (combinatie van) immunotherapie resulteert zowel lokaal als systemisch 
in: adequate T-cel activatie, een toename van effector T-cellen, weinig regulatoire T-cellen 
en het creëren van een IFNy geassocieerde afweerreactie. In deze omstandigheden kan 
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Lokale imiquimod therapie is in staat om het afweersysteem in de uVIN afwijking gunstig te 
beïnvloeden. Imiquimod resulteert in meer CD8+ cytotoxische T-cellen, minder regulatoire 
T-cellen, minder macrofagen en minder immature dendritische cellen. Het (deels) verdwijnen 
van uVIN na imiquimod is niet gerelateerd aan de van te voren aanwezige afweercellen 
in de afwijking. Dit betekend dat imiquimod een krachtige activator is van het lokale 
afweersysteem. Imiquimod heeft geen effect op de algehele HPV specifieke afweerreactie 
in het bloed. Systemische immunotherapie, met name HPV 16 SLP vaccinatie, resulteert wel 
in sterke systemische HPV specifieke T-cel responsen die geassocieerd zijn met het (deels) 
verdwijnen van uVIN. In de uVIN afwijking heeft systemische immunotherapie daarentegen 
weer weinig invloed op het lokale afweersysteem. Het verdwijnen van de uVIN afwijking na 
systemische immunotherapie is geassocieerd met de van te voren aanwezige afweer cellen. 
De combinatie van lokale en systemische immunotherapie combineert mogelijk het beste uit 
twee werelden: activatie van zowel het lokale als het algehele HPV specifieke afweersysteem. 
Een studie waar patiënten therapeutisch gevaccineerd werden na lokale behandeling met 
imiquimod liet inderdaad zien dat bij meer vrouwen de uVIN afwijking (deels) verdween.
De verbetering in uitkomst lijkt met name te zitten in het veranderen van het lokale afweer 
milieu waar de T-cellen hun functie moeten uitoefenen. Er treden al sterke systemische 
reacties op na therapeutische HPV vaccinatie, ook zonder het aanbrengen van imiquimod. 
Patiënten met een bij voorbaat gunstig afweer milieu, zoals aangetoond in dit proefschrift, 
met reversibele HLA klasse I expressie, veel CD8+ cytotoxische T-cellen, weinig regulatoire 
T-cellen en weinig tot geen macrofagen, zullen naar alle waarschijnlijkheid goed reageren op 
immunotherapie. uVIN patiënten die geen gunstige uitgangssituatie hebben voorafgaand 
aan immunotherapie, zijn mogelijk meer gelijk aan HPV geïnduceerde schaamlipkankers. 
Bij deze groep patiënten zullen de verschillende aspecten van het falen van het afweer 
systeem aangepakt moeten worden om wel resultaat te boeken. Naast een combinatie van 
therapeutische vaccinatie met lokaal imiquimod kan ook gedacht worden aan vermindering 
van regulatoire T-cellen of macrofagen. 
De karakteristieken van afweercellen, aanwezig in uVIN voorafgaand aan immunotherapie, 
kunnen mogelijk dienen als biomarkers in de individuele patiënt. Deze biomarkers kunnen 
dan idealiter een reactie op therapie voorspellen. Op deze manier zorg je er voor dat onnodige 
bijwerkingen van immunotherapie en de eventuele ontwikkeling van schaamlipkanker in de 
periode van immunotherapie kunnen worden voorkomen. 
De kennis van de afweercellen die een rol spelen in uVIN en de progressie die geboekt is in 
het veld van immunotherapie voor uVIN, maakt dat we nu weten dat deze uVIN afwijkingen 
in staat zijn om te verdwijnen bij de juiste activatie van het afweersysteem. Deze kennis 
vormt een basis om in de toekomst verder te gaan met verbetering van immunotherapieën 
en geeft wellicht de mogelijkheid om therapieën te individualiseren voor de patiënten op 
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List of Abbreviations
AIN  Anal intraepithelial neoplasia
APC  Antigen presenting cell
β2M  Beta-2 microglobulin
BSA  Bovine Serum Albumin
CBA  Cytometric bead array
CD Cluster of differentiation (cellular surface receptors that identify cell types 
and stage of differentiation) 
CIN  Cervical intraepithelial neoplasia
COX  Cyclooxygenase
CTL  CD8+ cytotoxic T lymphocyte
CTLA-4  Cytotoxic T-lymphocyte-associated protein 4 (CD152)
DAB  Diaminobenzidine
DC  Dendritic cell
FACS  Fluorescence-activated cell sorting
FBS  Fetal Bovine Serum
FDA  Food and Drug Administration
FFPE  Formalin-fixed paraffin embedded tissue
FIGO  International Federation of Gynecology and Obstetrics
FSC  Forward scatter
Gal  Galectin 
GM-CSF  Granulocyte-macrophage colony-stimulating factor
HLA  Human leukocyte antigen
HPV  Human papillomavirus
hrHPV  High-risk human papillomavirus
lrHPV  Low-risk human papillomavirus
HRP  Horse radish peroxidase




IMDM  Iscove’s Modified Dulbecco’s Media
ISSVD  International Society for the Study of Vulvovaginal Disease
KC  Keratinocytes
KIR  Killer-immunoglobulin-like receptors
LC  Langerhans cell
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LOH  Loss of heterozygosity
LUMC  Leiden University Medical Center
M1  Type 1 macrophages
M2  Type 2 macrophages
MDSC  Myeloid-derived suppressor cell
MICA  MHC class I chain-related molecule A
MHC  Major-histocompatability class
MLR  Mixed lymphocyte reaction
NF-kB  Nuclear factor-kappa B
NK  Natural killer
NKG2  Natural killer receptor family
NLR  Nucleotide-binding oligomerization domain-like receptors
PAIN  Peri-anal intraepithelial neoplasia
PAMP  Pathogen associated molecular pattern
PBMC  Peripheral blood mononuclear cell
PBS   Phosphate buffered saline
PCR  Polymerase chain reaction
PFS  Progression free survival
PHA  Phytohemagglutinine
PD1  Programmed cell death 1
PDL1  Programmed cell death ligand 1
PDT  Photodynamic therapy
PGE2  Prostaglandin E2
PRR  Pathogen recognition receptor
RFS  Recurrence free survival
RLR  RIG-1 like receptors
SCC  Squamous cell carcinoma
SSC  Sideward scatter
SI  Stimulation index
SF  Serum-free IMDM medium
SLP  Synthetic long peptide
STAT  Signal transduction activators of transcription
pSTAT  Phosphorylation of signal transduction activators of transcription
TCR  T-cell receptor
Th  CD4+ T helper
TIL  Tumor infiltrating lymphocyte
TIM3  T cell immunoglobulin mucin-3
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TNF  Tumor necrosis factor
Treg  Regulatory T cell
VAIN  Vaginal intraepithelial neoplasia
VIN  Vulvar intraepithelial neoplasia
dVIN  Differentiated type vulvar intraepithelial neoplasia
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Veel dank gaat ook uit naar de zes studenten die ik heb mogen begeleiden bij hun 
wetenschapsstage. Bedankt voor jullie harde werk en ideeën. Maija Dam, Kevin de Regt, 
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inspiratie te vinden voor toekomstig onderzoek. 
Tess Meuleman, vriend en bondgenoot. Samen hard werken, stoom afblazen, tijd voor een 
lach en een traan en samen bevlogen geraakt door de gynaecologie en immunologie. Fijn 
om zo’n goede vriendin ook collega te mogen noemen.  
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‘thuishaven’ tussen alle werkplekken. 
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